<mediawiki xmlns="http://www.mediawiki.org/xml/export-0.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.mediawiki.org/xml/export-0.3/ http://www.mediawiki.org/xml/export-0.3.xsd" version="0.3" xml:lang="en">
  <page>
    <title>ARDS</title>
    <id>502</id>
    <term>Acute respiratory distress syndrome</term><definition>A syndrome characterized by progressive life-threatening respiratory insufficiency in the absence of known lung diseases, usually following a systemic insult such as surgery or major trauma.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=ARDS</reference><category>Adverse</category></page>
  <page>
    <title>Abatement</title>
    <id>303</id>
    <term>Abatement</term><definition>Reducing the degree or intensity of, or eliminating, pollution.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Abdominal pain</title>
    <id>62</id>
    <term>Abdominal pain</term><definition>Sensation of discomfort, distress, or agony in the abdominal region; generally associated with functional disorders, tissue injuries, or diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Abdominal+pain</reference><category>Adverse</category></page>
  <page>
    <title>Abscess</title>
    <id>65</id>
    <term>Abscess</term><definition>Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Abscess</reference><category>Adverse</category></page>
  <page>
    <title>Absorbed Dose</title>
    <id>187</id>
    <term>Absorbed Dose</term><definition>The amount of a substance penetrating the exchange boundaries of an organism after contact. Absorbed dose for the inhalation and ingestion routes of exposure is calculated from the intake and the absorption efficiency. Absorbed dose for dermal contact depends on the surface area. In exposure assessment, the amount of a substance that penetrates an exposed organism's absorption barriers (e.g. skin, lung tissue, gastrointestinal tract) through physical or biological processes. The term is synonymous with internal dose.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Dose</category></page>
  <page>
    <title>Absorption</title>
    <id>183</id>
    <term>Absorption</term><definition>Absorption is the passage of one substance into or through another. 1. The penetration of one substance into or through another. 2. Specifically, the penetration of a substance into the body from the skin, lungs, or digestive tract. The uptake of water , other fluids, or dissolved chemicals by a cell or an organism (as tree roots absorb dissolved nutrients in soil.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Adme</category></page>
  <page>
    <title>Absorption barrier</title>
    <id>184</id>
    <term>Absorption barrier</term><definition>Any exposure surface that may allow diffusion of an agent into a target. Examples of absorption barriers are the skin, lung tissue, and gastrointestinal tract wall (cf. exposure surface).</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Adme</category></page>
  <page>
    <title>Acceptable Daily Intake (ADI)</title>
    <id>914</id>
    <term>Acceptable Daily Intake</term><definition>An estimate of the daily exposure dose that is likely to be without deleterious effect even if continued exposure occurs over a lifetime. The amount of a chemical a person can be exposed to on a daily basis over an extended period of time (usually a lifetime) without suffering deleterious effects. Estimated maximum amount of an agent, expressed on a body mass basis, to which an individual in a (sub) population may be exposed daily over its lifetime without appreciable health risk.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Dose</category></page>
  <page>
    <title>Access Relationships Help</title>
    <id>1366</id>
    <reference>http://dawnloadonline.com/SESS_cg5OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_access%2Brelationships%2Bhelp.html</reference><reference>http://www.rosenstiehl.net/forum/topic.php?id=6</reference><reference>http://wiki.sfbace.org/index.php?title=Everett_Area_Chat_Rooms</reference><reference>http://tugospelradio.com/foro/topic.php?id=8</reference><reference>http://www.amazonca.com/content/espaol-chat</reference><reference>http://www.bedroomgenius.com/content/trinidad-chat</reference></page>
  <page>
    <title>Accuracy</title>
    <id>186</id>
    <term>Accuracy</term><definition>The degree to which a measurement reflects the true quantitative value of a variable 1. The degree of agreement between a measured value and the true value; usually expressed as +/- percent of full scale. Closeness of agreement between the result of a measurement and the (conventional) true value of the measureand. Note 1. Use of the term precision for accuracy should be avoided. Note 2. True value is an ideal concept and, in general, cannot be known exactly.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Endpoints</category></page>
  <page>
    <title>Acidosis</title>
    <id>498</id>
    <term>Acidosis</term><definition>A pathologic condition resulting from accumulation of acid or depletion of the alkaline reserve (bicarbonate) content of the blood and body tissues, and characterized by an increase in hydrogen ion concentration (decrease in pH).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Acidosis</reference><category>Adverse</category></page>
  <page>
    <title>Acidosis, lactic</title>
    <id>499</id>
    <term>Acidosis, lactic</term><definition>Acidosis caused by accumulation of lactic acid more rapidly than it can be metabolized. It may occur spontaneously or in association with diseases such as diabetes mellitus, leukemia, or liver failure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AcidosisLactic</reference><category>Adverse</category></page>
  <page>
    <title>Acidosis, renal tubular</title>
    <id>366</id>
    <term>Acidosis, renal tubular</term><definition>A group of disorders of the kidney tubules characterized by the accumulation of metabolically produced acids with elevated plasma chloride, hyperchloremic metabolic acidosis. Defectiverenal acidification of urine (proximal tubules) or low renal acid excretion(distal tubules) can lead to complications such as hypokalemia, hypercalcinuriawith nephrolithiasis and nephrocalcinosis, and rickets.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Acidosis-Renal-Tubular</reference><category>Adverse</category></page>
  <page>
    <title>Acne</title>
    <id>500</id>
    <term>Acne</term><definition>A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Acne</reference><category>Adverse</category></page>
  <page>
    <title>Acneiform eruption</title>
    <id>501</id>
    <term>Acneiform eruption</term><definition>Visible efflorescent lesions of the skin caused by acne or resembling acne.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AcneiformEruption</reference><category>Adverse</category></page>
  <page>
    <title>Action levels</title>
    <id>185</id>
    <term>Action levels</term><definition>Regulatory levels recommended by EPA for enforcement by Food and Drug Administration and United States Department of Agriculture when pesticide residues occur in food or feed commodities for reasons other than the direct application of the pesticide. As opposed to "tolerances" which are established for residues occurring as a direct result of proper usage, action levels are set for inadvertent residues resulting from previous legal use or accidental contamination. In the Superfund program, the existence of a contaminant concentration in the environment high enough to warrant action or trigger a response under SARA and the National Oil and Hazardous Substances Contingency Plan. The term is also used in other regulatory programs.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Regulatory</category></page>
  <page>
    <title>Acute</title>
    <id>188</id>
    <term>Acute</term><definition>Having a sudden onset or lasting a short time. An acute stimulus is severe enough to induce a response rapidly. The word acute can be used to define either the exposure or the response to an exposure (effect). The duration of an acute aquatic toxicity test is generally 4 days or less and mortality is the response usually measured. 1. Acute-diseases or responses with short and generally severe course (often due to high pollutant concentrations).</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Acute</category></page>
  <page>
    <title>Acute Reference Dose (RfD)</title>
    <id>300</id>
    <term>Acute Reference Dose</term><definition>An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure for an acute duration (24 hours or less) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Acute</category></page>
  <page>
    <title>Acute contact toxicity test (honeybees)</title>
    <id>54</id>
    <term>Acute contact toxicity test (honeybees) </term><definition>Acute contact toxicity: is the adverse effects occurring within a maximum period of 96 h of a topical application of a single dose of a substance.Adult worker honeybees (Apis mellifera) are exposed to a range of doses of the test substance dissolved in appropriate carrier, by direct application to the thorax (or oplets). The test duration is 48 h. If the mortality rate is increasing between 24 h and 48 h whilst control mortality remains at an accepted level, i.e. &lt; 10 %, it is appropriate to extend the duration of the test to a maximum of 96 h. Mortality is recorded daily and compared with control values. The results are analysed in order to calculate the LD 50 at 24 h and 48 h, and in case the study is prolonged at 72 h and 96 h.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/C17web2001.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute exposure</title>
    <id>56</id>
    <term>Acute exposure</term><definition>Acute exposure - Exposure by the oral, dermal, or inhalation route for 24 hours or less.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><reference>http://rais.ornl.gov/homepage/glossary.shtml</reference><category>Acute</category></page>
  <page>
    <title>Acute oral toxicity</title>
    <id>41</id>
    <term>Acute oral toxicity </term><definition>Acute oral toxicity: refers to those adverse effects occurring following oral administration of a single dose of a substance or multiple doses given within 24 hours.</definition><reference>http://ecb.jrc.ec.europa.eu/DOCUMENTS/Testing-Methods/ANNEXV/B01bisweb2004.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute oral toxicity test (honeybees)</title>
    <id>53</id>
    <term>Acute oral toxicity test (honeybees)</term><definition>This toxicity test is a laboratory method, designed to assess the oral acute toxicity of plant protection products and other chemicals, to adult worker honeybees. In the assessment and evaluation of toxic characteristics of substances, determination of acute oral toxicity in honeybees may be required, e.g. when exposure of bees to a given chemical is likely. The acute oral toxicity test is carried out to determine the inherent toxicity of pesticides and other chemicals to bees. The results of this test should be used to define the need for further evaluation. In particular, this method can be used in stepwise programmes for evaluating the hazards of pesticides to bees, based on sequential progression from laboratory toxicity tests to semi-field and field experiments. Pesticides can be tested as active substances or as formulated products. A toxic standard should be used to verify the sensitivity of the bees and the precision of the test procedure.Adult worker honeybees (Apis mellifera) are exposed to a range of doses of the test substance dispersed in sucrose solution. The bees are then fed the same diet, free of the test substance. Mortality is recorded daily during at least 48 h and compared with control values. If the mortality rate is increasing between 24 h and 48 h whilst control mortality remains at an accepted level, i.e.&lt; 10 %, it is appropriate to extend the duration of the test to a maximum of 96 h. The results are analysed in order to calculate the LD50 at 24 h and 48 h and, in case the study is prolonged, at 72 h and 96 h.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/C16web2001.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute reference concentration (arfc)</title>
    <id>915</id>
    <term>Acute reference concentration </term><definition>(ARfC) An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure for an acute duration (24 hours or less) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Acute</category></page>
  <page>
    <title>Acute toxic class method</title>
    <id>42</id>
    <term>Acute toxic class method</term><definition>The acute toxic class method set out in this test is a stepwise procedure with the use of 3 animals of a single sex per step. Depending on the mortality and/or the moribund status of the animals, on average 2-4 steps may be necessary to allow judgment on the acute toxicity of the test substance. This procedure is reproducible, uses very few animals and is able to rank substances in a similar manner to the other acute toxicity testing methods.The acute toxic class method is based on biometric evaluations with fixed doses, adequately separated to enable a substance to be ranked for classification purposes and hazard assessment. The method as adopted in 1996 was extensively validated in vivo against LD50 data obtained from the literature, both nationally and internationally.</definition><reference>http://ecb.jrc.ec.europa.eu/DOCUMENTS/Testing-Methods/ANNEXV/B01bisweb2004.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity</title>
    <id>189</id>
    <term>Acute toxicity</term><definition>Any poisonous effect produced within a short period of time following an exposure, usually 24 to 96 hours. The ability of a substance to cause severe biological harm or death soon after a single exposure or dose. Also, any poisonous effect resulting from a single short-term exposure to a toxic substance. Adverse health effects from a single dose or exposure to a toxic chemical or other toxic substance. Acute toxicity is assessed using observations of accidental human exposures or by conducting LD50 tests on experimental animals, usually rodents.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (daphnia)</title>
    <id>52</id>
    <term>Acute toxicity (daphnia)</term><definition>The purpose of this test is to determine the median effective concentration for immobilization (EC50) of a substance to Daphnia in fresh water. It is desirable to have, as far as possible, information on the water solubility, vapour pressure, chemical stability , dissociation constants and biodegradability of the substance before starting the test.Additional information (for instance structural formula, degree of purity, nature and percentage of significant impurities, presence and amount of additives, and n-octanol/water partition coefficient) should be taken into consideration in both the planning of the test and interpretation of the results.A limit test may be performed at 100 mg per litre in order to demonstrate that the EC50 is greater than this concentration. The Daphnia are exposed to the test substance added to water at a range of concentrations for 48 hours.If a shorter test is used, justification should be given in the test report.Under otherwise identical test conditions, and an adequate range of test substance concentrations, different concentrations of a test substance exert different average degrees of effect on the swimming ability of Daphnia. Different concentrations result in different percentages of Daphnia being no longer capable of swimming at the end of the test. The concentrations causing zero or 100 % immobilization are derived directly from the test observations whereas the 48-hour EC50 is determined by calculation if possible.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/C02web1992.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (dermal)</title>
    <id>47</id>
    <term>Acute toxicity (dermal) </term><definition>The test substance is applied to the skin in graduated doses to several groups of experimental animals, one dose being used per group. Subsequently, observations of effects and deaths are made. Animals which die during the test are necropsied and at the conclusion of the test surviving animals are necropsied.Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Dosing test substances in a way known to cause marked pain and distress due to corrosive or irritating properties need not be carried out.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B03web1992.pdf</reference><reference>http://www.oecd.org/dataoecd/17/46/1948333.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (dermal irritation/corrosion)</title>
    <id>48</id>
    <term>Acute toxicity (dermal irritation/corrosion) </term><definition>In the preparation of this updated method special attention was given to possible improvements in relation to animal welfare concerns and to the evaluation of all existing information on the test substance in order to avoid unnecessary testing in laboratory animals. This method includes the recommendation that prior to undertaking the described in vivo test for corrosion/irritation of the substance, a weight-of-the-evidence analysis be performed on the existing relevant data. Where insufficient data are available, they can be developed through application of sequential testing. The testing strategy includes the performance of validated and accepted in vitro tests and is provided as an Annex to this method. In addition, where appropriate, the successive, instead of simultaneous, application of the three test patches to the animal in the initial in vivo test is recommended.In the interest of both sound science and animal welfare, in vivo testing should not be undertaken until all available data relevant to the potential dermal corrosivity/irritation of the substance have been evaluated in a weight-of-the-evidence analysis. Such data will include evidence from existing studies in humans and/or laboratory animals, evidence of corrosivity/irritation of one or more structurally related substances or mixtures of such substances, data demonstrating strong acidity or alkalinity of the substance, and results from validated and accepted in vitro or ex vivo tests. This analysis should decrease the need for in vivo testing for dermal corrosivity/irritation of substances for which sufficient evidence already exists from other studies as to those two endpoints.A preferred sequential testing strategy, which includes the performance of validated and accepted in vitro or ex vivo tests for corrosion/irritation, is included as an Annex to this Method. The strategy was developed at, and unanimously recommended by the participants of, an OECD workshop, and has been adopted as the recommended testing strategy in the Globally Harmonised System for the Classification of Chemical Substances (GHS). It is recommended that this testing strategy be followed prior to undertaking in vivo testing. For new substances it is the recommended stepwise testing approach for developing scientifically sound data on the corrosivity/irritation of the substance. For existing substances with insufficient data on dermal corrosion/irritation, the strategy should be used to fill missing data gaps.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B04web2004.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (eye irritation/corrosion)</title>
    <id>49</id>
    <term>Acute toxicity (eye irritation/corrosion) </term><definition>Eye irritation: is the production of changes in the eye following the application of a test substance to the anterior surface of the eye, which are fully reversible within 21 days of application.Eye corrosion: is the production of tissue damage in the eye, or serious physical decay of vision, following application of a test substance to the anterior surface of the eye, which is not fully reversible within 21 days of application.The substance to be tested is applied in a single dose to one of the eyes of the experimental animal; the untreated eye serves as the control. The degree of eye irritation/corrosion is evaluated by scoring lesions of conjunctiva, cornea, and iris, at specific intervals. Other effects in the eye and adverse systemic effects are also described to provide a complete evaluation of the effects. The duration of the study should be sufficient to evaluate the reversibility or irreversibility of the effects.Animals showing continuing signs of severe distress and/or pain at any stage of the test should be humanely killed, and the substance assessed accordingly. Criteria for making the decision to humanely kill moribund and severely suffering animals can be found in reference.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B05web2004.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (fish)</title>
    <id>51</id>
    <term>Acute toxicity (fish)</term><definition>The purpose of this test is to determine the acute lethal toxicity of a substance to fish in fresh water. It is desirable to have, as far as possible, information on the water solubility , vapour pressure, chemical stability, dissociation constants and biodegradability of the substance to help in the selection of the most appropriate test method (static, semi-static or flow-through) for ensuring satisfactorily constant concentrations of the test substance over the period of the test.Additional information (for instance structural formula, degree of purity, nature and percentage of significant impurities, presence and amounts of additives, and n-octanol/water partition coefficient) should be taken into consideration in both the planning of the test and interpretation of the results.Acute fish toxicity is expressed as the median lethal concentration (LC50), that is the concentration in water which kills 50% of a test batch of fish within a continuous period of exposure which must be stated.All concentrations of the test substance are given in weight by volume (milligrams per liter). They may also be expressed as weight by weight (mg.kg-l).A limit test may be performed at 100 mg per liter in order to demonstrate that the LC50 is greater than this concentration.The fish are exposed to the test substance added to water at a range of concentrations for a period of 96 hours. Mortalities are recorded at least at 24-hour intervals, and the concentrations killing 50% of the fish (LC50) at each observation time are calculated where possible.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/C01web1992.pdf</reference><category>acute</category></page>
  <page>
    <title>Acute toxicity (inhalation)</title>
    <id>44</id>
    <term>Acute toxicity (inhalation)</term><definition>Several groups of experimental animals are exposed for a defined period to the test substance in graduated concentrations, one concentration being used per group. Subsequently observations of effects and deaths are made. Animals which die during the test are necropsied and at the conclusion of the test surviving animals are necropsied.Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Dosing test substances in a way known to cause marked pain and distress due to corrosive or severe irritating properties need not be carried out.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B02web1992.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity (skin sensitization)</title>
    <id>50</id>
    <term>Acute toxicity (skin sensitization)</term><definition>Skin sensitization: (allergic contact dermatitis) is an immunologically mediated cutaneous reaction to a substance. In the human, the responses may be characteris ed by pruritis, erythema, oedema, papules,vesicles, bullae or a combination of these. In other species the reactions may differ and only erythema and oedema may be seen.The test animals are initially exposed to the test substance by intradermal injections and/or epidermal application (induction exposure). Following a rest period of 10 to 14 days (induction period), during which an immune response may develop, the animals are exposed to a challenge dose. The extent and degree of skin reaction to the challenge exposure in the test animals is compared with that demonstrated by control animals which undergo sham treatment during induction and receive the challenge exposure.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B06web1996.pdf</reference><category>Acute</category></page>
  <page>
    <title>Acute toxicity - fixed dose procedure</title>
    <id>43</id>
    <term>Acute toxicity - fixed dose procedure</term><definition>Traditional methods for assessing acute toxicity use death of animals as an endpoint. In 1984, a new approach to acute toxicity testing was suggested by the British Toxicology Society based on the administration at a series of fixed dose levels. The approach avoided using death of animals as an endpoint, and relied instead on the observation of clear signs of toxicity at one of a series of fixed dose levels. Following UK and international in vivo validation studies the procedure was adopted as a testing method in 1992. Subsequently, the statistical properties of the Fixed Dose Procedure have been evaluated using mathematical models in a series of studies. Together, the in vivo and modelling studies have demonstrated that the procedure is reproducible, uses fewer animals and causes less suffering than the traditional methods and is able to rank substances in a similar manner to the other acute toxicity testing methods.</definition><reference>http://ecb.jrc.ec.europa.eu/documents/Testing-Methods/ANNEXV/B01bisweb2004.pdf</reference><category>Acute</category></page>
  <page>
    <title>Added (additional) risk</title>
    <id>387</id>
    <term>Relative risk </term><definition>&#160;      Relative risk&#160; (RR)&#160; - The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor.</definition><reference>http://www.geocities.com/HotSprings/3468/gloss96.html#ecological</reference><category>Risk</category></page>
  <page>
    <title>Addiction</title>
    <id>503</id>
    <term>Addiction</term><definition>The condition of being abnormally dependent on some habit, esp compulsive dependency on narcotic drugs.</definition><category>Adverse</category></page>
  <page>
    <title>Additional Risk (AR)</title>
    <id>301</id>
    <term>Additional Risk</term><definition>&#160; (AR) The difference between the cancer incidence under the exposure condition and the background incidence in the absence of exposure [8]. The calculated difference in risk of a particular condition between those who are exposed and those who are not. This measure is derived by subtracting the rate (usually incidence or mortality) of the disease among the unexposed persons (Pu) from the corresponding rate among the exposed (Pe), i.e., AR= Pe-Pu. The AR is an absolute measure of the excess risk attributed to exposure.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Risk</category></page>
  <page>
    <title>Adme</title>
    <id>495</id>
    <term>ADME</term><category>Adme</category></page>
  <page>
    <title>Administered dose</title>
    <id>922</id>
    <term>Administered dose</term><definition>The mass of a substance given to an organism and in contact with an exchange boundary (i.e., gastrointestinal tract) per unit wet body weight (BW) per unit time (e.g., mg/kgBW/day). In exposure assessment, the amount of a substance given to a test subject (human or animal) to determine dose-response relationships. Since exposure to chemicals is usually inadvertent, this quantity is often called potential dose.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Dose</category></page>
  <page>
    <title>Adrenal insufficiency</title>
    <id>504</id>
    <term>Adrenal insufficiency</term><definition>Conditions in which the production of adrenal corticosteroids falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the adrenal glands, the pituitary gland, or the hypothalamus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AdrenalInsufficiency</reference><category>Adverse</category></page>
  <page>
    <title>Adsorption</title>
    <id>304</id>
    <term>Adsorption</term><definition>Adsorption is the adhesion of molecules of gas, liquid, or dissolved solids to a surface. The term also refers to a method of treating wastes in which activated carbon is used to remove organic compounds from wastewater.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Adme</category></page>
  <page>
    <title>Adverse ecological effects</title>
    <id>440</id>
    <term>Adverse ecological effects</term><definition>Adverse ecological effects - Changes that are considered undesirable because they alter valued structural or functional characteristics of ecosystems or their components.</definition><category>Ecotox</category></page>
  <page>
    <title>Adverse effect</title>
    <id>916</id>
    <term>Adverse effect</term><definition>A biochemical change, functional impairment, or pathologic lesion that affects the performance of the whole organism, or reduces an organism's ability to respond to an additional environmental challenge. Any biochemical change, functional impairment, or pathologic lesion which impairs performance and reduces the ability of an organism to respond to additional challenge. An adverse effect may have different degrees of severity, and should be distinguished from adaptive (beneficial) effects and compensatory (neutral) effects. Change in the morphology, physiology, growth, development, reproduction or life span of an organism, system, or (sub) population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences. change in morphology, physiology, growth, development, or life span of an organism, which results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other environmental influences.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Adverse</category></page>
  <page>
    <title>Aerodynamic diameter</title>
    <id>302</id>
    <term>Aerodynamic diameter</term><definition>Expression of aerodynamic behavior of an irregularly shaped particle in terms of the diameter of an idealized particle; that is, aerodynamic diameter is the diameter of a sphere of unit density that has aerodynamic behavior identical to that of the particle in question. Thus, particles having the same aerodynamic diameter may have different dimensions and shapes. The diameter of a sphere with unit density that has aerodynamic behavior identical to that of the particle in question; an expression of aerodynamic behavior of an irregularly shaped particle in terms of the diameter of an idealized particle. Particles having the same aerodynamic diameter may have different dimensions and shapes.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Chemistry</category></page>
  <page>
    <title>Aerosol</title>
    <id>917</id>
    <term>Aerosol</term><definition>&#160;System in which the dispersion medium is a gas and the dispersed phase (composed of solid particles or liquid droplet) does not settle out under the influence of gravity [13]. A suspension of liquid or solid particles in air.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Chemistry</category></page>
  <page>
    <title>Aggregate risk</title>
    <id>385</id>
    <term>Aggregate risk                                                                                                                                                                                                             </term><definition>Aggregate risk The risk associated with all pathways &amp; routes of exposure to a single chemical.</definition><category>Risk</category></page>
  <page>
    <title>Aggression</title>
    <id>505</id>
    <term>Aggression</term><definition>A form of behavior which leads to self-assertion; it may arise from innate drives and/or a response to frustration; may be manifested by destructive and attacking behavior, by covert attitudes of hostility and obstructionism, or by healthy self-expressive drive to mastery.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Aggression</reference><category>Adverse</category></page>
  <page>
    <title>Agoraphobia</title>
    <id>507</id>
    <term>Agoraphobia</term><definition>Obsessive, persistent, intense fear of open places.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Agoraphobia</reference><category>Adverse</category></page>
  <page>
    <title>Agranulocytosis</title>
    <id>508</id>
    <term>Agranulocytosis</term><definition>A decrease in the number of granulocytes; (basophils; eosinophils; and neutrophils).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Agranulocytosis</reference><category>Adverse</category></page>
  <page>
    <title>Air monitoring</title>
    <id>919</id>
    <term>Air monitoring</term><definition>The continuous sampling for, and measuring of, pollutants present in the atmosphere. Periodic or continuous surveillance or testing to determine the level of compliance with statutory requirements and/or pollutant levels in various media or in humans, plants, and animals.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Risk</category></page>
  <page>
    <title>Air pollutant</title>
    <id>920</id>
    <term>Air pollutant</term><definition>Dust, fumes, mist, smoke and other particulate matter, vapor, gas, odorous substances, or any combination thereof; any air pollution agent or combination of such agents, including any physical, chemical, biological, radioactive (including source material, special nuclear material, and by-product material) substance or matter which is emitted into or otherwise enters the ambient air. Any substance in air that could, in high enough concentration, harm man, other animals, vegetation, or material. Pollutants may include almost any natural or artificial composition of airborne matter capable of being airborne. They may be in the form of solid particles, liquid droplets, gases, or in combination thereof. Generally, they fall into two main groups: (1) those emitted directly from identifiable sources and (2) those produced in the air by interaction between two or more primary pollutants, or by reaction with normal atmospheric constituents, with or without photoactivation. Exclusive of pollen, fog, and dust, which are of natural origin, about 100 contaminants have been identified. Air pollutants are often grouped in categories for ease in classification; some of he categories are: solids, sulfur compounds, volatile organic chemicals, particulate matter, nitrogen compounds, oxygen compounds, halogen compounds, radioactive compound, and odors.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Risk</category></page>
  <page>
    <title>Air pollution</title>
    <id>921</id>
    <term>Air pollution</term><definition>The contamination of the atmosphere by any toxic or radioactive gases and particulate matter as a result of human activity.</definition><reference>http://www.shsu.edu/~chemistry/Glossary/a.html#A</reference><category>Risk</category></page>
  <page>
    <title>Air quality criteria</title>
    <id>176</id>
    <term>Air quality criteria</term><definition>The levels of pollution and lengths of exposure above which adverse effects may occur on health and welfare.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Risk</category></page>
  <page>
    <title>Air quality standards</title>
    <id>177</id>
    <term>Air quality standards</term><definition>The level of pollutants prescribed by law or regulation that cannot be exceeded during a specified time in a defined area.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Standards</category></page>
  <page>
    <title>Airborne particulates</title>
    <id>848</id>
    <term>Airborne particulates</term><definition>Total suspended particulate matter found in the atmosphere as solid particles or liquid droplets. Chemical composition of particulates varies widely, depending on location and time of year. Airborne particulates include: windblown dust, emissions from industrial processes, smoke from the burning of wood and coal, and motor vehicle or non-road engine exhausts.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Chemistry</category></page>
  <page>
    <title>Akathisia, drug-induced</title>
    <id>509</id>
    <term>Akathisia, drug-induced</term><definition>A condition associated with the use of certain medications and characterized by an internal sense of motor restlessness often described as an inability to resist the urge to move.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AkathisiaDrugInduced</reference><category>Adverse</category></page>
  <page>
    <title>Akinesia</title>
    <id>510</id>
    <term>Akinesia</term><definition>Paralysis of the motor nerves; loss of movement.</definition><category>Adverse</category></page>
  <page>
    <title>Akinetic mutism</title>
    <id>511</id>
    <term>Akinetic mutism</term><definition>A syndrome characterized by a silent and inert state without voluntary motor activity despite preserved sensorimotor pathways and vigilance. Bilateral frontal lobe dysfunction involving the anterior cingulate gyrus and related brain injuries are associated with this condition. This may result in impaired abilities to communicate and initiate motor activities.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AkineticMutism</reference><category>Adverse</category></page>
  <page>
    <title>Albuminuria</title>
    <id>512</id>
    <term>Albuminuria</term><definition>The presence of albumin in the urine, an indicator of kidney diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Albuminuria</reference><category>Adverse</category></page>
  <page>
    <title>All Agriculture Jobs In India</title>
    <id>1363</id>
    <reference>http://thedirsite.com/SESS_yu1MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_all%2Bagriculture%2Bjobs%2Bin%2Bindia.html</reference><reference>http://www.vertaaldebijbel.nl/forum/topic.php?id=13</reference><reference>http://advancedpowers.com/wiki/index.php/Aol_Cutting_Jobs_2000</reference><reference>http://imakechange.com/bbpress/topic.php?id=444</reference><reference>http://buffwiki.org/index.php?title=Agriculture_Jobs_Ut</reference><reference>http://www.deadtomorrow.com/forum/topic.php?id=2466</reference><reference>http://wiki.electrolab.fr/Airborne_Jobs</reference><reference>http://lethbridgewiki.com/index.php?title=Airline_Jobs_Nh</reference></page>
  <page>
    <title>All Airforce Jobs And Discriptions</title>
    <id>1357</id>
    <reference>http://dawnloadonline.com/SESS_g0MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_all%2Bairforce%2Bjobs%2Band%2Bdiscriptions.html</reference><reference>http://sleepsexfetish.com/forum/topic/augusta-state-university-jobs</reference><reference>http://alumni.sjvc.edu/node/6555</reference><reference>http://www.letsdialogue.com/bbpress/topic.php?id=21</reference><reference>http://theoraclemachine.net/ach-specialist-jobs</reference><reference>http://www.watchnursejackieonline.com/content/acting-jobs-nashville-tn</reference></page>
  <page>
    <title>All Albuquerque Jobs Uklug Co Uk</title>
    <id>1355</id>
    <reference>http://awarefinance.com/SESS_2MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_all%2Balbuquerque%2Bjobs%2Buklug%2Bco%2Buk.html</reference><reference>http://fargo68.com/?q=node/26953</reference><reference>http://interact.ipcf.cnr.it/?q=en/node/75226</reference><reference>http://tineriibloggeri.com/forum/topic.php?id=21</reference><reference>http://miuniversidadculiacan.com/foro/bbpress/topic.php?id=10</reference><reference>http://husk.eecs.berkeley.edu/courses/cs298-52-sp11/index.php/Alticor_Jobs</reference><reference>http://invivus.at/foren/topic/bartending-jobs-baltimore</reference><reference>http://www.diywoodbuildings.com/forum/topic.php?id=6</reference><reference>http://www.h2web.at/wordpress/bbpress/topic.php?id=2579</reference><reference>http://www.greenvillagegreen.com/?q=content/accounting-jobs-los-angeles-ca</reference></page>
  <page>
    <title>All American Health Jobs</title>
    <id>1364</id>
    <reference>http://dawnloadonline.com/SESS_3elMjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_all%2Bamerican%2Bhealth%2Bjobs.html</reference><reference>http://renegadesupplements.com/content/accounting-jobs-san-antonio-tx-0</reference><reference>http://dixiehighway.us/index.php?title=Antiques_Jobs_In_Nyc</reference><reference>http://calgarycorporatechallenge.com/forum/topic.php?id=1283</reference><reference>http://forum.boxset.ru/topic.php?id=27</reference><reference>http://www.zalassalas.lv/forums/topic/bartending-jobs-in-el-paso</reference></page>
  <page>
    <title>Allen County Ft Wayne Jobs</title>
    <id>1359</id>
    <reference>http://mydrugdir.com/SESS_2igMjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_allen%2Bcounty%2Bft%2Bwayne%2Bjobs.html</reference><reference>http://www.storabilar.se/forum/topic/bartending-jobs-in-northern-new-jersey</reference><reference>http://www.hotcase.org/index.php?title=Alberta_Truck_Driving_Jobs</reference><reference>http://forum.cruxsoftware.co.uk/topic.php?id=7389</reference><reference>http://actuparchives.org/?q=node/4259</reference><reference>http://www.anjin.biz/forum/topic.php?id=18</reference></page>
  <page>
    <title>Allen County In Jobs</title>
    <id>1358</id>
    <reference>http://awarefinance.com/SESS_pv4MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_allen%2Bcounty%2Bin%2Bjobs.html</reference><reference>http://www.watchnursejackieonline.com/content/acting-jobs-nashville-tn</reference><reference>http://sleepsexfetish.com/forum/topic/augusta-state-university-jobs</reference><reference>http://deathknight.info/wiki/index.php?title=Alternative_Medicine_Jobs_Buffalo&amp;action=submit</reference><reference>http://www.letsdialogue.com/bbpress/topic.php?id=21</reference><reference>http://theoraclemachine.net/ach-specialist-jobs</reference><reference>http://dowhatyouloveandgetpaid.com/forum/topic.php?id=5</reference><reference>http://provokeclothing.com/forum/topic.php?id=2077</reference><reference>http://alumni.sjvc.edu/node/6555</reference></page>
  <page>
    <title>Allen County Indiana Ag Jobs</title>
    <id>1356</id>
    <reference>http://thedirsite.com/SESS_qy4MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_allen%2Bcounty%2Bindiana%2Bag%2Bjobs.html</reference><reference>http://www.hypnotistentertainment.com/forum/topic.php?id=8</reference><reference>http://www.selmanart.com/boards/bbpress/topic.php?id=12</reference><reference>http://issues.andy-walters.com/node/57487</reference><reference>http://www.facelift-pedia.com/forums/topic.php?id=33</reference><reference>http://cherryhill.elauwitmedia.com/forum/topic.php?id=3151</reference><reference>http://www.hillquest.com/forums/topic.php?id=80</reference><reference>http://reallyfreecreditreport.com/wiki/index.php?title=Apply_Online_To_Goodyear_Jobs</reference><reference>http://ultracentrifugation.org/index.php?title=American_Jobs_In_Uae</reference><reference>http://www.jdmsquad.com/foro/topic.php?id=22</reference><reference>http://www.michiganoldeblue.com/bbs/topic.php?id=3337</reference></page>
  <page>
    <title>Allen County Indiana Jobs</title>
    <id>1362</id>
    <reference>http://banansearch.com/SESS_z5MjE3fHwxMjk2MDgxOTYzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_allen%2Bcounty%2Bindiana%2Bjobs.html</reference><reference>http://buffwiki.org/index.php?title=Agriculture_Jobs_Ut</reference><reference>http://lethbridgewiki.com/index.php?title=Airline_Jobs_Nh</reference><reference>http://advancedpowers.com/wiki/index.php/Aol_Cutting_Jobs_2000</reference><reference>http://imakechange.com/bbpress/topic.php?id=444</reference><reference>http://wonderwiki.net/index.php?title=American_Airlines_Jobs</reference><reference>http://www.mac-dive.com/help/index.php?title=Amateur_Deep_Throat_Blow_Jobs</reference><reference>http://www.deadtomorrow.com/forum/topic.php?id=2466</reference><reference>http://www.vertaaldebijbel.nl/forum/topic.php?id=13</reference></page>
  <page>
    <title>Allergic contact dermatitis</title>
    <id>513</id>
    <term>Allergic contact dermatitis</term><definition>A contact dermatitis due to allergic sensitization to various substances. These substances subsequently produce inflammatory reactions in the skin of those who have acquired hypersensitivity to them as a result of prior exposure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AllergicContactDermatitis</reference><category>Adverse</category></page>
  <page>
    <title>Allergic reaction</title>
    <id>514</id>
    <term>Allergic reaction</term><definition>Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AllergicReaction</reference><category>Adverse</category></page>
  <page>
    <title>Alopecia</title>
    <id>515</id>
    <term>Alopecia (hair loss)</term><definition>Absence of hair from areas where it is normally present.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Alopecia</reference><category>Adverse</category></page>
  <page>
    <title>Amblyopia</title>
    <id>516</id>
    <term>Amblyopia</term><definition>A nonspecific term referring to impaired vision. Major subcategories include stimulus deprivation-induced amblyopia and toxic amblyopia. Stimulus deprivation-induced amblyopia is a developmental disorder of the visual cortex. A discrepancy between visual information received by the visual cortex from each eye results in abnormal cortical development.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Amblyopia</reference><category>Adverse</category></page>
  <page>
    <title>Amenorrhea</title>
    <id>517</id>
    <term>Amenorrhea</term><definition>Absence of menstruation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Amenorrhea</reference><category>Adverse</category></page>
  <page>
    <title>Amnesia</title>
    <id>518</id>
    <term>Amnesia</term><definition>Pathologic partial or complete loss of the ability to recall past experiences (amnesia, retrograde) or to form new memories (amnesia, anterograde).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Amnesia</reference><category>Adverse</category></page>
  <page>
    <title>Analysis</title>
    <id>850</id>
    <term>Analysis</term><definition>Detailed examination of anything complex made in order to understand its nature or to determine its essential features.</definition><category>Biology</category></page>
  <page>
    <title>Anaphylaxis</title>
    <id>519</id>
    <term>Anaphylaxis</term><definition>An acute hypersensitivity reaction due to exposure to a previously encountered antigen. The reaction may include rapidly progressing urticaria, respiratory distress, vascular collapse, systemic shock, and death.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Anaphylaxis</reference><category>Adverse</category></page>
  <page>
    <title>Anecdotal data</title>
    <id>918</id>
    <term>Anecdotal data</term><definition>Data based on the description of individual cases rather than controlled studies.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Risk</category></page>
  <page>
    <title>Anemia</title>
    <id>520</id>
    <term>Anemia</term><definition>A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Anemia</reference><category>Adverse</category></page>
  <page>
    <title>Anemia, aplastic</title>
    <id>521</id>
    <term>Anemia, aplastic</term><definition>A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AnemiaAplastic</reference><category>Adverse</category></page>
  <page>
    <title>Anemia, hemolytic</title>
    <id>522</id>
    <term>Anemia, hemolytic</term><definition>Substance induce anemia due to decreased life span of erythrocytes.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AnemiaHemolytic</reference><category>Adverse</category></page>
  <page>
    <title>Anemia, macrocytic</title>
    <id>523</id>
    <term>Anemia, macrocytic</term><definition>Anemia characterized by larger than normal erythrocytes, increased mean corpuscular volume (MCV) and increased mean corpuscular hemoglobin (MCH).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AnemiaMacrocytic</reference><category>Adverse</category></page>
  <page>
    <title>Anemia, megaloblastic</title>
    <id>524</id>
    <term>Anemia, megaloblastic</term><definition>A disorder characterized by the presence of anemia, abnormally large red blood cells (megalocytes or macrocytes), and megaloblasts.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AnemiaMegaloblastic</reference><category>Adverse</category></page>
  <page>
    <title>Anemia, sideroblastic</title>
    <id>525</id>
    <term>Anemia, sideroblastic</term><definition>Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AnemiaSideroblastic</reference><category>Adverse</category></page>
  <page>
    <title>Angioedema</title>
    <id>526</id>
    <term>Angioedema</term><definition>Swelling involving the deep dermis, subcutaneous, or submucosal tissues, representing localized edema. Angioedema often occurs in the face, lips, tongue, and larynx.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Angioedema</reference><category>Adverse</category></page>
  <page>
    <title>Antagonism</title>
    <id>178</id>
    <term>Antagonism</term><definition>Interference or inhibition of the effect of one chemical by the action of another. Antagonism: The ability of a substance to prevent or interfere with another substance interacting with its biological targets, thereby reducing or preventing its. When the effect of the combination is less than that suggested by the component toxic effects. Antagonism must be defined in the context of the definition of "no interaction," which is usually dose or response addition.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Biology</category></page>
  <page>
    <title>Anuria</title>
    <id>528</id>
    <term>Anuria</term><definition>Absence of urine formation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Anuria</reference><category>Adverse</category></page>
  <page>
    <title>Anxiety</title>
    <id>529</id>
    <term>Anxiety</term><definition>Feeling or emotion of dread, apprehension, and impending disaster but not disabling as with anxiety disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Anxiety</reference><category>Adverse</category></page>
  <page>
    <title>Apathy</title>
    <id>530</id>
    <term>Apathy</term><definition>Want of feeling; privation of passion, emotion, or excitement; dispassion; applied either to the body or the mind. As applied to the mind, it is a calmness, indolence, or state of indifference, incapable of being ruffled or roused to active interest or exertion by pleasure, pain, or passion.</definition><category>Adverse</category></page>
  <page>
    <title>Aphasia</title>
    <id>531</id>
    <term>Aphasia</term><definition>A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Aphasia</reference><category>Adverse</category></page>
  <page>
    <title>Apnea</title>
    <id>532</id>
    <term>Apnea</term><definition>A transient absence of spontaneous respiration.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Apnea</reference><category>Adverse</category></page>
  <page>
    <title>Appetite depressants</title>
    <id>527</id>
    <term>Appetite depressants</term><definition>Substance that leads to anorexia or diminished appetite, appetite suppressant.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AppetiteDepressants</reference><category>Adverse</category></page>
  <page>
    <title>Applied dose</title>
    <id>849</id>
    <term>Applied dose</term><definition>The amount of a substance in contact with the primary absorption boundaries of an organism (e.g., skin, lung, gastrointestinal tract) and available for absorption. In exposure assessment, the amount of a substance in contact with the primary absorption boundaries of an organism (e.g., skin, lung tissue, gastrointestinal track) and available for absorption. The amount of a substance presented to an absorption barrier (i.e., skin, lung, or digestive tract) and available for absorption, but not yet having crossed the outer boundary of an organism. The amount of a substance in contact with the primary absorption boundaries of an organism (e.g., skin, lung, gastrointestinal tract) and available for absorption. Applied Amount of chemical in as above Dermal: (mg chem/kg soil) (kg soil directly touching skin) (% (e.g., of chem in soil actually skin, lungs, gastrointestinal touching skin) = mg chem. touching skin) = mg chem. actually touching skin. Respiratory: lung) = mg chemical actually (&#181;g chem/m air) (m air mcg/m3 directly touching lung) (% of chemical actually touching lung absorption. Oral: (mg chem/kg food) (kg food consumed/day) (% of chemical touching g.i. tract) = mg chemical actually touching g.i. tract absorption (also absorbed dose rate: mg/day) chemical available to organ or cell (dose rate: mg chemical available to organ/day).</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Dose</category></page>
  <page>
    <title>Apraxia</title>
    <id>533</id>
    <term>Apraxia</term><definition>A group of cognitive disorders characterized by the inability to perform previously learned skills that cannot be attributed to deficits of motor or sensory function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Apraxia</reference><category>Adverse</category></page>
  <page>
    <title>Arachnoiditis</title>
    <id>534</id>
    <term>Arachnoiditis</term><definition>Acute or chronic inflammation of the arachnoid membrane of the meninges most often involving the spinal cord or base of the brain.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Arachnoiditis</reference><category>Adverse</category></page>
  <page>
    <title>Areflexia</title>
    <id>535</id>
    <term>Areflexia</term><definition>Absence of a reflex; a sign of possible nerve damage.</definition><category>Adverse</category></page>
  <page>
    <title>Arrhythmias, cardiac</title>
    <id>536</id>
    <term>Arrhythmias, cardiac</term><definition>Any disturbances of the normal rhythmic beating of the heart or myocardial contraction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=ArrhythmiasCardiac</reference><category>Adverse</category></page>
  <page>
    <title>Arthralgia</title>
    <id>537</id>
    <term>Arthralgia</term><definition>Pain in the joint.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Arthralgia</reference><category>Adverse</category></page>
  <page>
    <title>Arthritis</title>
    <id>538</id>
    <term>Arthritis</term><definition>Inflammation of a joint or joints.</definition><category>Adverse</category></page>
  <page>
    <title>Arthropathy</title>
    <id>539</id>
    <term>Arthropathy</term><definition>Any disease of the joints.</definition><category>Adverse</category></page>
  <page>
    <title>Ascites</title>
    <id>540</id>
    <term>Ascites</term><definition>Accumulation or retention of free fluid within the peritoneal cavity.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ascites</reference><category>Adverse</category></page>
  <page>
    <title>Aseptic meningitis</title>
    <id>541</id>
    <term>Aseptic meningitis</term><definition>A syndrome characterized by headache, neck stiffness, low grade fever, and CSF lymphocytic pleocytosis in the absence of an acute bacterial pathogen.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AsepticMeningitis</reference><category>Adverse</category></page>
  <page>
    <title>Aspiration pneumonia</title>
    <id>542</id>
    <term>Aspiration pneumonia</term><definition>A type of lung inflammation resulting from the aspiration&#160; into the upper respiratory tract.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AspirationPneumonia</reference><category>Adverse</category></page>
  <page>
    <title>Assessment</title>
    <id>179</id>
    <term>Assessment</term><definition>Evaluation or appraisal of an analysis of facts and the inference of possible consequences concerning a particular object or process. Combination of analysis of facts and inference of possible consequences concerning a particular object.</definition><category>Risk</category></page>
  <page>
    <title>Assessment endpoint</title>
    <id>851</id>
    <term>Assessment endpoint</term><definition>Qualitative/Quantitative expression of a specific factor with which a risk may be associated as determined through an appropriate risk assessment. Quantitative expression of a specific factor with which a risk may be associated as determined through an appropriate risk assessment. An explicit expression of the environmental value that is to be protected, operationally defined by an ecological entity and its attributes. For example, salmon are valued ecological entities; reproduction and age class structure are some of their important attributes. Together &#8220;salmon reproduction and age class structure&#8221; form an assessment endpoint.</definition><reference>http://www.epa.gov/OCEPAterms/aterms.html</reference><category>Endpoints</category></page>
  <page>
    <title>Assessment factor</title>
    <id>180</id>
    <term>Assessment factor</term><category>Risk</category></page>
  <page>
    <title>Asthenia</title>
    <id>837</id>
    <term>Asthenia</term><definition>Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Asthenia</reference><category>Adverse</category></page>
  <page>
    <title>Asthma</title>
    <id>543</id>
    <term>Asthma</term><definition>A form of bronchial disorder associated with airway obstruction, marked by recurrent attacks of paroxysmal dyspnea, with wheezing due to spasmodic contraction of the bronchi.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Asthma</reference><category>Adverse</category></page>
  <page>
    <title>Ataxia</title>
    <id>545</id>
    <term>Ataxia</term><definition>Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ataxia</reference><category>Adverse</category></page>
  <page>
    <title>Atrial flutter</title>
    <id>546</id>
    <term>Atrial flutter</term><definition>Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AtrialFlutter</reference><category>Adverse</category></page>
  <page>
    <title>Atrioventricular block</title>
    <id>547</id>
    <term>Atrioventricular block</term><definition>Impaired impulse conduction from heart atria to heart ventricles. AV block can mean delayed or completely blocked impulse conduction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=AtrioventricularBlock</reference><category>Adverse</category></page>
  <page>
    <title>Attributable risk</title>
    <id>854</id>
    <term>Attributable risk</term><definition>The rate of a disease in exposed individuals that can be attributed to the exposure. This measure is derived by subtracting the rate (usually incidence or mortality) of the disease among nonexposed persons from the corresponding rate among exposed individuals.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Risk</category></page>
  <page>
    <title>Average daily dose</title>
    <id>435</id>
    <term>Average daily dose</term><definition>Average daily dose (ADD) - Dose rate averaged over a pathway-specific period of exposure expressed as a daily dose on a per-unit-body-weight basis.</definition><reference>http://www.epa.gov/iris/gloss8.htm).</reference><category>Dose</category></page>
  <page>
    <title>Back pain</title>
    <id>45</id>
    <term>Back pain</term><definition>Acute or chronic pain located in the posterior regions of the thorax; lumbosacral region; or the adjacent regions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Backaches</reference><category>Adverse</category></page>
  <page>
    <title>Background level</title>
    <id>852</id>
    <term>Background level</term><definition>1. In air pollution, the level of pollutants present in ambient air from natural sources. 2. More generally, the level of pollution present in any environmental medium attributable to natural or ubiquitous sources. &#160;Two types of background levels may exist for chemical substances: (a) Naturally occurring levels: Ambient concentrations of substances present in the environment, without human influence; (b) Anthropogenic levels: Concentrations of substances present in the environment due to human-made, non-site sources (e.g., automobiles, industries). The amount of an agent in a medium (e.g., water, soil) that is not attributed to the source(s) under investigation in an exposure assessment. Can be naturally occurring or anthropogenic.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><reference>http://extoxnet.orst.edu/faqs/glossary.htm</reference><category>Epidemiology</category></page>
  <page>
    <title>Bacterial infection</title>
    <id>46</id>
    <term>Bacterial infection</term><definition>Infections by bacteria, general or unspecified.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Bacterial+infection</reference><category>Adverse</category></page>
  <page>
    <title>Baseline risk assessment</title>
    <id>853</id>
    <term>Baseline risk assessment</term><definition>A baseline risk assessment is an assessment conducted before cleanup activities begin at a site to identify and evaluate the threat to human health and the environment.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm</reference><category>Risk</category></page>
  <page>
    <title>Behavioral symptoms</title>
    <id>550</id>
    <term>Behavioral symptoms</term><definition>Observable manifestations of impaired psychological functioning.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BehavioralSymptoms</reference><category>Adverse</category></page>
  <page>
    <title>Benchmark Dose (BMD) or Concentration (BMC)</title>
    <id>181</id>
    <term>Benchmark Dose or Concentration </term><definition>Benchmark Dose (BMD) or Concentration (BMC) A dose or concentration that produces a predetermined change in response rate of an adverse effect (called the benchmark response or BMR) compared to background.</definition><reference>http://permanent.access.gpo.gov/lps38234/cfpub.epa.gov/ncea/cfm/bmds.cfm-ActType=default.htm</reference><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Dose</category></page>
  <page>
    <title>Benchmark Response (BMR)</title>
    <id>182</id>
    <term>Benchmark Response </term><definition>(BMR) An adverse effect, used to define a benchmark dose from which an RfD (or RfC) can be developed. The change in response rate over background of the BMR is usually in the range of 5-10%, which is the limit of responses typically observed in well-conducted animal experiments.</definition><reference>http://permanent.access.gpo.gov/lps38234/cfpub.epa.gov/ncea/cfm/bmds.cfm-ActType=default.htm</reference><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><category>Adverse</category></page>
  <page>
    <title>Benefit</title>
    <id>855</id>
    <term>Benefit</term><definition>The degree to which effects are judged desirable. The change in the baseline value of each decision objective as a result of implementing a decision option. For comparison of benefits across decision objectives, benefits for individual decision objectives will have to be normalized, using a scaling function. Benefits may be unrelated to a&#1077; consistent with external preferences. For any given decision objective, benefits may increase (desirable), decrease (undesirable), or remain the same following implementation of a decision option.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Risk</category></page>
  <page>
    <title>Best Available Control Measures (BACM)</title>
    <id>190</id>
    <term>Best Available Control Measures</term><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Best Available Control Technology (BACT)</title>
    <id>191</id>
    <term>Best Available Control Technology </term><definition>(BACT) For any specific source, the currently available technology producing the greatest reduction of air pollutant emissions,taking into account energy, environmental, economic, and other costs. The most stringent technology available for controlling emissions; major sources are required to use BACT, unless it can be demonstrated that it is not feasible for energy, environmental, or economic reasons.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Developmentaltox</category></page>
  <page>
    <title>Best Demonstrated Available Technology (BDAT)</title>
    <id>85</id>
    <term>Best Demonstrated Available Technology</term><definition>As identified by EPA, the most effective commercially available means of treating specific types of hazardous waste. The BDATs may change with advances in treatment technologies.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Developmentaltox</category></page>
  <page>
    <title>Best Management Practice (BMP)</title>
    <id>192</id>
    <term>Best Management Practice</term><definition>Methods that have been determined to be the most effective, practical means of preventing or reducing pollution from non-point sources.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Developmentaltox</category></page>
  <page>
    <title>Bias</title>
    <id>86</id>
    <term>Bias</term><definition>Any difference between the true value and that actually obtained due to all causes other than sampling variability.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Developmentaltox</category></page>
  <page>
    <title>Bioaccumulation</title>
    <id>193</id>
    <term>Bioaccumulation</term><definition>General term describing a process by which chemicals are taken up by an organism either directly from exposure to a contaminated medium or by consumption of food containing the chemical. 1. The process whereby certain toxic substances collect in living tissues, thus posing substantial hazard to human health or the environment. Bioaccumulation is the process by which chemicals concentrate in an organism. For example, DDT concentrates in fish and birds that eat fish. This concentration effect is expressed as the ratio of the concentration of the chemical in an organism (like a fish) to its concentration in the surrounding medium (usually water). Bioaccumulation refers to the uptake of chemicals both from water (bioconcentration) and from ingested food and sediment. The accumulation within living organisms of toxic substances occuring in the environment.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><reference>http://extoxnet.orst.edu/faqs/glossary.htm</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#b</reference><category>Ecotox</category></page>
  <page>
    <title>Bioassay</title>
    <id>194</id>
    <term>Bioassay</term><definition>Using living organisms to measure the effect of a substance, factor, or condition.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Developmentaltox</category></page>
  <page>
    <title>Bioavailability</title>
    <id>195</id>
    <term>Bioavailability</term><definition>The degree to which an agent is capable of being absorbed by an organism and available for metabolism or interaction with biologically significant receptors. Bioavailability involves both release from a medium (if present) and absorption by an organism. Degree of ability to be absorbed and ready to interact in organism metabolism.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#b</reference><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Bioconcentration</title>
    <id>89</id>
    <term>Bioconcentration</term><definition>Bioaccumulation is the process by which chemicals concentrate in an organism. The accumulation of a chemical in tissues of a fish or other organism to levels greater than in the surrounding medium. For example, DDT concentrates in fish and birds that eat fish. This concentration effect is expressed as the ratio of the concentration of the chemical in an organism (like a fish) to its The tendency of a chemical to accumulate in a living organism to levels in excess of the concentration in its surrounding environment.  Bioconcentration factor (BCF) - provides a measure of the extent of chemical partitioning at equilibrium between a biological medium such as fish tissue or plant tissue and an external medium such as water. The higher the BCF, the greater the likely accumulation in living tissue.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#b</reference><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Biologic indicator</title>
    <id>93</id>
    <term>Biologic indicator</term><definition>Species or group of species which is representative and typical for a specific status of an ecosystem, which appears frequently enough to serve for monitoring and whose population shows a sensitive response to changes, e.g. the appearance of a pesticide in the ecosystem. A study that uses (a) biomedical testing or (b) the measurement of a substance (an analyte), its metabolite, or another marker of exposure in human body fluids or tissues to confirm human exposure to a hazardous substance.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-A</reference><category>Ecotox</category></page>
  <page>
    <title>Biologic monitoring</title>
    <id>92</id>
    <term>Biologic monitoring</term><definition>Text providing a definition of term (Normal paragraph formatMeasuring hazardous substances in biologic materials (such as blood, hair, urine, or breath) to determine whether exposure has occurred. A blood test for lead is an example of biologic monitoring.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-A</reference><category>Risk</category></page>
  <page>
    <title>Biological control</title>
    <id>91</id>
    <term>Biological control</term><definition>In pest control, the use of animals and organisms that eat or otherwise kill or out-compete pests.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Risk</category></page>
  <page>
    <title>Biological half life</title>
    <id>90</id>
    <term>Biological half life</term><definition>Biological half-life The time required for a biological system (such as a human or animal) to eliminate, by natural processes, half the amount of a substance (such as a radioactive material) that has been absorbed into that system indicators of exposure study. &#160;Refers to the process whereby certain substances such as pesticides or heavy metals move up the food chain, work their way into rivers or lakes, and are eaten by aquatic organisms such as fish, which in turn are eaten by large birds, animals or humans. The substances become concentrated in tissues or internal organs as they move up the chain.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Endpoints</category></page>
  <page>
    <title>Biological magnification</title>
    <id>196</id>
    <term>Biological magnification</term><definition>The concentration of certain substances up a food chain. A very important mechanism in concentrating pesticides and heavy metals in organisms such as fish. Refers to the process whereby certain substances such as pesticides or heavy metals move up the food chain, work their way into rivers or lakes, and are eaten by aquatic organisms such as fish, which in turn are eaten by large birds, animals or humans. The substances become concentrated in tissues or internal organs as they move up the chain.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Biomarker</title>
    <id>94</id>
    <term>Biomarker</term><definition>Indicator (molecular, biochemical, cellular or organism) signaling an event or condition in a biological system or sample and giving a measure of exposure to, effect of, or susceptibility to, a xenobiotic. Biochemical, physiological, and histological changes in organisms that can be used to estimate either exposure to chemicals or the effects of exposure to chemicals.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#b</reference><category>Biology</category></page>
  <page>
    <title>Biota</title>
    <id>95</id>
    <term>Biota</term><definition>The sum total of the living organisms of any designated area.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Biology</category></page>
  <page>
    <title>Biotransformation</title>
    <id>856</id>
    <term>Biotransformation</term><definition>Conversion of a substance into other compounds by organisms; includes biodegredation.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Adme</category></page>
  <page>
    <title>Bipolar Disorder</title>
    <id>402</id>
    <term>Bipolar Disorder</term><definition>A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BipolarDisorder</reference><category>Adverse</category></page>
  <page>
    <title>Blepharitis</title>
    <id>551</id>
    <term>Blepharitis</term><definition>Inflammation of the eyelids.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Blepharitis</reference><category>Adverse</category></page>
  <page>
    <title>Blepharospasm</title>
    <id>552</id>
    <term>Blepharospasm</term><definition>Excessive winking; tonic or clonic spasm of the orbicularis oculi muscle.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Blepharospasm</reference><category>Adverse</category></page>
  <page>
    <title>Blindness</title>
    <id>553</id>
    <term>Blindness</term><definition>The inability to see or the loss or absence of perception of visual stimuli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Blindness</reference><category>Adverse</category></page>
  <page>
    <title>Blisters</title>
    <id>554</id>
    <term>Blisters</term><definition>Visible accumulations of fluid within or beneath the epidermis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Blisters</reference><category>Adverse</category></page>
  <page>
    <title>Bloating</title>
    <id>626</id>
    <term>Bloating</term><definition>Abdominal distention from swallowed air or intestinal gas from fermentation. As a symptom, the patient feels a full and tight abdomen, which may cause abdominal pain sometimes accompanied by borborygmus.</definition><category>Adverse</category></page>
  <page>
    <title>Body burden</title>
    <id>857</id>
    <term>Body burden</term><definition>The total amount of a specific substance (for example, lead) in an organism, including the amount stored, the amount that is mobile, and the amount absorbed. The amount of a chemical stored in the body at a given time, especially a potential toxin in the body as the result of exposure. The concentration or total amount of a substance in a living organism; implies accumulation of a substance above background levels in exposed organisms.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#b</reference><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Adme</category></page>
  <page>
    <title>Bone marrow suppression</title>
    <id>625</id>
    <term>Bone marrow suppression</term><definition>Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine. NSAIDS may also cause bone marrow suppression. The risk is especially high in chemotherapy for leukaemia.</definition><category>Adverse</category></page>
  <page>
    <title>Bone pain</title>
    <id>624</id>
    <term>Bone pain</term><definition>Bone pain (or Ostealgia, or Osteodynia) is generally referred to as having pain within the affected bone. The cause of bone pain is unknown, unless further testing is done.</definition><category>Adverse</category></page>
  <page>
    <title>Bounding estimate</title>
    <id>96</id>
    <term>Bounding estimate</term><definition>An estimate of exposure, dose, or risk that is higher than that incurred by the person with the highest exposure, dose or risk in the population being assessed. Bounding estimates are useful in developing statements that exposures, doses, or risks are "not greater than" the estimated value.</definition><reference>http://www.epa.gov/OCEPAterms/bterms.html</reference><category>Risk</category></page>
  <page>
    <title>Bradycardia</title>
    <id>555</id>
    <term>Bradycardia</term><definition>Cardiac arrhythmias that are characterized by excessively slow heart rate, usually below 50 beats per minute in human adults. They can be classified broadly into sinoatrial node dysfunction and atrioventricular block.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Bradycardia</reference><category>Adverse</category></page>
  <page>
    <title>Bradypnea</title>
    <id>623</id>
    <term>Bradypnea</term><definition>Abnormally slow breathing rate.</definition><category>Adverse</category></page>
  <page>
    <title>Bronchiolitis obliterans</title>
    <id>558</id>
    <term>Bronchiolitis obliterans</term><definition>Inflammation of the bronchioles with obstruction by fibrous granulation tissue or bronchial exudate.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BronchiolitisObliterans</reference><category>Adverse</category></page>
  <page>
    <title>Bronchitis</title>
    <id>559</id>
    <term>Bronchitis</term><definition>Inflammation of the large airways in the lung including any part of the bronchi, from the primary bronchi to the tertiary bronchi.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Bronchitis</reference><category>Adverse</category></page>
  <page>
    <title>Bronchoconstriction</title>
    <id>560</id>
    <term>Bronchoconstriction</term><definition>Narrowing of the caliber of the bronchi, physiologically or as a result of pharmacological intervention.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Bronchoconstriction</reference><category>Adverse</category></page>
  <page>
    <title>Bullous dermatosis</title>
    <id>561</id>
    <term>Bullous dermatosis</term><definition>Skin diseases characterized by local or general distributions of blisters.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BullousDermatosis</reference><category>Adverse</category></page>
  <page>
    <title>Bullous pemphigoid</title>
    <id>562</id>
    <term>Bullous pemphigoid</term><definition>A chronic and relatively benign subepidermal blistering disease usually of the elderly and without histopathologic acantholysis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BullousPemphigoid</reference><category>Adverse</category></page>
  <page>
    <title>Bundle-branch block</title>
    <id>447</id>
    <term>Bundle-branch block</term><definition>A form of heart block in which one ventricle is excited before the other because of absence of conduction in one of the branches of the bundle of his.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=BundleBranchBlock</reference><category>Adverse</category></page>
  <page>
    <title>Burns</title>
    <id>564</id>
    <term>Burns</term><definition>Injuries to tissues caused by contact with heat, steam, chemicals (burns, chemical), electricity (burns, electric), or the like.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Burns</reference><category>Adverse</category></page>
  <page>
    <title>CAS (Chemical Abstracts Service registry number)</title>
    <id>457</id>
    <term>CAS (Chemical Abstracts Service registry number) </term><definition>The Chemical Abstract Services unique number for each chemical. It can be used to search for a specific chemical regardless of the choice of chemical name.</definition><reference>http://www.cas.org/aboutcas/faq.html</reference><category>Chemistry</category></page>
  <page>
    <title>CERCLA (Comprehensive Environmental Restoration and Compensation Liability Act)</title>
    <id>858</id>
    <term>CERCLA </term><definition>(Comprehensive Environmental Restoration and Compensation Liability Act) Cleanup Program focuseson human health and environmental concerns related to human health. The cleanupprogram is primarily carried out by EPA, working with States, on sitesdesignated for cleanup on the NPL. Cleanup Program emphasizes local sourcecontrol, prevention of further spread from sources. Cleanup Program isprohibited from "restoring" natural resources, although cleanup mayprevent further injuries to natural resources. CERCLA, also known as Superfund, is the federal law that concerns the removal or cleanup of hazardous substances in the environment and at hazardous waste sites. ATSDR, which was created by CERCLA, is responsible for assessing health issues and supporting public health activities related to hazardous waste sites or other environmental releases of hazardous substances. This law was later amended by the  Superfund Amendments and Reauthorization Act (SARA) .</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.atsdr.cdc.gov/glossary.html#Comprehensive%20Environmental%20Response</reference><category>Regulatory</category></page>
  <page>
    <title>C A S E Jobs</title>
    <id>1370</id>
    <reference>http://godsearchs.com/SESS_fi7MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_c%2Ba%2Bs%2Be%2Bjobs.html</reference><reference>http://www.skirgaila.lt/akomanda/index.php?title=Cairns_Junior_Jobs</reference><reference>http://algorithmsnyc.org/index.php/Car_Paint_Jobs_In_Harford_County</reference><reference>http://www.pokerbastards.com/forum/topic.php?id=27</reference><reference>http://haygon.atlanticanomaly.com/forum/topic.php?id=2317</reference><reference>http://mediawikihost.com/index.php?title=Book_Proofreaders_Jobs_Work_From_Home</reference><reference>http://www.dkindustrial.net/TheWiki/index.php?title=Branson_Landing_Jobs</reference><reference>http://macroscope.world.coocan.jp/wiki/index.php?title=Business_Advisor_Jobs_Chicago</reference><reference>http://www.phoviet.com/forums/topic.php?id=2320</reference><reference>http://wiki.tattoo.tv/index.php?title=Boob_Jobs_In_Oregon</reference></page>
  <page>
    <title>C And Matlab And Resume Jobs</title>
    <id>1373</id>
    <reference>http://allforresult.com/SESS_gw7MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_c%2Band%2Bmatlab%2Band%2Bresume%2Bjobs.html</reference><reference>http://www.alembicgrimoire.org/wiki/index.php?title=Caretaking_Jobs</reference><reference>http://www.openpalace.org/wiki/Call_Centers_Jobs_Ca</reference><reference>http://gaminglist.org/index.php?title=Career_Jobs_Online_Games_For_Kids</reference><reference>http://opiskelijatoiminta.net/foorumi/topic.php?id=94</reference><reference>http://www.goodwilldenver.org/user/profile/iridnat</reference><reference>http://aldousxml.com/forum/topic.php?id=13</reference><reference>http://gourbangreen.com/drupal/?q=node/3259</reference></page>
  <page>
    <title>C Aptain Jobs</title>
    <id>1374</id>
    <reference>http://awarefinance.com/SESS_sx8MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_c%2Baptain%2Bjobs.html</reference><reference>http://ismdoug.com/content/bhp-jobs</reference><reference>http://www.esenthel.com/wiki/index.php?title=Canton_Texas_Jobs</reference><reference>http://www.blacktriangles.com/wiki/index.php?title=Cardiovascular_Technologist_Jobs</reference><reference>http://estore.my/forum/topic.php?id=3102</reference><reference>http://web.icicom.up.pt/mediawiki/index.php/Cal_Air_Guard_Jobs</reference><reference>http://www.omapedia.org/wiki/California_Surveying_Jobs</reference><reference>http://www.coffeepartyusa.com/content/bexar-county-justice-center-jobs</reference></page>
  <page>
    <title>C B Richard Ellis Jobs</title>
    <id>1367</id>
    <reference>http://banansearch.com/SESS_im9MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_c%2Bb%2Brichard%2Bellis%2Bjobs.html</reference><reference>http://www.forum.inse.in/topic.php?id=43</reference><reference>http://foodklub.com/index.php?title=Borger_Patrol_Jobs</reference><reference>http://www.darkheavenisle.com/?q=node/1458</reference><reference>http://www.sapientbizresources.com/Blog/bbpress/topic.php?id=10</reference><reference>http://wiki.tattoo.tv/index.php?title=Boob_Jobs_In_Slovakia</reference><reference>http://cypher.extremecast.com/wiki/index.php/Caroline_Jobs</reference><reference>http://www.ourkilcock.ie/forum/topic/city-of-copperas-cove-jobs</reference><reference>http://feedback.pdxradio.com/topic/city-of-petersburg-jobs-virginia</reference></page>
  <page>
    <title>Cable Jobs In Buffalo Ny</title>
    <id>1375</id>
    <reference>http://mydrugdir.com/SESS_9d3MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_cable%2Bjobs%2Bin%2Bbuffalo%2Bny.html</reference><reference>http://estore.my/forum/topic.php?id=3102</reference><reference>http://www.blacktriangles.com/wiki/index.php?title=Cardiovascular_Technologist_Jobs</reference><reference>http://ismdoug.com/content/bhp-jobs</reference><reference>http://web.icicom.up.pt/mediawiki/index.php/Cal_Air_Guard_Jobs</reference><reference>http://www.thaiclimbing.com/forum/topic.php?id=33</reference><reference>http://www.esenthel.com/wiki/index.php?title=Canton_Texas_Jobs</reference><reference>http://nc.jsa.org/forum/topic.php?id=42</reference><reference>http://www.omapedia.org/wiki/California_Surveying_Jobs</reference><reference>http://www.nzconnections.net.nz/Blue_Care_Network_Michigan_Jobs</reference><reference>http://www.coffeepartyusa.com/content/bexar-county-justice-center-jobs</reference></page>
  <page>
    <title>Cable Jobs In Dallas</title>
    <id>1372</id>
    <reference>http://godsearchs.com/SESS_jd6MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_cable%2Bjobs%2Bin%2Bdallas.html</reference><reference>http://doc.ginkgo-cadx.com/index.php?title=Capital_University_Jobs</reference><reference>http://www.wearsideyfc.co.uk/forum/topic.php?id=50</reference><reference>http://www.andamany.pl/bbpress/topic.php?id=961</reference><reference>http://forum.tweeplotto.com/topic.php?id=16</reference><reference>http://boardwalkempirewiki.com/index.php5?title=Bseet_Jobs</reference><reference>http://cone.informatik.uni-freiburg.de/dynamo09/index.php/Cairns_Entry_Level_Jobs</reference><reference>http://drupalway.com/node/9727</reference><reference>http://wiki.umonya.co.za/wiki/Brown_County_Indiana_Jobs</reference></page>
  <page>
    <title>Cable Jobs In Edmonton Canada</title>
    <id>1368</id>
    <reference>http://banansearch.com/SESS_68sMjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_cable%2Bjobs%2Bin%2Bedmonton%2Bcanada.html</reference><reference>http://phoenix.dn.ua/forum/topic.php?id=13</reference><reference>http://www.rgbn.org.uk/wiki/black-hood-jobs</reference><reference>http://www.naslinux.org/index.php/Career_Builder_Com_Kansas_City_Jobs</reference><reference>http://www.donghuong.net/node/128989</reference><reference>http://www.mnalibrary.org/mnahistory/Cad_Aerospace_Jobs</reference><reference>http://www.playstationwiki.com/index.php?title=Brwing_Jobs_In_Germany</reference></page>
  <page>
    <title>Cable Jobs In Fort Worth Texas</title>
    <id>1371</id>
    <reference>http://bestentrypoint.com/SESS_c52MjE3fHwxMjk2MDk3MzMzfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_cable%2Bjobs%2Bin%2Bfort%2Bworth%2Btexas.html</reference><reference>http://www.phoviet.com/forums/topic.php?id=2320</reference><reference>http://haygon.atlanticanomaly.com/forum/topic.php?id=2317</reference><reference>http://mediawikihost.com/index.php?title=Book_Proofreaders_Jobs_Work_From_Home</reference><reference>http://www.pokerbastards.com/forum/topic.php?id=27</reference><reference>http://macroscope.world.coocan.jp/wiki/index.php?title=Business_Advisor_Jobs_Chicago</reference><reference>http://www.dkindustrial.net/TheWiki/index.php?title=Branson_Landing_Jobs</reference><reference>http://algorithmsnyc.org/index.php/Car_Paint_Jobs_In_Harford_County</reference><reference>http://www.skirgaila.lt/akomanda/index.php?title=Cairns_Junior_Jobs</reference><reference>http://wiki.tattoo.tv/index.php?title=Boob_Jobs_In_Oregon</reference></page>
  <page>
    <title>Cancer</title>
    <id>324</id>
    <term>Cancer</term><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Cancer risk (inhalation)</title>
    <id>106</id>
    <term>Cancer risk (inhalation)</term><definition>The cancer risk from inhalation exposure, CR(inhal) is the 1 in 10,000 (E-4) lifetime excess cancer risk following exposure by inhalation (expressed in microgram/cu.m), as derived by RIVM. For comparison purposes on ITER, this value has been converted to a 1 in 100,000 (E-5) risk level, and has also been converted to milligrams/cu.m.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-A-</reference><category>Dose</category></page>
  <page>
    <title>Cancer risk (oral)</title>
    <id>925</id>
    <term>Cancer risk (oral)</term><definition>Cancer Risk CR(oral) The cancer risk from oral exposure, CR(oral) is the 1 in 10,000 (E-4) lifetime excess cancer risk following oral exposure (expressed in microgram/kg bw-day), as derived by RIVM. For comparison purposes on ITER, this value has been converted to a 1 in 100,000 (E-5) risk level, and has also been converted to milligrams/kg-day.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-A-</reference><category>Dose</category></page>
  <page>
    <title>Capillary leak syndrome</title>
    <id>565</id>
    <term>Capillary leak syndrome</term><definition>A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Capillary</reference><category>Adverse</category></page>
  <page>
    <title>Carcinogen</title>
    <id>323</id>
    <term>Carcinogen</term><reference>http://rais.ornl.gov/homepage/glossary.shtml</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Carcinogenesis</title>
    <id>325</id>
    <term>Carcinogenesis</term><definition>Development of carcinoma or, in more recent usage, producing any kind of malignancy.</definition><reference>http://www.bio.hw.ac.uk/edintox/glossall.htm</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Carcinogenic</title>
    <id>326</id>
    <term>Carcinogenic</term><definition>any agent (chemical, physical or biological?), that can act on living tissue in such a way as to cause a malignant neoplasm.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Carcinogenic potency</title>
    <id>322</id>
    <term>Carcinogenic potency</term><definition>&#1058;he gradient of the dose-response curve for a carcinogen.</definition><reference>http://rais.ornl.gov/homepage/glossary.shtml</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Carcinogenic risk</title>
    <id>388</id>
    <term>Carcinogenic risk</term><reference>http://risk.lsd.ornl.gov/homepage/glossary.shtml#Health%20effect)</reference><category>Risk</category></page>
  <page>
    <title>Cardiac tamponade</title>
    <id>566</id>
    <term>Cardiac tamponade</term><definition>Compression of the heart by accumulated fluid (pericardial effusion) or blood (hemopericardium) in the pericardium surrounding the heart.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiactamponade</reference><category>Adverse</category></page>
  <page>
    <title>Cardiogenic shock</title>
    <id>567</id>
    <term>Cardiogenic shock</term><definition>Shock resulting from diminution of cardiac output in heart disease.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiogenicshock</reference><category>Adverse</category></page>
  <page>
    <title>Cardiomegaly</title>
    <id>568</id>
    <term>Cardiomegaly</term><definition>Enlargement of the heart, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both heart ventricles or heart atria. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (heart failure) or several forms of cardiomyopathies.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiomegaly</reference><category>Adverse</category></page>
  <page>
    <title>Cardiomyopathy</title>
    <id>569</id>
    <term>Cardiomyopathy</term><definition>A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself. Cardiomyopathies are classified according to their predominant pathophysiological features (dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy) or their etiological/pathological factors (cardiomyopathy, alcoholic; endocardial fibroelastosis).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiomyopathy</reference><category>Adverse</category></page>
  <page>
    <title>Cardiomyopathy, dilated</title>
    <id>570</id>
    <term>Cardiomyopathy, dilated</term><definition>A form of cardiac muscle disease that is characterized by ventricular dilation, contractile dysfunction of the left or both heart ventricles, and congestive heart failure (heart failure, congestive) symptoms.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiomyopathydilated</reference><category>Adverse</category></page>
  <page>
    <title>Cardiotoxins</title>
    <id>571</id>
    <term>Cardiotoxins</term><definition>Agents that have a damaging effect on the heart. Such damage can occur from alkylating agents; free radicals; or metabolites from oxidative stress and in some cases is countered by cardiotonic agents. induction of long QT syndrome or torsades de pointes has been the reason for viewing some drugs as cardiotoxins.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cardiotoxins</reference><category>Adverse</category></page>
  <page>
    <title>Carpal tunnel syndrome</title>
    <id>572</id>
    <term>Carpal tunnel syndrome</term><definition>Entrapment of the median nerve in the carpal tunnel, which is formed by the flexor retinaculum and the carpal bones. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers which may radiate proximally. Impairment of sensation in the distribution of the median nerve and thenar muscle atrophy may occur.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Carpaltunnelsyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Case-control study</title>
    <id>197</id>
    <term>Case-control study</term><definition>Term (Heading format) An inquiry in whichgroups of individuals are selected in terms of whether they do (the cases) ordo not (the controls) have the disease of which the etiology is to be studied,and the groups are then compared with respect to existing or pastcharacteristics judged to be of possible relevance to the etiology of thedisease. A study in which the risk factors of people with a diseaseare compared with those without a disease. Case control studies selectsubjects based on their disease status. The study population is comprised ofindividuals that are disease positive, while the controls are disease negative.The case control study then looks back through time at potential exposuresthese populations may have encountered. A study that compares exposures of people who have a disease or condition (cases) with people who do not have the disease or condition (controls). Exposures that are more common among the cases may be considered as possible risk factors for the disease.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-A-</reference><category>Developmentaltox</category></page>
  <page>
    <title>Case-fatality rate</title>
    <id>789</id>
    <term>Case-fatality rate</term><definition>A ratio of the number of deaths due to a disease to the number of cases of that disease in a specified period of time. It expresses the frequency with which affected individuals die of the disease.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Cataract</title>
    <id>573</id>
    <term>Cataract</term><definition>Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cataract</reference><category>Adverse</category></page>
  <page>
    <title>Catatonia</title>
    <id>574</id>
    <term>Catatonia</term><definition>A neuropsychiatric disorder characterized by one or more of the following essential features: immobility, mutism, negativism (active or passive refusal to follow commands), mannerisms, stereotypies, posturing, grimacing, excitement, echolalia, echopraxia, muscular rigidity, and stupor; sometimes punctuated by sudden violent outbursts, panic, or hallucinations.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Catatonia</reference><category>Adverse</category></page>
  <page>
    <title>Categories</title>
    <id>3</id>
    </page>
  <page>
    <title>Cauda equina syndrome</title>
    <id>575</id>
    <term>Cauda equina syndrome</term><definition>Disease or injury involving multiple spinal nerve roots. Polyradiculitis refers to inflammation of multiple spinal nerve roots.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Caudaequinasyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Cellulitis</title>
    <id>576</id>
    <term>Cellulitis</term><definition>An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cellulitis</reference><category>Adverse</category></page>
  <page>
    <title>Cerebellar Ataxia</title>
    <id>644</id>
    <term>Cerebellar Ataxia</term><definition>Incoordination of voluntary movements that occur as a manifestation of cerebellar diseases. Characteristicfeatures include a tendency for limb movements to overshoot or undershoot atarget (dysmetria), a tremor that occurs during attempted movements (intentiontremor), impaired force and rhythm of diadochokinesis (rapidly alternating movements),and gait ataxia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=CerebellarAtaxia</reference><category>Adverse</category></page>
  <page>
    <title>Cerebral edema</title>
    <id>577</id>
    <term>Cerebral edema</term><definition>Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see hypoxia, brain). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive hydrocephalus).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cerebral</reference><category>Adverse</category></page>
  <page>
    <title>Cerebral hemorrhage</title>
    <id>578</id>
    <term>Cerebral hemorrhage</term><definition>Bleeding into a cerebral hemisphere of the brain, including lobar, subcortical white matter, and basal ganglia hemorrhages.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cerebralhemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Cerebral infarction</title>
    <id>579</id>
    <term>Cerebral infarction</term><definition>The formation of an area of necrosis in the cerebrum caused by an insufficiency of arterial or venous blood flow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cerebralinfarction</reference><category>Adverse</category></page>
  <page>
    <title>Cerebral ischemia</title>
    <id>580</id>
    <term>Cerebral ischemia</term><definition>Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cerebralischemia</reference><category>Adverse</category></page>
  <page>
    <title>Cerebral vasculitis</title>
    <id>581</id>
    <term>Cerebral vasculitis</term><definition>Primary vasculitis is usually caused by autoimmune or idiopathic factors, while secondary vasculitis is caused by existing disease process. Clinical manifestations are highly variable but include headache; seizures; behavioral alterations; intracranial hemorrhages; transient ischemic attack; and brain infarction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cerebralvasculitis</reference><category>Adverse</category></page>
  <page>
    <title>Chemical-specific adjustment factor (CSAF)</title>
    <id>97</id>
    <term>Chemical specific adjustment factor  </term><definition>Chemical-specific adjustment factor (CSAF) Defaultsafety/uncertainty factors have been used for over 40 years to estimatehealth-based guidance values based on no-observed-adverse-effect levels (NOAELs)or lowest-observedadverse-effect levels (LOAELs) from studies in animals. Avalue of 100 is normally used by bodies such as the Joint FAO/WHO Committee onFood Additives and Contaminants (JECFA) and the Joint FAO/WHO Meeting onPesticide Residues (JMPR) to derive an acceptable daily intake (ADI), atolerable daily intake (TDI) or a reference dose (RfD) for the generalpopulation based on a NOAEL or LOAEL from a chronic study in animals. Theapproach under which CSAFs would be used in risk assessment has been such thatin the absence of data, the usual default uncertainty factor would be used.This does not necessarily mean that the default of 100 is the ideal value; itis simply recognition that this reflects the common current approach toderiving a health-based guidance value for the general population.</definition><reference>http://www.inchem.org/documents/harmproj/harmproj/harmproj2.pdf</reference><reference>http://www.tera.org/Publications/risk%20policy%20report-nauman%20et%20al%202005.pdf</reference><category>Dose</category></page>
  <page>
    <title>Chestpain</title>
    <id>582</id>
    <term>Chest pain</term><definition>Pressure, burning, or numbness in the chest.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Chestpain</reference><category>Adverse</category></page>
  <page>
    <title>Chills</title>
    <id>583</id>
    <term>Chills</term><definition>The sudden sensation of being cold. It may be accompanied by shivering.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Chills</reference><category>Adverse</category></page>
  <page>
    <title>Cholangitis</title>
    <id>584</id>
    <term>Cholangitis</term><definition>Inflammation of the biliary ductal system (bile ducts); intrahepatic, extrahepatic, or both.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cholangitis</reference><category>Adverse</category></page>
  <page>
    <title>Cholecystitis</title>
    <id>585</id>
    <term>Cholecystitis</term><definition>Inflammation of the gallbladder; generally caused by impairment of bile flow, gallstones in the biliary tract, infections, or other diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cholecystitis</reference><category>Adverse</category></page>
  <page>
    <title>Cholestasis</title>
    <id>586</id>
    <term>Cholestasis</term><definition>Impairment of bile flow due to obstruction in small bile ducts (intrahepatic cholestasis) or obstruction in large bile ducts (extrahepatic cholestasis).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cholestasis</reference><category>Adverse</category></page>
  <page>
    <title>Cholestatic jaundice</title>
    <id>587</id>
    <term>Cholestatic jaundice</term><definition>Jaundice, the condition with yellowish staining of the skin and mucous membranes, that is due to impaired bile flow in the biliary tract, such as intrahepatic cholestasis, or extrahepatic cholestasis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cholestaticjaundice</reference><category>Adverse</category></page>
  <page>
    <title>Chorea</title>
    <id>588</id>
    <term>Chorea</term><definition>Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as choreatic disorders. Chorea is also a frequent manifestation of basal ganglia diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Chorea</reference><category>Adverse</category></page>
  <page>
    <title>Choreoathetosis</title>
    <id>622</id>
    <term>Choreoathetosis</term><definition>Choreoathetosis is the occurrence of involuntary movements in a combination of chorea and athetosis.</definition><category>Adverse</category></page>
  <page>
    <title>Chronic</title>
    <id>472</id>
    <term>Chronic </term><definition>Having a persistent, recurring or long-term nature. As distinguished from acute.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Chronic</category></page>
  <page>
    <title>Chronic effect</title>
    <id>342</id>
    <term>Chronic effect</term><definition>An adverse effect on ahuman or animal in which symptoms recur frequently or develop slowly over along period of time.</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Chronic</category></page>
  <page>
    <title>Chronic exposure</title>
    <id>790</id>
    <term>Chronic exposure</term><definition>Multiple exposures occurring over an extended period of time, or a significant fraction of the animal's or the individual's life-time.</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Chronic</category></page>
  <page>
    <title>Chronic fatigue syndrome</title>
    <id>589</id>
    <term>Chronic fatigue syndrome</term><definition>A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Chronicfatiguesyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Chronic hazard or toxicity</title>
    <id>408</id>
    <term>Chronic hazard or toxicity </term><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Hazards</category></page>
  <page>
    <title>Chronic study (Chronic exposure)</title>
    <id>407</id>
    <term>Chrinic study / Chronic exposure </term><definition>Chronic exposure A continuous or intermittent long-term contact between an agent and a target.</definition><category>Chronic</category></page>
  <page>
    <title>Churg-Strauss syndrome</title>
    <id>590</id>
    <term>Churg-Strauss syndrome</term><definition>Widespread necrotizing angiitis with granulomas. Pulmonary involvement is frequent. Asthma or other respiratory infection may precede evidence of vasculitis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=ChurgStrausssyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Cirrhosis</title>
    <id>621</id>
    <term>Cirrhosis</term><definition>Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrotic scar tissue as well as regenerative nodules, leading to progressive loss of liver function.</definition><category>Adverse</category></page>
  <page>
    <title>Cleanup</title>
    <id>409</id>
    <term>Cleanup</term><definition>Actions taken to deal with a release or threat of release of a hazardous substance that could affect humans and/or the environment. The term "cleanup" is sometimes used interchangeably with the terms remedial action, removal action, response action, or corrective action. Cleanup is the term used for actions taken to deal with a release or threat of release of a hazardous substance that could affect humans and or the environment. The term sometimes is used interchangeably with the terms remedial action, removal action, response action, or corrective action.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#c</reference><category>Hazards</category></page>
  <page>
    <title>Cleft palate</title>
    <id>591</id>
    <term>Cleft palate</term><definition>Congenital fissure of the soft and/or hard palate, due to faulty fusion.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cleftpalate</reference><category>Adverse</category></page>
  <page>
    <title>Coagulopathy</title>
    <id>620</id>
    <term>Coagulopathy</term><definition>Inability of the blod to clot or coagulate normally.</definition><category>Adverse</category></page>
  <page>
    <title>Coefficient of haze</title>
    <id>343</id>
    <term>Coefficient of haze (&#1057;&#1054;&#1053;) </term><definition>A measurement of visibility interference in the atmosphere.</definition><reference>http://www.scorecard.org/about/glossary.tcl)</reference><category>Dose</category></page>
  <page>
    <title>Cohort study</title>
    <id>859</id>
    <term>Cohort study</term><definition>An epidemiologic study that observes subjects in differently exposed groups andcompares the incidence of symptoms. Although ordinarily prospective in nature,such a study is sometimes carried out retrospectively, using historical data. See prospective study. Prospective study - &#1072;n inquiry in which groups of individuals are selected in terms of whether they are or are not exposed to certain factors, and then followed over time to determine differences in the rate at which disease develops in relation to exposure to the factor. Also called cohort study.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#a</reference><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Epidemiology</category></page>
  <page>
    <title>Colic</title>
    <id>592</id>
    <term>Colic</term><definition>A clinical syndrome with intermittent abdominal pain characterized by sudden onset and cessation. It is usually associated with obstruction of the intestines; of the cystic duct; or of the urinary tract.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Colic</reference><category>Adverse</category></page>
  <page>
    <title>Colitis</title>
    <id>593</id>
    <term>Colitis</term><definition>Inflammation of the colon section of the large intestine (intestine, large), usually with symptoms such as diarrhea (often with blood and mucus), abdominal pain, and fever.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Colitis</reference><category>Adverse</category></page>
  <page>
    <title>Coma</title>
    <id>594</id>
    <term>Coma</term><definition>A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem reticular formation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Coma</reference><category>Adverse</category></page>
  <page>
    <title>Common mode failures</title>
    <id>924</id>
    <term>Common mode failures</term><definition>Several errors in atechnological system occurring simultaneously.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Risk</category></page>
  <page>
    <title>Community</title>
    <id>198</id>
    <term>Community</term><definition>&#160; Anassemblage of populations of different species within a specified location inspace and time. In ecology, an assemblage of populations ofdifferent species within a specified location in space and time. Sometimes, aparticular subgrouping may be specified, such as the fish community in a lakeor the soil arthropod community in a forest.</definition><reference>http://www.epa.gov/OCEPAterms/cterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#c</reference><category>Biology</category></page>
  <page>
    <title>Comparative Effect Level (CEL)</title>
    <id>410</id>
    <term>Comparative Effect Level (CEL)</term><definition>A dose by which potency of chemicals may be compared; e.g. the dose causing a maximum of 15% cholinesterase inhibition.</definition><category>Dose</category></page>
  <page>
    <title>Comparative risk</title>
    <id>860</id>
    <term>Comparative risk</term><definition>1. An expression of therisks associated with two (or more) actions leading to the same goal; may beexpressed quantitatively (a ratio of 1.5) or qualitatively (one risk greaterthan another risk). 2. Any comparison among the risks of two or more hazardswith respect to a common scale.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Risk</category></page>
  <page>
    <title>Comparative risk assessment</title>
    <id>861</id>
    <term>Comparative risk assessment</term><definition>A process that generallyuses a professional judgment approach to evaluate the relative magnitude of effectsand set priorities among a wide range of environmental problems (e.g., U.S.EPA, 1993d). Some applications of this process are similar to the problemformulation portion of an ecological risk assessment in that the outcome mayhelp select topics for further evaluation and help focus limited resources onareas having the greatest risk reduction potential. In other situations, acomparative risk assessment is conducted more like a preliminary riskassessment. For example, EPA&#8217;s Science Advisory Board used professionaljudgment and an ecological risk assessment approach to analyze futureecological risk scenarios and risk management alternatives.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#c</reference><category>Risk</category></page>
  <page>
    <title>Compartment syndrome</title>
    <id>595</id>
    <term>Compartment syndrome</term><definition>Conditions in which increased pressure within a limited space compromises the blood circulation and function of tissue within that space. Some of the causes of increased pressure are trauma, tight dressings, hemorrhage, and exercise. Sequelae include nerve compression (nerve compression syndromes); paralysis; and ischemic contracture.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Compartmentsyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Concentration-effect relationship</title>
    <id>412</id>
    <term>Concentration-effect relationship </term><definition>Relationship between the exposure, expressed in concentration, of a given organism, system or (sub) population to an agent in a specific pattern during a given time and the magnitude of a continuously-graded effect to that organism, system or (sub) population.</definition><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Concentration ratio</title>
    <id>411</id>
    <term>Concentration ratio </term><definition>The ratio of the concentration of a compound or radionuclide in an organism or its tissues to the concentration in the surrounding under equilibrium, or steady-state conditions.</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Conceptual model</title>
    <id>199</id>
    <term>Conceptual model</term><definition>&#160; Aconceptual model in problem formulation is a written description and visualrepresentation of predicted relationships between ecological entities and thestressors to which they may be exposed. Describes a series of working hypotheses of how thestressor might affect ecological components. Describes ecosystem or ecosystemcomponents potentially at risk, and the relationships between measurement andassessment endpoints and exposure scenarios.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#c</reference><category>Ecotox</category></page>
  <page>
    <title>Confabulation</title>
    <id>603</id>
    <term>Confabulation</term><definition>A plausible but imagined memory that fills in gaps in what is remembered.</definition><category>Adverse</category></page>
  <page>
    <title>Confidence interval</title>
    <id>200</id>
    <term>Confidence interval</term><definition>A range of values (a1&lt; a &lt; a2) determined from a sample of definite rules so chosen that, inrepeated random samples from the hypothesized population, an arbitrarily fixedproportion of that range will include the true value, x, of an estimatedparameter. The limits, a1 and a2, are called confidence limits; the relativefrequency with which these limits include are called the confidencecoefficient; and the complementary probability is called the confidence level.As with significance levels, confidence levels are commonly chosen as 0.05 or0.01, the corresponding confidence coefficients being 0.95 or 0.99. Confidenceintervals should not be interpreted as implying that the parameter itself has arange of values; it has only one value, a. On the other hand, the confidencelimits (a1, a2) being derived from a sample, are random variables, the valuesof which on a particular sample either do or do not include the true value ofthe parameter. However, in repeated samples, a certain proportion of theseintervals will include a provided that the actual population satisfied theinitial hypothesis.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Dose</category></page>
  <page>
    <title>Confounding factors</title>
    <id>98</id>
    <term>Confounding factors</term><definition>Variables that may introduce differences between cases and controls which do not reflect differences in the variables of primary interest. A condition or variable that is both a risk factor for disease and associated with an exposure of interest. This association between the exposure of interest and the confounder (a true risk factor for disease) may make it falsely appear that the exposure of interest is associated with disease.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/iris/help_gloss.htm#c</reference><category>Risk</category></page>
  <page>
    <title>Confusion</title>
    <id>596</id>
    <term>Confusion</term><definition>A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Confusion</reference><category>Adverse</category></page>
  <page>
    <title>Conjunctivitis</title>
    <id>597</id>
    <term>Conjunctivitis</term><definition>Inflammation of the conjunctiva.</definition><category>Adverse</category></page>
  <page>
    <title>Consciousness disorders</title>
    <id>598</id>
    <term>Consciousness disorders</term><definition>Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respond to environmental stimuli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Consciousnessdisorders</reference><category>Adverse</category></page>
  <page>
    <title>Constipation</title>
    <id>599</id>
    <term>Constipation</term><definition>Infrequent or difficult evacuation of feces. These symptoms are associated with a variety of causes, including low dietary fiber intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Constipation</reference><category>Adverse</category></page>
  <page>
    <title>Contamination</title>
    <id>99</id>
    <term>Contamination</term><definition>Contact with an admixture of an unnatural agent, with the implication that the amount is measurable.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Ecotox</category></page>
  <page>
    <title>Control Group (or Reference Group)</title>
    <id>202</id>
    <term>Control Group or Reference Group</term><definition>Control Group (or Reference Group) A group used as the baseline for comparison in epidemiologic studies or laboratory studies. This group is selected because it either lacks the disease of interest (case-control group) or lacks the exposure of concern (cohort study).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#c</reference><category>Developmentaltox</category></page>
  <page>
    <title>Convulsants</title>
    <id>600</id>
    <term>Convulsants</term><definition>Substances that act in the brain stem or spinal cord to produce tonic or clonic convulsions, often by removing normal inhibitory tone. They were formerly used to stimulate respiration or as antidotes to barbiturate overdose.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Convulsants</reference><category>Adverse</category></page>
  <page>
    <title>Cooking Jobs In Boise Idaho</title>
    <id>1376</id>
    <reference>http://starsearchtool.com/SESS_rx3MjE3fHwxMjk2MDk5MjEyfHwxOTUyfHwoRU5HSU5FKSBNZWRpYVdpa2k%3D_cooking%2Bjobs%2Bin%2Bboise%2Bidaho.html</reference><reference>http://zipgrid.com/wiki/index.php/Counslling_Jobs_Bereavement_Development</reference><reference>http://poliecon.com/wiki/index.php?title=Convicted_Felons_Jobs</reference><reference>http://paulbaumgarten.net/wiki/index.php/Covance_Jobs</reference><reference>http://www.bojon.info/index.php?title=Comsec_Jobs</reference><reference>http://www.junbish.org/afg/node/181148</reference><reference>http://forum.tunethetemple.com/topic.php?id=69</reference></page>
  <page>
    <title>Corneal edema</title>
    <id>601</id>
    <term>Corneal edema</term><definition>An excessive amount of fluid in the cornea due to damage of the epithelium or endothelium causing decreased visual acuity.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cornealedema</reference><category>Adverse</category></page>
  <page>
    <title>Corneal opacity</title>
    <id>602</id>
    <term>Corneal opacity</term><definition>Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cornealopacity</reference><category>Adverse</category></page>
  <page>
    <title>Coronary steal</title>
    <id>619</id>
    <term>Coronary steal</term><definition>A condition characterized by shunting of all relatively well oxygenated blood from a critical area of low perfusion, to an area of higher perfusion; it is unique as it may be iatrogenic and occur in pharmacologic stress imaging&#8211;see there, using dipyridamole to induce vasoconstriction; this causes a fall in blood flow to the subendocardium distal to the site of the stenosed coronary artery.</definition><category>Adverse</category></page>
  <page>
    <title>Coronary vasospasm</title>
    <id>604</id>
    <term>Coronary vasospasm</term><definition>Spasm of the large- or medium-sized coronary arteries.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Coronary</reference><category>Adverse</category></page>
  <page>
    <title>Cortical blindness</title>
    <id>605</id>
    <term>Cortical blindness</term><definition>Total loss of vision in all or part of the visual field due to bilateral occipital lobe (i.e., visual cortex) damage or dysfunction. Anton syndrome is characterized by the psychic denial of true, organic cortical blindness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Corticalblindness</reference><category>Adverse</category></page>
  <page>
    <title>Cost-benefit analysis</title>
    <id>867</id>
    <term>Cost-benefit analysis</term><definition>A formal quantitative procedure comparing costs and benefits of a proposed project or act under a set of preestablished rules. To determine a rank ordering of projects to maximize rate of return when available funds are unlimited, the quotient of benefits divided by costs is the appropriate form; to maximize absolute return given limited resources, benefits-costs is the appropriate form. Cost-benefit-risk assessment" is the quantification and monetary valuation of the expenditures, gains, and losses, and the calculation of net benefits to society associated with the adoption of a particular regulation (or alternative management strategy) to address an environmental hazard. Quantitative environmental risk analysis (that is, risk assessment) is a necessary prerequisite to the conduct of cost-benefit-risk assessment of environmental regulations, because the " benefits" are the risks avoided (that is, the adverse effects on human health or the environment, or risks of such effects, that the regulation is meant to address.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Risk</category></page>
  <page>
    <title>Cost-effective alternative</title>
    <id>105</id>
    <term>Cost-effective alternative</term><definition>An alternative control or corrective method identified after analysis as being the best available in terms of reliability, performance, and cost. Although costs are one important consideration, regulatory and compliance analysis does not require EPA to choose the least expensive alternative. For example, when selecting or approving a method for cleaning up a Superfund site the Agency balances costs with the long-term effectiveness of the methods proposed and the potential danger posed by the site.</definition><reference>http://www.epa.gov/OCEPAterms/cterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Alternatives</category></page>
  <page>
    <title>Cough</title>
    <id>606</id>
    <term>Cough</term><definition>A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cough</reference><category>Adverse</category></page>
  <page>
    <title>Craigslist Jobs Detroit</title>
    <id>1353</id>
    <reference>http://banansearch.com/tds/go.php?sid=4&amp;fpr=qo6OTN8fDEyOTU5MTUyOTl8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D&amp;q=craigslist%2Bjobs%2Bdetroit</reference><reference>http://bit.ly/i4RDkW#</reference></page>
  <page>
    <title>Cranial nerve palsy</title>
    <id>607</id>
    <term>Cranial nerve palsy</term><definition>Disorders of one or more of the twelve cranial nerves. With the exception of the optic and olfactory nerves, this includes disorders of the brain stem nuclei from which the cranial nerves originate or terminate.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cranialnervepalsy</reference><category>Adverse</category></page>
  <page>
    <title>Criteria</title>
    <id>926</id>
    <term>Criteria</term><definition>As used in the Clean Air Act, information on adverse effects of air pollutants on human health or the environment at various concentrations. The information is collected pursuant to section 108 of the Clean Air Act and used to set national ambient air quality standards. Descriptive factors taken into account by EPA in setting standards for various pollutants. These factors are used to determine limits on allowable concentration levels, and to limit the number of violations per year. When issued by EPA, the criteria provide guidance to the states on how to establish their standards.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><reference>http://www.epa.gov/OCEPAterms/cterms.html</reference><category>Standards</category></page>
  <page>
    <title>Criteria pollutants</title>
    <id>107</id>
    <term>Criteria pollutants</term><definition>The 1970 amendments to the Clean Air Act required EPA to set National Ambient Air Quality Standards for certain pollutants known to be hazardous to human health. EPA has identified and set standards to protect human health and welfare for six pollutants: ozone, carbon monoxide, total suspended particulates, sulfur dioxide, lead, and nitrogen oxide. The term, "criteria pollutants" derives from the requirement that EPA must describe the characteristics and potential health and welfare effects of these pollutants. It is on the basis of these criteria that standards are set or revised.</definition><reference>http://www.epa.gov/OCEPAterms/cterms.html</reference><category>Standards</category></page>
  <page>
    <title>Critical concentration</title>
    <id>791</id>
    <term>Critical &#1089;oncentration</term><definition>An ambient chemical concentration expressed in units of &#181;g/m3 and used in the operational derivation of the inhalation RfC. This concentration will be the NOAEL Human Equivalent Concentration (HEC) adjusted from principal study data.</definition><reference>http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=36512#search=%22Guidelines%20for%20Ecological%20Risk%20Assessment%22</reference><category>Dose</category></page>
  <page>
    <title>Critical effect</title>
    <id>868</id>
    <term>Critical effect</term><definition>The first adverse effect, or its known precursor, that occurs as the dose rate increases. There is an assumption that for some toxic responses, there is a level (threshold) below which adverse effects will not occur. The critical effect is often the basis of noncancer risk values, on the assumption that if the critical effect is prevented, then all subsequent adverse effects are prevented. The first adverse effect, or its known precursor, that occurs as a dose rate increases. Designation is based on evaluation of overall database.</definition><reference>http://www.epa.gov/OCEPAterms/cterms.html</reference><reference>http://www.epa.gov/iris/help_gloss.htm#c</reference><category>Adverse</category></page>
  <page>
    <title>Critical organ</title>
    <id>869</id>
    <term>Critical organ</term><definition>That part of the body that is most susceptible to radiation damage under the specific conditions under consideration.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Adverse</category></page>
  <page>
    <title>Critical toxic effect</title>
    <id>108</id>
    <term>Critical toxic effect</term><definition>The most sensitive and specific biological change which is outside of acceptable physiological variation.</definition><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Adverse</category></page>
  <page>
    <title>Cross-sectional study</title>
    <id>442</id>
    <term>Cross-sectional study</term><reference>http://sra.org/resources_glossary_a-c.php</reference><category>Epidemiology</category></page>
  <page>
    <title>Crystalluria</title>
    <id>618</id>
    <term>Crystalluria</term><definition>The excretion of crystals in the urine, producing renal irritation.</definition><category>Adverse</category></page>
  <page>
    <title>Cumulative dose</title>
    <id>344</id>
    <term>Cumulative dose</term><definition>The amount of multiple (two or more) substances which share a common mechanism of toxicity available for interaction with biological targets from multiple routes of exposure.</definition><reference>http://www.euro.who.int/document/e76979.pdf</reference><category>Dose</category></page>
  <page>
    <title>Cyanosis</title>
    <id>609</id>
    <term>Cyanosis</term><definition>A bluish or purplish discoloration of the skin and mucous membranes due to an increase in the amount of deoxygenated hemoglobin in the blood or a structural defect in the hemoglobin molecule.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cyanosis</reference><category>Adverse</category></page>
  <page>
    <title>Cystitis</title>
    <id>610</id>
    <term>Cystitis</term><definition>Inflammation of the urinary bladder, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cystitis</reference><category>Adverse</category></page>
  <page>
    <title>Cytotoxins</title>
    <id>612</id>
    <term>Cytotoxins</term><definition>Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from cytostatic agents in degree of effect. some of them are used as cytotoxic antibiotics. The mechanism of action of many of these are as alkylating agents or mitosis modulators.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Cytotoxins</reference><category>Adverse</category></page>
  <page>
    <title>Dating Online Perth Free</title>
    <id>1361</id>
    <reference>http://banansearch.com/SESS_qj8OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_dating%2Bonline%2Bperth%2Bfree.html</reference><reference>http://wiki.gabble-on.com/index.php?title=Dating_Free_Jewish_Personals_Site_Web</reference><reference>http://inter-solve.com/node/144402</reference><reference>http://www.izondata.com/kb/index.php?title=Speed_Dating_Minneapolis_Minnesota</reference><reference>http://miuniversidadculiacan.com/foro/bbpress/topic.php?id=12</reference><reference>http://ahlajaw.freeiz.com/Forum/topic.php?id=2267</reference><reference>http://www.topbigdeals.com/content/embed-chat-room-html</reference><reference>http://www.wikisym.org/wiki/index.php/Cathouse_Chat_Immigration</reference><reference>http://laplantesamples.com/wikki/index.php?title=Mike_Myers_Dating_Life</reference><reference>http://www.mega-shock.com/topic.php?id=617</reference><reference>http://ddd.theinfosphere.org/Nude_Dating_Tv</reference><reference>http://thailandfoodie.com/forums/topic/6</reference><reference>http://www.claudiosilva.net/index.php?title=Totally_Free_Personals_Internet_Dating</reference><reference>http://www.donegalyouthservice.ie/fas/node/4804</reference><reference>http://nosubject.com/Italy_Chat</reference><reference>http://meihn.com/node/40841</reference></page>
  <page>
    <title>De1</title>
    <id>1299</id>
    <term>De1</term></page>
  <page>
    <title>De2</title>
    <id>1300</id>
    <term>De2</term></page>
  <page>
    <title>Deglutition Disorders</title>
    <id>646</id>
    <term>Deglutition Disorders</term><definition>Difficulty in swallowing. Dysphagiais classified into two distinct types: oropharyngeal dysphagia due to malfunctionof the pharynx and upper esophageal sphincter; and esophageal dysphagia due tomalfunction of the esophagus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=DeglutitionDisorders</reference><category>Adverse</category></page>
  <page>
    <title>Dehydration</title>
    <id>613</id>
    <term>Dehydration</term><definition>The condition that results from excessive loss of water from a living organism.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dehydration</reference><category>Adverse</category></page>
  <page>
    <title>Delirium</title>
    <id>614</id>
    <term>Delirium</term><definition>A disorder characterized by confusion; inattentiveness; disorientation; illusions; hallucinations; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Delirium</reference><category>Adverse</category></page>
  <page>
    <title>Delusion</title>
    <id>615</id>
    <term>Delusion</term><definition>A false belief regarding the self or persons or objects outside the self that persists despite the facts, and is not considered tenable by one's associates.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Delusion</reference><category>Adverse</category></page>
  <page>
    <title>Dementia</title>
    <id>616</id>
    <term>Dementia</term><definition>An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dementia</reference><category>Adverse</category></page>
  <page>
    <title>Dependence</title>
    <id>627</id>
    <term>Dependence</term><definition>The quality or condition of relying upon, being influenced by, or being subservient to a person or object reflecting a particular need.</definition><category>Adverse</category></page>
  <page>
    <title>Depersonalization</title>
    <id>628</id>
    <term>Depersonalization</term><definition>State in which an individual perceives or experiences a sensation of unreality concerning the self or the environment; it is seen in disorders such as schizophrenia, affection disorders, organic mental disorders, and personality disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Depersonalization</reference><category>Adverse</category></page>
  <page>
    <title>Depression</title>
    <id>629</id>
    <term>Depression</term><definition>Depressive states usually of moderate intensity in contrast with major depression present in neurotic and psychotic disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Depression</reference><category>Adverse</category></page>
  <page>
    <title>Dermatitis</title>
    <id>630</id>
    <term>Dermatitis</term><definition>Any inflammation of the skin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dermatitis</reference><category>Adverse</category></page>
  <page>
    <title>Dermatitis herpetiformis</title>
    <id>631</id>
    <term>Dermatitis herpetiformis</term><definition>Rare, chronic, papulo-vesicular disease characterized by an intensely pruritic eruption consisting of various combinations of symmetrical, erythematous, papular, vesicular, or bullous lesions. The disease is strongly associated with the presence of HLA-B8 and HLA-DR3 antigens. A variety of different autoantibodies has been detected in small numbers in patients with dermatitis herpetiformis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dermatitisherpetiformis</reference><category>Adverse</category></page>
  <page>
    <title>Dermatomyositis</title>
    <id>632</id>
    <term>Dermatomyositis</term><definition>A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dermatomyositis</reference><category>Adverse</category></page>
  <page>
    <title>Deterministic effect</title>
    <id>345</id>
    <term>Deterministic effect</term><definition>The health effects, the severity of which varies with the dose and for which a threshold is believed to exist.</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Dose</category></page>
  <page>
    <title>Developmental toxicity</title>
    <id>434</id>
    <term>Developmental Toxicity</term><category>Developmentaltox</category></page>
  <page>
    <title>Diarrhea</title>
    <id>633</id>
    <term>Diarrhea</term><definition>An increased liquidity or decreased consistency of feces, such as running stool.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Diarrhea</reference><category>Adverse</category></page>
  <page>
    <title>Diplopia</title>
    <id>634</id>
    <term>Diplopia</term><definition>A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disordersassociated with this condition include refractive errors; strabismus;oculomotor nerve diseases; trochlear nerve diseases; abducens nerve diseases;and diseases of the brain stem and occipital lobe.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Diplopia</reference><category>Adverse</category></page>
  <page>
    <title>Disability weight</title>
    <id>346</id>
    <term>Disability weight</term><definition>Measure of the relative valuations of a health state on an interval scale. In the GBD (q.v.), health state valuations lie between 0 (full health q.v.) and 1 (state equivalent to death). The disability weight quantifies judgments about overall levels of health associated with different health states (q.v.), not judgments on the relative values of lives lived, persons, or of overall well-being, quality of life or utility.</definition><category>Dose</category></page>
  <page>
    <title>Disseminated intravascular coagulation</title>
    <id>635</id>
    <term>Disseminated intravascular coagulation</term><definition>Adisorder characterized by procoagulant substances entering the generalcirculation causing a systemic thrombotic process. The activation of theclotting mechanism may arise from any of a number of disorders. A majority ofthe patients manifest skin lesions, sometimes leading to purpura fulminans.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=DissemIntravascCoagulation</reference><category>Adverse</category></page>
  <page>
    <title>Dizziness</title>
    <id>636</id>
    <term>Dizziness</term><definition>An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dizziness</reference><category>Adverse</category></page>
  <page>
    <title>Dose</title>
    <id>413</id>
    <term>Dose</term><definition>The amount or concentration of undesired matter or energy deposited at the site of effect.See also absorbed dose.Total amount of an agent administered to, taken up or absorbed by an organism, system or (sub) population. total amount of a substance administered to, taken, or absorbed by an organism. The amount of substance available for interaction with metabolic processes or biologically-significant receptors after crossing the outer boundary of an organism.</definition><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Dose-effect</title>
    <id>795</id>
    <term>Dose-effect </term><definition>The relationship between dose (usually an estimate of dose) and the gradation of the effect in a population, that is a biological change measured on a graded scale of severity, although at other times one may only be able to describe a qualitative effect that occurs within some range of exposure levels.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Dose-effect relationship</title>
    <id>353</id>
    <term>Dose-effect relationship </term><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Dose-rate</title>
    <id>796</id>
    <term>Dose-rate </term><definition>Dose per unit time (e.g., mg/day). Also called dosage. Dose rates are often expressed on a per-unit-body-weight basis (mg/kg/day). Dose rates may also be expressed as an average over a time period (i.e., lifetime).</definition><category>Dose</category></page>
  <page>
    <title>Dose-related effect</title>
    <id>354</id>
    <term>Dose-related effect </term><definition>Any effect to an organism, system or (sub) population as a result of the quantity of an agent administered to, taken up or absorbed by that organism, system or (sub) population. Dose-related effect: change to a system as a function of the quantity of a substance administered, taken, or absorbed by it.</definition><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Dose-response</title>
    <id>419</id>
    <term>Dose-response</term><definition>The relationship between dose (usually an estimate of dose) and the gradation of the effect in a population, that is a biological change measured on a graded scale of severity, although at other times one may only be able to describe a qualitative effect that occurs within some range of exposure levels.  Relationship between the amount of an agent administered to, taken up or absorbed by an organism, system or (sub) population and the change developed in that organism, system or (sub) population in reaction to the agent. Synonymous with Dose-response relationship.</definition><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Dose-response assessment</title>
    <id>473</id>
    <term>Dose-response assessment </term><definition>The process of characterizing the relation between the dose of an agent administered or received and the incidence of an adverse health effect in exposed populations and estimating the incidence of the effect as a function of human exposure to the agent.&#160;&#160;Analysis of the relationship between the total amount of an agent administered to, taken up or absorbed by an organism, system or (sub)population and the changes developed in that organism, system or (sub)population in reaction to that agent, and inferences derived from such an analysis with respect to the entire population. Dose-Response Assessment is the second of four steps in risk assessment.</definition><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Dose-response curve</title>
    <id>420</id>
    <term>Dose-response curve </term><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Dose-response relationship</title>
    <id>797</id>
    <term>Dose-response relationship</term><definition>Relationship between the amount of an agent administered to, taken up or absorbed by an organism, system or (sub) population and the change developed in that organism, system or (sub) population in reaction to the agent.</definition><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><category>Dose</category></page>
  <page>
    <title>Dose additivity</title>
    <id>414</id>
    <term>Dose additivity</term><reference>http://oaspub.epa.gov/eims/eimscomm.getfile?p_download_id=439798</reference><category>Dose</category></page>
  <page>
    <title>Drug Safety</title>
    <id>438</id>
    <term>Drug Safety</term><category>Drugsafety</category></page>
  <page>
    <title>Drug eruption</title>
    <id>637</id>
    <term>Drug eruption</term><definition>Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=DrugEruption</reference><category>Adverse</category></page>
  <page>
    <title>Dry eye syndrome</title>
    <id>638</id>
    <term>Dry eye syndrome</term><definition>Corneal and conjunctival dryness due to deficient tear production, predominantly in menopausal and post-menopausal women. Filamentary keratitis or erosion of the conjunctival and corneal epithelium may be caused by these disorders. Sensation of the presence of a foreign body in the eye and burning of the eyes may occur.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=DryEye</reference><category>Adverse</category></page>
  <page>
    <title>Dupuytren's contracture</title>
    <id>639</id>
    <term>Dupuytren's contracture</term><definition>A fibromatosis of the palmar fascia characterized by thickening and contracture of the fibrous bands on the palmar surfaces of the hand and fingers.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=DupuytrenContracture</reference><category>Adverse</category></page>
  <page>
    <title>Dysarthria</title>
    <id>640</id>
    <term>Dysarthria</term><definition>Disorders of speech articulation caused by imperfect coordination of pharynx, larynx, tongue, or face muscles.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dysarthria</reference><category>Adverse</category></page>
  <page>
    <title>Dysesthesia</title>
    <id>641</id>
    <term>Dysesthesia</term><definition>Subjective cutaneous sensations (e.g., cold, warmth, tingling, pressure, etc.) that are experienced spontaneously in the absence of stimulation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dysesthesia</reference><category>Adverse</category></page>
  <page>
    <title>Dyskinesia</title>
    <id>642</id>
    <term>Dyskinesia</term><definition>Abnormalinvoluntary movements which primarily affect the extremities, trunk, or jawthat occur as a manifestation of an underlying disease process. Conditionswhich feature recurrent or persistent episodes of dyskinesia as a primarymanifestation of disease may be referred to as dyskinesia syndromes.Dyskinesias are also a relatively common manifestation of basal gangliadiseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dyskinesia</reference><category>Adverse</category></page>
  <page>
    <title>Dyslipidemia</title>
    <id>643</id>
    <term>Dyslipidemia</term><definition>Abnormalitiesin the serum levels of lipids, including overproduction or deficiency. Abnormalserum lipid profiles may include high total cholesterol, high triglycerides,low high density lipoprotein cholesterol, and elevated low density lipoproteincholesterol.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dyslipidemia</reference><category>Adverse</category></page>
  <page>
    <title>Dyspepsia</title>
    <id>645</id>
    <term>Dyspepsia</term><definition>Impaired digestion, especially after eating.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dyspepsia</reference><category>Adverse</category></page>
  <page>
    <title>Dyspnea</title>
    <id>647</id>
    <term>Dyspnea</term><definition>Difficult or labored breathing.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dyspnea</reference><category>Adverse</category></page>
  <page>
    <title>Dystonia</title>
    <id>648</id>
    <term>Dystonia</term><definition>Anattitude or posture due to the co-contraction of agonists and antagonistmuscles in one region of the body. It most often affects the large axialmuscles of the trunk and limb girdles. Conditions which feature persistent orrecurrent episodes of dystonia as a primary manifestation of disease arereferred to as dystonic disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dystonia</reference><category>Adverse</category></page>
  <page>
    <title>Dysuria</title>
    <id>649</id>
    <term>Dysuria</term><definition>Painful urination.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Dysuria</reference><category>Adverse</category></page>
  <page>
    <title>EEGL</title>
    <id>814</id>
    <term>Emergency exposure guidance Level (EEGL)</term><definition>is defined by the National Academy of Sciences as the ceiling concentration of a substance in air that may be judged by the Department of Defence to be acceptable for the performance of specific tasks during rare emergency conditions lasting for periods of 1-24 hours. &#8220;Emergency&#8221; connotes an unexpected situation with potential for loss of life. EEGLs are designed to provide guidelines for military personnel operating under emergency conditions that are peculiar to military operations and for which regulatory agencies have not set standards. The methods used to derive the EEGLs are not always explicitly stated and EEGLS were not derived with the intent to protect the general public.</definition><category>Dose</category></page>
  <page>
    <title>Ecchymosis</title>
    <id>650</id>
    <term>Ecchymosis</term><definition>Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ecchymosis</reference><category>Adverse</category></page>
  <page>
    <title>Ecological effects characterization</title>
    <id>493</id>
    <term>Ecological effects characterization</term><definition>Describes how toxic a pesticide is to different organisms and/or to other ecological entities (i.e., community), what effects it produces, how the effects relate to the assessment endpoints, and how these effects change with varying levels of pesticide exposure. The process for examining effects is called ecological effects characterization, whereas the process for examining exposure is called exposure characterization. During the analysis phase, risk assessors: select data that can be used to characterize exposure and ecological effects; characterize exposure by examining sources of the pesticide(s) or stressors, distribution of the pesticides in the environment, and extent of contact with pesticides; characterize effects by examining stressor-response relationships, evidence for cause and effect, relationship between measures of effect and assessment endpoints; summarize conclusions about exposure and effects.</definition><reference>http://www.epa.gov/oppefed1/ecorisk_ders/toera_analysis_eco.htm</reference><category>Ecotox</category></page>
  <page>
    <title>Ecological epidemiology</title>
    <id>443</id>
    <term>Ecological epidemiology</term><definition>- A branch of epidemiology which views disease as a result of the ecological interactions between populations of hosts and parasites.</definition><reference>http://www.geocities.com/HotSprings/3468/gloss96.html#horizontal</reference><category>Epidemiology</category></page>
  <page>
    <title>Ecological exposure characterization</title>
    <id>492</id>
    <term>Ecological exposure characterization</term><category>Ecotox</category></page>
  <page>
    <title>Ecological fallacy</title>
    <id>811</id>
    <term>Ecological fallacy</term><definition>The inference that a correlation between variables derived from data grouped in social or other aggregates (ecological units) will hold between persons (individual units).</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Ecotox</category></page>
  <page>
    <title>Ecological impact</title>
    <id>812</id>
    <term>Ecological impact</term><definition>Effect on living organism and their non-living (abiotic) environment due to human activity or natural phenomenon.</definition><reference>http://www.businessdictionary.com/definition/ecological-impact.html</reference><category>Ecotox</category></page>
  <page>
    <title>Ecological indicator</title>
    <id>813</id>
    <term>Ecological indicator</term><definition>Collective term for exposure, habitat response, and stressor inticators. Species&#160;(such as gladioli and lichens) that have particular requirements regarding soil, temprature,&#160; rainfall, etc., and whose presence indicates that those requirements are being satisfied in that environment. A characteristic of the environment that, when measured, quantifies magnitude of stress, habitat characteristics, degree of exposure to a stressor, or ecological response to exposure. The term is a collective term for response, exposure, habitat, and stressor indicators.</definition><reference>http://www.businessdictionary.com/definition/ecological-indicator.html</reference><category>Ecotox</category></page>
  <page>
    <title>Ecological risk assessment</title>
    <id>494</id>
    <term>Ecological risk assessment</term><definition>is a process for organizing and analyzing data, information, assumptions, and uncertainties to evaluate the likelihood that one or more stressors are causing or will cause adverse ecological effects. Ecological risk assessment provides risk managers with a tool for considering available scientific information when selecting a course of action, in addition to other factors that may affect their decision (e.g., social, legal, political, or economic). Ecological risk assessment includes three phases (problem formulation, analysis, and risk characterization). Within problem formulation, important areas include identifying goals and assessment endpoints, preparing a conceptual model, and developing an analysis plan. The analysis phase involves evaluating exposure to stressors and the relationship between stressor levels and ecological effects. In risk characterization, key elements are estimating risk through integration of exposure and stressor-response profiles, describing risk by discussing lines of evidence and determining ecological adversity, and preparing a report.</definition><reference>http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=15200</reference><reference>http://www.epa.gov/superfund/programs/nrd/era2.htm#pagetop</reference><category>Ecotox</category></page>
  <page>
    <title>Ecology</title>
    <id>100</id>
    <term>Ecology</term><definition>The science dealing with the relationship of all living things with each other and with their environment. The relationship of living things to one another and their environment, or the study of such relationships.</definition><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://www.epa.gov/OCEPAterms/eterms.htm</reference><reference>http://sra.org/resources_glossary_d-f.phpl</reference><category>Ecotox</category></page>
  <page>
    <title>Ecosystem</title>
    <id>101</id>
    <term>Ecosystem</term><definition>The interacting system of a biological community and its nonliving surroundings. The biotic community and abiotic environment within a specified location in space and time.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Eczema</title>
    <id>651</id>
    <term>Eczema</term><definition>A pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Eczema</reference><category>Adverse</category></page>
  <page>
    <title>Effect</title>
    <id>102</id>
    <term>Effect</term><definition>A biological change caused by an exposure. Change in the state or dynamics of an organism, system or (sub) population caused by the exposure to an agent. Effect: change in the state or dynamics of a system caused by the action of an agent.</definition><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Biology</category></page>
  <page>
    <title>Effect assessment</title>
    <id>798</id>
    <term>Effect assessment</term><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html</reference><category>Dose</category></page>
  <page>
    <title>Effective dose (ED10)</title>
    <id>788</id>
    <term>Effective dose (ED10)</term><definition>Effective dose (ED10) - The dose corresponding to a 10% increase in an adverse effect, relative to the control respons.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><category>Dose</category></page>
  <page>
    <title>Efficacy</title>
    <id>103</id>
    <term>Efficacy</term><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://rais.ornl.gov/home/glossary.html#E</reference><category>Risk</category></page>
  <page>
    <title>Effluent</title>
    <id>201</id>
    <term>Effluent</term><definition>Waste material discharged into the environment, treated or untreated. Generally refers to water pollution. Wastewater--treated or untreated--that flows out of a treatment plant, sewer, or industrial outfall. Generally refers to wastes discharged into surface waters.</definition><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Electrolyte imbalance</title>
    <id>653</id>
    <term>Electrolyte imbalance</term><definition>Disturbances in the body's water-electrolyte balance.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Electrolyteimbalance</reference><category>Adverse</category></page>
  <page>
    <title>Embryotoxicity</title>
    <id>654</id>
    <term>Embryotoxicity</term><definition>The state of being toxic to an embryo, resulting in abnormal development or death.</definition><category>Adverse</category></page>
  <page>
    <title>Emesis</title>
    <id>652</id>
    <term>Emesis</term><definition>Theforcible expulsion of the contents of the stomach through the mouth.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Emesis</reference><category>Adverse</category></page>
  <page>
    <title>Emission</title>
    <id>863</id>
    <term>Emission</term><definition>Like effluent but used in regard to air pollution. Pollution discharged into the atmosphere from smokestacks, other vents, and surface areas of commercial or industrial facilities; from residential chimneys; and from motor vehicle, locomotive, or aircraft exhausts.</definition><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Emission rate</title>
    <id>864</id>
    <term>Emission rate</term><definition>The amount of pollutant emitted per unit of time.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Encephalitis</title>
    <id>655</id>
    <term>Encephalitis</term><definition>Inflammation of the brain due to infection, autoimmune processes, toxins, and other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Encephalitis</reference><category>Adverse</category></page>
  <page>
    <title>Endocarditis</title>
    <id>656</id>
    <term>Endocarditis</term><definition>Inflammation of the inner lining of the heart (endocardium), the continuous membrane lining the four chambers and heart valves.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Endocarditis</reference><category>Adverse</category></page>
  <page>
    <title>Endocrine disruptors</title>
    <id>657</id>
    <term>Endocrine disruptors</term><definition>Exogenous agents, synthetic and naturally occurring, which are capable of disrupting the functions of the endocrine system including the maintenance of homeostasis and the regulation of developmental processes. Endocrinedisruptors are compounds that can mimic hormones, or enhance or block thebinding of hormones to their receptors, or otherwise lead to activating orinhibiting the endocrine signaling pathways and hormone metabolism.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Endocrinedisruptors</reference><category>Adverse</category></page>
  <page>
    <title>Enterocolitis</title>
    <id>658</id>
    <term>Enterocolitis</term><definition>Inflammation of the mucosa of both the small intestine and the large intestine.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Enterocolitis</reference><category>Adverse</category></page>
  <page>
    <title>Enuresis</title>
    <id>659</id>
    <term>Enuresis</term><definition>Involuntary discharge of urine after expected age of completed development of urinary control. This can happen during the daytime (diurnal enuresis) while one is awake or during sleep (nocturnal enuresis). Enuresis can be in children or in adults (as persistent primary enuresis and secondary adult-onset enuresis).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Enuresis</reference><category>Adverse</category></page>
  <page>
    <title>Environment</title>
    <id>865</id>
    <term>Environment</term><definition>Water, air, land, and all plants and man and other animals living therein, and the interrelationships which exist among them. The sum of all external conditions affecting the life, development and survival of an organism.</definition><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental Impact Statement (EIS)</title>
    <id>203</id>
    <term>Environmental Impact Statement </term><definition>(EIS) &#160;Environmental impact statements are prepared under the National Environmental Policy Act by Federal agencies as they evaluate the environmental consequences of proposed actions. EISs describe baseline environmental conditions; the purpose of, need for, and consequences of a proposed action; the no-action alternative; and the consequences of a reasonable range of alternative actions. A separate risk assessment could be prepared for each alternative, or a comparative risk assessment might be developed. However, risk assessment is not the only approach used in EISs.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental assessment</title>
    <id>866</id>
    <term>Environmental assessment</term><definition>An environmental analysis prepared pursuant to the National Environmental Policy Act to determine whether a federal action would significantly affect the environment and thus require a more detailed environmental impact statement.</definition><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental audit</title>
    <id>104</id>
    <term>Environmental audit</term><definition>An independent assessment of the current status of a party's compliance with applicable environmental requirements or of a party's environmental compliance policies, practices, and controls. An environmental audit usually refers to a review or investigation that determines whether an operating facility is in compliance with relevant environmental regulations. The audit may include checks for possession of required permits, operation within permit limits, proper reporting, and record keeping. The typical result is a corrective action or compliance plan for the facility.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#E</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental equity</title>
    <id>927</id>
    <term>Environmental equity</term><definition>Equal protection from environmental hazards of individuals, groups or communities regardless of race, ethnicity, or economic status.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental impact appraisal</title>
    <id>204</id>
    <term>Environmental impact appraisal</term><definition>An environmental review supporting a negative declaration, i.e., the action is not a major Federal action significantly affecting the environment. It describes a proposed EPA action, its expected environmental impact, and the basis for the conclusion that no significant impact is anticipated.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Environmental pathway</title>
    <id>109</id>
    <term>Environmental pathway</term><definition>All routes of transport by which a toxicant can travel from its release site to human populations including air, food chain, and water.   The connected set of environmental media through which a potentially harmful substance travels from source to receptor. [S. L.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Ecotox</category></page>
  <page>
    <title>Eosinophilia</title>
    <id>660</id>
    <term>Eosinophilia</term><definition>Abnormal increase in eosinophils in the blood, tissues or organs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Eosinophilia</reference><category>Adverse</category></page>
  <page>
    <title>Eosinophilic pneumonia</title>
    <id>661</id>
    <term>Eosinophilic pneumonia</term><definition>A condition characterized by infiltration of the lung with eosinophils due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Eosinophilicpneumonia</reference><category>Adverse</category></page>
  <page>
    <title>Epidemiology</title>
    <id>110</id>
    <term>Epidemiology</term><definition>The study of the distribution and dynamics of diseases and injuries in human populations. Specifically, the investigation of the possible causes of a disease and its transmission. Study of the analysis of the distribution of illnesses, physiological variables and social consequences of illnesses in human population groups, as well as factors influencing this distribution (WHO definition).</definition><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-D-</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Epidemiology</category></page>
  <page>
    <title>Epilepsy</title>
    <id>662</id>
    <term>Epilepsy</term><definition>A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Epilepsy</reference><category>Adverse</category></page>
  <page>
    <title>Epistaxis</title>
    <id>663</id>
    <term>Epistaxis</term><definition>Bleeding from the nose.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Epistaxis</reference><category>Adverse</category></page>
  <page>
    <title>Erectile dysfunction</title>
    <id>664</id>
    <term>Erectile dysfunction</term><definition>The inability in the male to have a penile erection due to psychological or organ dysfunction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Erectiledysfunction</reference><category>Adverse</category></page>
  <page>
    <title>Erythema</title>
    <id>665</id>
    <term>Erythema</term><definition>Redness of the skin produced by congestion of the capillaries.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Erythema</reference><category>Adverse</category></page>
  <page>
    <title>Erythema multiforme</title>
    <id>666</id>
    <term>Erythema multiforme</term><definition>A skin and mucous membrane disease characterized by an eruption of macules, papules, nodules, vesicles, and/or bullae with characteristic "bull's-eye" lesions usually occurring on the dorsal aspect of the hands and forearms.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Erythemamultiforme</reference><category>Adverse</category></page>
  <page>
    <title>Erythema nodosum</title>
    <id>667</id>
    <term>Erythema nodosum</term><definition>An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Erythemanodosum</reference><category>Adverse</category></page>
  <page>
    <title>Esophagitis</title>
    <id>668</id>
    <term>Esophagitis</term><definition>Inflammation, acute or chronic, of the esophagus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Esophagitis</reference><category>Adverse</category></page>
  <page>
    <title>Estimated Exposure Dose (EED)</title>
    <id>437</id>
    <term>Estimated Exposure Dose (EED)</term><definition>Estimated Exposure Dose (EED) - The measured or calculated        dose to which humans are likely to be exposed considering all sources        and routes of exposure.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><category>Dose</category></page>
  <page>
    <title>Euphoria</title>
    <id>669</id>
    <term>Euphoria</term><definition>An exaggerated feeling of physical and emotional well-being not consonant with apparent stimuli or events; usually of psychologic origin, but also seen in organic brain disease and toxic states.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Euphoria</reference><category>Adverse</category></page>
  <page>
    <title>Exanthema</title>
    <id>670</id>
    <term>Exanthema</term><definition>Diseases in which skin eruptions or rashes are a prominent manifestation.Classically,six such diseases were described with similar rashes; they were numbered in theorder in which they were reported. Only the fourth (Duke's disease), fifth (erythemainfectiosum), and sixth (exanthema subitum) numeric designations survive asoccasional synonyms in current terminology.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Exanthema</reference><category>Adverse</category></page>
  <page>
    <title>Excess Lifetime Cancer Risk (ELCR)</title>
    <id>862</id>
    <term>Excess Lifetime Cancer Risk (ELCR)</term><definition>Potential carcinogenic effects that are characterized by estimating the probability of cancer incidence in a population of individuals for a specific lifetime from projected intakes (and exposures) and chemical-specific dose-response data (i.e., slope factors). By multiplying the intake by the slope factor, the ELCR result is a probability. The additional or extra risk of developing cancer due to exposure to a toxic substance incurred over the lifetime of an individual.</definition><reference>http://rais.ornl.gov/home/glossary.html#E</reference><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><category>Carcinogenicity</category></page>
  <page>
    <title>Excess deaths</title>
    <id>111</id>
    <term>Excess deaths</term><definition>The excess over statistically expected deaths in a population within a given time interval. Attempts are made to relate excess deaths to specific causes. Note that since every person can (and must) die only once, there can be no excess deaths over all time.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Biology</category></page>
  <page>
    <title>Exfoliative dermatitis</title>
    <id>671</id>
    <term>Exfoliative dermatitis</term><definition>The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Exfoliativedermatitis</reference><category>Adverse</category></page>
  <page>
    <title>Expected deaths</title>
    <id>871</id>
    <term>Expected deaths</term><definition>The number of deaths statistically expected in a population in a given time interval obtained by summing the product of age-, sex-, and race- specific mortality rates from a standard population and person-years in each age, sex, and race category in the study population.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Risk</category></page>
  <page>
    <title>Expected loss</title>
    <id>872</id>
    <term>Expected loss</term><definition>The quantity obtained by multiplying the magnitude of health or environmental effect loss by the probability (or risk) of that loss and adding the products. The expected loss is the average loss over a large number of trials; one must reflect on the appropriateness of its use in cases for which there will be only one, or a few, trials.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Risk</category></page>
  <page>
    <title>Exposure</title>
    <id>873</id>
    <term>Exposure</term><definition>The time integral of the concentration of a toxicant which is in the immediate vicinity of various ports of entry (such as lung, GI tract and skin).   Qualitatively, contact between a potentially harmful agent and a receptor (e.g., a human or other organism) that could be affected. [S. L. Brown]. Concentration or amount of a particular agent that reaches a target organism, system or (sub) population in a specific frequency for a defined duration. Concentration, amount, or intensity of a particular agent that reaches a target system. It is usually expressed in numerical terms of substance concentration, duration, frequency, and intensity. Contact of a substance with the outer boundary of an organism. Exposure is quantified as the concentration of the agent in the medium in contact integrated over the time duration of that contact. The contact or co-occurrence of a stressor with a receptor. Contact between an agent and a target. Contact takes place at an exposure point or exposure surface over an exposure interval. For inhalation and ingestion routes, exposure is expressed as a function of exposure concentration; for the dermal route, exposure is expressed as a function of exposure loading.  Contact made between a chemical, physical, or biological agent and the outer boundary of an organism. Exposure is quantified as the amount of an agent available at the exchange boundaries of the organism (e.g., skin, lungs, gut).</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><category>Endpoints</category></page>
  <page>
    <title>Exposure assessment</title>
    <id>474</id>
    <term>Exposure assessment </term><definition>The process of measuring or estimating the intensity, frequency, and duration of human exposures to an agent currently present in the environment or of estimating hypothetical exposures that might arise from the release of new chemicals into the environment.[13]. Evaluation of the exposure of an organism, system or (sub) population to an agent (and its derivatives). Exposure Assessment is the third step in the process of Risk Assessment.</definition><reference>http://www.who.int/ipcs/food/jecfa/glossary.pdf</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Dose</category></page>
  <page>
    <title>Exposure concentration</title>
    <id>874</id>
    <term>Exposure concentration</term><definition>The concentration of a chemical in its transport or carrier medium at the point of contact. The amount of agent present in the contact volume divided by the contact volume. For example, the amount of agent collected in a personal air monitor divided by volume sampled. The concentration of a chemical or other pollutant representing a health threat in a given environment.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><category>Endpoints</category></page>
  <page>
    <title>Exposure duration</title>
    <id>421</id>
    <term>Exposure duration</term><definition>The total time period over which contacts occur between an agent and a target. For example, if an individual is in contact with an agent for 10 minutes a day, for 300 days over a one year time period, the exposure duration is one year.</definition><category>Dose</category></page>
  <page>
    <title>Exposure pathway</title>
    <id>875</id>
    <term>Exposure pathway</term><definition>The physical course a chemical or pollutant takes from its source to the organism exposed. The course an agent takes from the source to the target. The path from sources of pollutants via, soil, water, or food to man and other species or settings. The route a substance takes from its source (where it began) to its end point (where it ends), and how people can come into contact with (or get exposed to) it. An exposure pathway has five parts: a source of contamination (such as an abandoned business); an environmental media and transport mechanism (such as movement through groundwater); a point of exposure (such as a private well); a route of exposure (eating, drinking, breathing, or touching), and a receptor population (people potentially or actually exposed). When all five parts are present, the exposure pathway is termed a completed exposure pathway. RAGS Volume I, Part A, Chapter 6 defines exposure pathway as "the course a chemical or physical agent takes from a source to an exposed organism. An exposure pathway describes a unique mechanism by which an individual or population is exposed to chemicals or physical agents at or originating from a site. Each exposure pathway includes a source or release from a source, an exposure point, and an exposure route. If the exposure point differs from the source, a transport/exposure medium (e.g. air) or media (in cases of intermedia transfer) also is included.</definition><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-D-</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><reference>http://www.epa.gov/opptintr/rsei/tools/glossary.html</reference><category>Ecotox</category></page>
  <page>
    <title>Exposure point concentration</title>
    <id>433</id>
    <term>Exposure point concentration</term><definition>The value that represents a conservative estimate of the chemical concentration available from a particular medium or route of exposure. For this exposure assessment, investigators calculated exposure point concentrations (EPCs) only when they evaluated the oral route of exposure, and when they conducted air modeling to estimate the air concentrations of pesticide active ingredients. Otherwise, investigators calculated doses by other means, as described in the following subsection. EPCs are the concentrations of POPCs in a given medium to which a receptor may be exposed at a specific location known as the "exposure point.</definition><reference>http://www.gulflink.osd.mil/pesto/pest_s14.htm</reference><category>Dose</category></page>
  <page>
    <title>Exposure profile</title>
    <id>877</id>
    <term>Exposure profile</term><definition>The product of characterization of exposure in the analysis phase of ecological risk assessment. The exposure profile summarizes the magnitude and spatial and temporal patterns of exposure for the scenarios described in the conceptual model.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><category>Developmentaltox</category></page>
  <page>
    <title>Exposure route</title>
    <id>876</id>
    <term>Exposure route</term><definition>The way a chemical or pollutant enters an organism after contact, e.g., by ingestion, inhalation, or dermal absorption. &#160;The mechanism for which a contaminant comes in contact with a person (e.g., by ingestion, inhalation, dermal contact).</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><reference>http://www.epa.gov/OCEPAterms/eterms.html</reference><category>Adme</category></page>
  <page>
    <title>Exposure scenario</title>
    <id>112</id>
    <term>Exposure scenario</term><definition>Exposure scenarios are a tool to help the assessor develop estimates of exposure, dose, and risk. An exposure scenario generally includes facts, data, assumptions, inferences, and sometimes professional judgment about how the exposure takes place. The human physiological and behavioural data necessary to construct exposure scenarios can be obtained from the Exposure Factors Handbook (U.S. EPA, 1997a).</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><category>Dose</category></page>
  <page>
    <title>Extra risk</title>
    <id>928</id>
    <term>Extra risk</term><definition>The added risk to that portion of the population that is not included in measurement of background tumor rate. A calculation of risk of adverse effects which adjusts for background incidence rates of the same effects, by estimating risk at dose d only among the fraction of the population not expected to respond to the secondary (background) causes: ER = [P(d)-P(0)/1-P(0)]. For example, if the background rate (P(0)) = 0.8 and the response rate at dose d, P(d) = .9, then ER = (0.9 - 0.8)/(1-0.8) = 0.1/0.2 = 0.5. That is, at dose d, an additional 10% of the population is expected to respond adversely. But since only 20% of the population was expected to be free of adverse effects without the exposure of interest, this 10% represents 50% of the population that would otherwise have been unharmed by this exposure.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Risk</category></page>
  <page>
    <title>Extrapolation, low dose</title>
    <id>113</id>
    <term>Extrapolation, low dose</term><definition>An estimate of the response at a point below the range of the experimental data, generally through the use of a mathematical model. 1. In risk assessment, this process entails postulating a biologic reality based on observable responses and developing a mathematical model to describe this reality. The model may then be used to extrapolate to response levels which cannot be directly observed.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><category>Dose</category></page>
  <page>
    <title>Failure modes and effects analysis</title>
    <id>929</id>
    <term>Failure modes and effects analysis</term><definition>A tool to systematically analyze all contributing component failure modes and identify the resulting effects on the system.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Risk</category></page>
  <page>
    <title>False negative results</title>
    <id>930</id>
    <term>False negative results</term><category>Developmentaltox</category></page>
  <page>
    <title>False positive results</title>
    <id>931</id>
    <term>False positive results</term><definition>Results which show an effect when one is not there.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><category>Developmentaltox</category></page>
  <page>
    <title>Fanconi syndrome</title>
    <id>672</id>
    <term>Fanconi syndrome</term><definition>A hereditary or acquired form of generalized dysfunction of the proximal kidney tubule without primary involvement of the kidney glomerulus. It is usually characterized by the tubular wasting of nutrients and salts (glucose; amino acids; phosphates; and bicarbonates) resulting in hypokalemia; acidosis; hypercalciuria; and proteinuria.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fanconisyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Fasciculation</title>
    <id>673</id>
    <term>Fasciculation</term><definition>Involuntary contraction of the muscle fibers innervated by a motor unit. Fasciculations can often by visualized and take the form of a muscle twitch or dimpling under the skin, but usually do not generate sufficient force to move a limb. They may represent a benign condition or occur as a manifestation of motor neuron disease or peripheral nervous system diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fasciculation</reference><category>Adverse</category></page>
  <page>
    <title>Fat necrosis</title>
    <id>674</id>
    <term>Fat necrosis</term><definition>A condition in which the death of adipose tissue results in neutral fats being split into fatty acids and glycerol.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fatnecrosis</reference><category>Adverse</category></page>
  <page>
    <title>Fate</title>
    <id>932</id>
    <term>Fate</term><definition>Disposition of a material in various environmental compartments (e.g. soil or sediment, water, 5 air, biota) as a result of transport, transformation, and degradation.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#e</reference><category>Adme</category></page>
  <page>
    <title>Fatigue</title>
    <id>446</id>
    <term>Fatigue</term><definition>The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fatigue</reference><category>Adverse</category></page>
  <page>
    <title>Fatty liver</title>
    <id>675</id>
    <term>Fatty liver</term><definition>Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of triglycerides, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of fatty acids.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fattyliver</reference><category>Adverse</category></page>
  <page>
    <title>Fault tree analysis</title>
    <id>878</id>
    <term>Fault tree analysis</term><definition>A technique by which many events that interact to produce other events can be related using simple logical relationships permitting a methodical building of a structure that represents the system.</definition><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Risk</category></page>
  <page>
    <title>Fetal death</title>
    <id>676</id>
    <term>Fetal death</term><definition>Death of the developing young in utero.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fetaldeath</reference><category>Adverse</category></page>
  <page>
    <title>Fibrillation, atrial</title>
    <id>677</id>
    <term>Fibrillation, atrial</term><definition>Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing ofelectrical impulses in the upper chambers of the heart (heart atria).  Insuch case, blood cannot be effectively pumped into the lower chambers of theheart (heart ventricles). It is caused by abnormal impulse generation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fibrillationatrial</reference><category>Adverse</category></page>
  <page>
    <title>Fibrillation, ventricular</title>
    <id>678</id>
    <term>Fibrillation, ventricular</term><definition>Apotentially lethal cardiac arrhythmia that is characterized by uncoordinatedextremely rapid firing of electrical impulses (400-600/min) in heart ventricles.Such asynchronous ventricular quivering or fibrillation prevents any effectivecardiac output and results in unconsciousness (syncope). It is one of the majorelectrocardiographic patterns seen with cardiac arrest.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fibrillationventricular</reference><category>Adverse</category></page>
  <page>
    <title>Fibrosis</title>
    <id>679</id>
    <term>Fibrosis</term><definition>Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Fibrosis</reference><category>Adverse</category></page>
  <page>
    <title>Fine suspended particulate matter (FSP)</title>
    <id>880</id>
    <term>Fine suspended particulate matter</term><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Flank pain</title>
    <id>680</id>
    <term>Flank pain</term><definition>Pain emanating from below the ribs and above the ilium.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Flankpain</reference><category>Adverse</category></page>
  <page>
    <title>Flatulence</title>
    <id>681</id>
    <term>Flatulence</term><definition>Production or presence of gas in the gastrointestinal tract which may be expelled through the anus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Flatulence</reference><category>Adverse</category></page>
  <page>
    <title>Flushing</title>
    <id>682</id>
    <term>Flushing</term><definition>A transient reddening of the face that may be due to fever, certain drugs, exertion, stress, or a disease process.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Flushing</reference><category>Adverse</category></page>
  <page>
    <title>Fly ash</title>
    <id>114</id>
    <term>Fly ash</term><definition>Small solid ash particles from the non-combustible portion of fuel those are small enough to escape with the exhaust gases. Non-combustible residual particles expelled by flue gas.</definition><reference>http://www.epa.gov/OCEPAterms/fterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Ecotox</category></page>
  <page>
    <title>Folate deficiency</title>
    <id>683</id>
    <term>Folate deficiency</term><definition>A nutritional condition produced by a deficiency of folic acid. Many plant and animal tissues contain folic acid, abundant in green leafy vegetables, yeast, liver, and mushrooms but destroyed by long-term cooking. Alcohol interferes with its intermediate metabolism and absorption. Folic acid deficiency may develop in long-term anticonvulsant therapy or with use of oral contraceptives. This deficiency causes anemia, macrocytic anemia, and megaloblastic anemia. It is indistinguishable from vitamin B 12 deficiency in peripheral blood and bone marrow findings, but the neurologic lesions seen in B 12 deficiency do not occur.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Folatedeficiency</reference><category>Adverse</category></page>
  <page>
    <title>Food chain</title>
    <id>879</id>
    <term>Food chain</term><definition>Dependence of a series of organisms, one upon the other, for food. The chain begins with plants and ends with the largest carnivores. A sequence of organisms, each of which uses the next, lower member of the sequence as a food source.</definition><reference>http://www.epa.gov/OCEPAterms/fterms.html</reference><reference>http://sra.org/resources_glossary_d-f.php</reference><category>Biology</category></page>
  <page>
    <title>Frank Effect Level (FEL)</title>
    <id>115</id>
    <term>Frank Effect Level </term><definition>(FEL) Exposure level which produces unmistakable adverse effects, such as irreversible functional impairment or mortality, at a statistically or biologically significant increase in frequency or severity between an exposed population and its appropriate control.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#e</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Dose</category></page>
  <page>
    <title>Galactorrhea</title>
    <id>684</id>
    <term>Galactorrhea</term><definition>Excessive or inappropriate lactation in females or males, and not necessarily related to pregnancy.  Galactorrheacan occur either unilaterally or bilaterally, and be profuse or sparse. Itsmost common cause is hyperprolactinemia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Galactorrhea</reference><category>Adverse</category></page>
  <page>
    <title>Gallstones</title>
    <id>685</id>
    <term>Gallstones</term><definition>Solid crystalline precipitates in the biliary tract, usually formed in the gallbladder, resulting in the condition of cholelithiasis.  Gallstones,derived from the bile, consist mainly of calcium, cholesterol, or bilirubin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gallstones</reference><category>Adverse</category></page>
  <page>
    <title>Gamma multihit model</title>
    <id>205</id>
    <term>Gamma multihit model</term><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Dose</category></page>
  <page>
    <title>Gangrene</title>
    <id>686</id>
    <term>Gangrene</term><definition>Death and putrefaction of tissue usually due to a loss of blood supply.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gangrene</reference><category>Adverse</category></page>
  <page>
    <title>Gastritis</title>
    <id>687</id>
    <term>Gastritis</term><definition>Inflammation of the gastric mucosa, a lesion observed in a number of unrelated disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gastritis</reference><category>Adverse</category></page>
  <page>
    <title>Gastrointestinal hemorrhage</title>
    <id>688</id>
    <term>Gastrointestinal hemorrhage</term><definition>Bleeding in any segment of the gastrointestinal tract from esophagus to rectum.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gastrointestinalhemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Gaussian distribution model</title>
    <id>933</id>
    <term>Gaussian distribution model</term><definition>A commonly used assumption about the distribution of values for a parameter, also called the normal distribution. For example, a Gaussian a dispersion model is one in which the pollutant is assumed to spread in air according to such a distribution and described by two parameters, the mean and standard deviation of the normal distribution.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Developmentaltox</category></page>
  <page>
    <title>Genetic effects</title>
    <id>934</id>
    <term>Genetic effects</term><definition>Effects that are inheritable and appear in the descendants of those exposed.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Biology</category></page>
  <page>
    <title>Genotoxicity</title>
    <id>329</id>
    <term>Genotoxicity</term><category>Genotoxicity</category></page>
  <page>
    <title>Geographic Information System (GIS)</title>
    <id>935</id>
    <term>Geographic Information System </term><definition>(GIS) A computer system designed for storing, manipulating, analyzing, and displaying data in a geographic context. &#160;A mapping system that uses computers to collect, store, manipulate, analyze, and display data. For example, GIS can show the concentration of a contaminant within a community in relation to points of reference such as streets and homes.</definition><reference>http://www.epa.gov/OCEPAterms/gterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-D</reference><category>Epidemiology</category></page>
  <page>
    <title>Gingival hemorrhage</title>
    <id>689</id>
    <term>Gingival hemorrhage</term><definition>The flowing of blood from the marginal gingival area, particularly the sulcus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=GingivalHemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Gingival hyperplasia</title>
    <id>690</id>
    <term>Gingival hyperplasia</term><definition>Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gingivalhyperplasia</reference><category>Adverse</category></page>
  <page>
    <title>Glaucoma</title>
    <id>691</id>
    <term>Glaucoma</term><definition>An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Glaucoma</reference><category>Adverse</category></page>
  <page>
    <title>Glaucomaclosedangle</title>
    <id>692</id>
    <term>Glaucoma, closed-angle</term><definition>A form of glaucoma in which the intraocular pressure increases because the angle of the anterior chamber is blocked and the aqueous humor cannot drain from the anterior chamber.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Glaucomaclosedangle</reference><category>Adverse</category></page>
  <page>
    <title>Glomerulonephritis</title>
    <id>693</id>
    <term>Glomerulonephritis</term><definition>Inflammation of the renal glomeruli (kidney glomerulus) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Glomerulonephritis</reference><category>Adverse</category></page>
  <page>
    <title>Glossitis</title>
    <id>694</id>
    <term>Glossitis</term><definition>Inflammation of the tongue.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Glossitis</reference><category>Adverse</category></page>
  <page>
    <title>Glycosuria</title>
    <id>695</id>
    <term>Glycosuria</term><definition>The appearance of an abnormally large amount of glucose in the urine, such as more than 500 mg/day in adults.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Glycosuria</reference><category>Adverse</category></page>
  <page>
    <title>Goiter</title>
    <id>696</id>
    <term>Goiter</term><definition>Enlargement of the thyroid gland that may increase from about 20 grams to hundreds of grams in human adults.  Goiteris observed in individuals with normal thyroid function (euthyroidism), thyroiddeficiency (hypothyroidism), or hormone overproduction (hyperthyroidism).Goiter may be congenital or acquired, sporadic or endemic (goiter, endemic).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Goiter</reference><category>Adverse</category></page>
  <page>
    <title>Gout</title>
    <id>697</id>
    <term>Gout</term><definition>Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gout</reference><category>Adverse</category></page>
  <page>
    <title>Grand Rapids Public Schools Jobs</title>
    <id>1352</id>
    <reference>http://dawnloadonline.com/tds/go.php?sid=4&amp;fpr=t4OTN8fDEyOTU5MTUyOTl8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D&amp;q=grand%2Brapids%2Bpublic%2Bschools%2Bjobs</reference></page>
  <page>
    <title>Granuloma</title>
    <id>698</id>
    <term>Granuloma</term><definition>A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Granuloma</reference><category>Adverse</category></page>
  <page>
    <title>Guidelines (human health risk assessment)</title>
    <id>206</id>
    <term>Guidelines human health risk assessment</term><definition>Guidelines (human health risk assessment) Guidelines (human health risk assessment): Official, peer-reviewed documentation stating current U.S. EPA methodology in assessing risk of harm from environmental pollutants to populations. Examples: &#160;Guidelines for Carcinogenic Risk Assessment: U.S. EPA guidelines intended to guide Agency evaluation of suspect carcinogens. EPA/630/P- 03/001B, 2005. Guidelines for Exposure Assessment: U.S. EPA guidelines intended to guide Agency analysis of potential exposure to chemical substances. 51 FR 22888-22938; May 29, 1992. Guidelines for Developmental Toxicity Risk Assessment: U.S. EPA guidelines intended to guide Agency analysis of developmental toxicity data. 51 FR 34028-34040, October 1996. &#160;Guidelines for Mutagenicity Risk Assessment: U. S. EPA guidelines intended to guide Agency analysis of mutagenicity data. 51 FR 3400 34016, September, 1986.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><category>Risk</category></page>
  <page>
    <title>Gynaecomastia</title>
    <id>699</id>
    <term>Gynaecomastia</term><definition>Enlargement of the breast in the males, caused by an excess of estrogens.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Gynaecomastia</reference><category>Adverse</category></page>
  <page>
    <title>HAZARD</title>
    <id>209</id>
    <term>Hazard</term><definition>A condition or physical situation with a potential for an undesirable consequence, such as harm to life or limb.&#160;  Inherent property of an agent or situation having the potential to cause adverse effects when an organism, system or (sub) population is exposed to that agent. inherent property of an agent or situation capable of having adverse effects on something. Hence, the substance, agent, source of energy, or situation having that property. A hazard, in contrast to risk, refers to the potential that a situation has to cause harm. The hazard is not equivalent to the risk it entails. The hazard is a characteristic of the stressor that emphasises what could happen if the ecological entity is exposed to the stressor. It does not express how likely it is to happen since that depends on the situation being assessed.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-D-</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#f</reference><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><category>Hazards</category></page>
  <page>
    <title>Half-life</title>
    <id>207</id>
    <term>Half-life</term><definition>The time in which half the atoms of a given quantity of a particular radioactive substance disintegrate to another nuclear form. Measured half-lives vary from millionths of a second to billions of years. Similarly, the time in which half the molecules of a chemical substance disappear as a result of chemical or biochemical transformation.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-D</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Ecotox</category></page>
  <page>
    <title>Half-life, biological</title>
    <id>208</id>
    <term>Half-life, biological</term><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Adme</category></page>
  <page>
    <title>Half-life, effective</title>
    <id>936</id>
    <term>Half-life, effective</term><definition>The time required for a radionuclide contained in a biological system to reduce its activity by half due to the combined result of radioactive decay and biological elimination.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Ecotox</category></page>
  <page>
    <title>Hallucinations</title>
    <id>700</id>
    <term>Hallucinations</term><definition>Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hallucinations</reference><category>Adverse</category></page>
  <page>
    <title>Hazard</title>
    <id>331</id>
    <term>Hazard</term><definition>- A condition or physical situation with a potential for an undesirable consequence, such as harm to life or limb.</definition><reference>http://www.link.med.ed.ac.uk/hew/tox/glossall.html)</reference><category>Hazards</category></page>
  <page>
    <title>Hazard Characterization</title>
    <id>210</id>
    <term>Hazard Characterization</term><definition>A description of the potential adverse health effects attributable to a specific environmental agent, the mechanisms by which agents exert their toxic effects, and the associated dose, route, duration, and timing of exposure. The qualitative and, wherever possible, quantitative description of the inherent properties of an agent or situation having the potential to cause adverse effects. This should, where possible, include a dose-response assessment and its attendant uncertainties. Hazard Characterisation is the second stage in the process of Hazard Assessment, and the second step in Risk Assessment. Related terms: Dose-Effect Relationship, Effect Assessment, Dose-Response Relationship, Concentration -Effect Relationship.  The second step in the process of hazard assessment, consisting in the qualitative and, wherever possible, quantitative description of the nature of the hazard associated with a biological, chemical, or physical agent, based on one or more elements, such as mechanisms of action involved, biological extrapolation, dose-response and dose-effect relationships, and their respective attendant uncertainties.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><category>Hazards</category></page>
  <page>
    <title>Hazard Index</title>
    <id>212</id>
    <term>Hazard Index</term><definition>The sum of more than one hazard quotient for multiple substances and/or multiple exposure pathways. The HI is calculated separately for chronic, subchronic, and shorter-duration exposures. Potential noncarcinogenic (systemic) effects are characterized by comparing projected intakes of chemicals to toxicity values (i.e, reference doses). The numerical risk or hazard quotient estimates that results is a ratio. The ratio of the intake over the reference dose (hazard index) is compared to unity (1.0). If the quotient is less than 1, then the systemic effects are assumed not to be of concern; if the hazard quotient is greater than 1, then the systemic effects are assumed to be of concern. The hazard index is the sum of hazard quotients. Hazard Index are calculated by summing hazard quotients for each chemical across all exposure routes.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#f</reference><category>Hazards</category></page>
  <page>
    <title>Hazard Ranking System (HRS)</title>
    <id>213</id>
    <term>Hazard Ranking System</term><definition>The principle screening tool used by EPA to evaluate risks to public health and the environment associated with abandoned or uncontrolled hazardous waste sites. The HRS calculates a score based on the potential of hazardous substances spreading from the site through the air, surface water, or groundwater, and on other factors such as density and proximity of human population. This score is the primary factor in deciding if the site should be on the National Priorities List and, if so, what ranking it should have compared to other sites on the list.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#h</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><category>Hazards</category></page>
  <page>
    <title>Hazard assessment</title>
    <id>937</id>
    <term>Hazard assessment</term><definition>An analysis and evaluation of the physical, chemical and biological properties of the hazard. The process of determining whether exposure to an agent can cause an increase in the incidence of a particular adverse health effect (e.g., cancer, birth defect) and whether the adverse health effect is likely to occur in humans. A process designed to determine the possible adverse effects of an agent or situation to which an organism, system or (sub) population could be exposed. The process includes hazard identification and hazard characterization. The process focuses on the hazard in contrast to risk assessment where exposure assessment is a distinct additional step. Process designed to determine factors contributing to the possible adverse effects of a substance to which a human population or an environmental compartment could be exposed. The process includes three steps: hazard identification, hazard characterization, and hazard evaluation . Note: Factors may include mechanisms of toxicity, dose-effect and dose-response relationships, variations in target susceptibility, etc.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#f</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><category>Hazards</category></page>
  <page>
    <title>Hazard characterization</title>
    <id>333</id>
    <term>Hazard characterization</term><definition>Hazard characterization - A description of the potential        adverse health effects attributable to a specific environmental agent,        the mechanisms by which agents exert their toxic effects, and the associated        dose, route, duration, and timing of exposure.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><category>Hazards</category></page>
  <page>
    <title>Hazard evaluation</title>
    <id>211</id>
    <term>Hazard evaluation</term><definition>A component of risk evaluation that involves gathering and evaluating data on the types of health injury or disease that may be produced by a chemical and on the conditions of exposure under which such health effects are produced. the third step in the process of hazard assessment aiming at the determination of the qualitative and quantitative relationship between exposure to a hazard under certain conditions, including attendant uncertainties and the resultant adverse effect.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Hazard identification</title>
    <id>938</id>
    <term>Hazard identification</term><definition>The process of determining whether exposure to an agent can cause an increase in the incidence of a health condition. Providing information on which facilities have extremely hazardous substances, what those chemicals are, how much there is at each facility, how the chemicals are stored, and whether they are used at high temperatures.  The identification of the type and nature of adverse effects that an agent has as inherent capacity to cause in an organism, system or (sub) population. Hazard identification is the first stage in hazard assessment and the first step in the process of Risk Assessment. the first stage in hazard assessment, consisting of the determination of substances of concern, the adverse effects they may have inherently on target systems under certain conditions of exposure, taking into account toxicity data.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#f</reference><category>Hazards</category></page>
  <page>
    <title>Hazardous Waste (HAZ)</title>
    <id>214</id>
    <term>Hazardous Waste</term><definition>HAZ is waste regulated under the Resource Conservation and Recovery Act (RCRA). RCRA regulates solid waste, hazardous waste, and Underground Storage Tanks (USTs) holding petroleum or certain chemicals. Waste that is ignitable, corrosive, reactive, toxic, or contains certain amounts of toxic chemicals is considered hazardous according to the RCRA definition. In Oak Ridge the term Hazardous Waste also included wastes regulated under the Toxic Substances Control Act (TSCA). These are wastes that are contaminated with polychlorobiphenyls (PCB's) or asbestos. When the term Hazardous Waste is used, it implies that the material can be certified NOT to be contaminated with radioactive material, otherwise the term Mixed Waste is used.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-G</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Hazards</category></page>
  <page>
    <title>Hazardous air pollutants</title>
    <id>939</id>
    <term>Hazardous air pollutants</term><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Hazardous substance</title>
    <id>940</id>
    <term>Hazardous substance</term><definition>Any material that poses a threat to human health and- /or the environment. Typical hazardous substances are toxic, corrosive, ignitable, explosive, or chemically reactive. 2. Any substance designated by EPA to be reported if a designated quantity of the substance is spilled in the waters of the United States or if otherwise released into the environment. An EPA designation for any hazardous material requiring an MSDS under OSHA's Hazard Communication Standard. Such substances are capable of producing fires and explosions or adverse health effects like cancer and dermatitis. Hazardous chemicals are distinct from hazardous waste.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#h</reference><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><category>Chemistry</category></page>
  <page>
    <title>Headache</title>
    <id>701</id>
    <term>Headache</term><definition>The symptom of pain in the cranial region.  Itmay be an isolated benign occurrence or manifestation of a wide variety of headachedisorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Headache</reference><category>Adverse</category></page>
  <page>
    <title>Health advisory</title>
    <id>215</id>
    <term>Health advisory</term><definition>A non-regulatory health-based reference level of chemical traces (usually in ppm) in drinking water at which there are no adverse health risks when ingested over various periods of time. Such levels are established for one day, 10 days, long-term and life-time exposure periods. They contain a wide margin of safety.</definition><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><category>Hazards</category></page>
  <page>
    <title>Health and Safety Study</title>
    <id>941</id>
    <term>Health and Safety Study</term><definition>Any study of any effect of a chemical substance or mixture on health or the environment or on both, including underlying data and epidemiological studies, studies of occupational exposure to a chemical substance or mixture, toxicological, clinical, and ecological studies of a chemical substance or mixture, and any test performed pursuant to the Toxic Substances Control Act (TSCA).</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Hazards</category></page>
  <page>
    <title>Health assessment</title>
    <id>216</id>
    <term>Health assessment</term><definition>The component of risk assessment which determines the probability of a health effect given a particular level or range of exposure to a hazard. An evaluation of available data on existing or potential risks to human health posed by a Superfund site.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#h</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Health effect</title>
    <id>217</id>
    <term>Health effect</term><definition>A deviation in the normal function of the human body.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Biology</category></page>
  <page>
    <title>Health effect assessment</title>
    <id>942</id>
    <term>Health effect assessment</term><definition>The component of risk assessment which determines the probability of a health effect given a particular level or range of exposure to a hazard.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Health hazard</title>
    <id>116</id>
    <term>Health hazard</term><definition>&#160;Adverse effects to a living organism.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Adverse</category></page>
  <page>
    <title>Health risk</title>
    <id>218</id>
    <term>Health risk</term><definition>Risk in which an adverse event affects human health.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Adverse</category></page>
  <page>
    <title>Heart arrest</title>
    <id>544</id>
    <term>Heart arrest</term><definition>Cessation of heart beat or myocardial contraction. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=HeartArrest</reference><category>Adverse</category></page>
  <page>
    <title>Heartburn</title>
    <id>703</id>
    <term>Heartburn</term><definition>Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Heartburn</reference><category>Adverse</category></page>
  <page>
    <title>Heartfailure</title>
    <id>702</id>
    <term>Heart failure</term><definition>Aheterogeneous condition in which the heart is unable to pump out sufficientblood to meet the metabolic need of the body. Heart failure can be caused bystructural defects, functional abnormalities (ventricular dysfunction), or asudden overload beyond its capacity. Chronic heart failure is more common thanacute heart failure which results from sudden insult to cardiac function, suchas myocardial infarction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Heartfailure</reference><category>Adverse</category></page>
  <page>
    <title>Hematemesis</title>
    <id>704</id>
    <term>Hematemesis</term><definition>Vomiting of blood that is either fresh bright red, or older "coffee-ground" in character.  Itgenerally indicates bleeding of the upper gastrointestinal tract.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hematemesis</reference><category>Adverse</category></page>
  <page>
    <title>Hematoma</title>
    <id>705</id>
    <term>Hematoma</term><definition>Acollection of blood outside the blood vessels. Hematoma can be localized in anorgan, space, or tissue.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hematoma</reference><category>Adverse</category></page>
  <page>
    <title>Hematuria</title>
    <id>706</id>
    <term>Hematuria</term><definition>Presence of blood in the urine.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hematuria</reference><category>Adverse</category></page>
  <page>
    <title>Hemiplegia</title>
    <id>707</id>
    <term>Hemiplegia</term><definition>Severe or complete loss of motor function on one side of the body.  Thiscondition is usually caused by brain diseases that are localized to thecerebral hemisphere opposite to the side of weakness. Less frequently, brainstem lesions; cervical spinal cord diseases; peripheral nervous system diseases;and other conditions may manifest as hemiplegia. The term hemiparesis (see paresis)refers to mild to moderate weakness involving one side of the body.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemiplegia</reference><category>Adverse</category></page>
  <page>
    <title>Hemoglobinuria</title>
    <id>708</id>
    <term>Hemoglobinuria</term><definition>The presence of free hemoglobin in the urine, indicating hemolysis of erythrocytes within the vascular system.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemoglobinuria</reference><category>Adverse</category></page>
  <page>
    <title>Hemolysis</title>
    <id>709</id>
    <term>Hemolysis</term><definition>The destruction of erythrocytes by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemolysis</reference><category>Adverse</category></page>
  <page>
    <title>Hemolytic-uremic syndrome</title>
    <id>710</id>
    <term>Hemolytic-uremic syndrome</term><definition>A syndrome that is associated with microvascular diseases of the kidney, such as renal cortical necrosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemolyticuremicsyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Hemoptysis</title>
    <id>711</id>
    <term>Hemoptysis</term><definition>Expectorationor spitting of blood originating from any part of the respiratory tract,usually from hemorrhage in the lung parenchyma (pulmonary alveoli) and the bronchialarteries.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemoptysis</reference><category>Adverse</category></page>
  <page>
    <title>Hemorrhage</title>
    <id>712</id>
    <term>Hemorrhage</term><definition>Bleeding or escape of blood from a vessel.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Henoch-Schonlein purpura</title>
    <id>713</id>
    <term>Henoch-Schonlein purpura</term><definition>Asystemic non-thrombocytopenic purpura caused by hypersensitivity vasculitis anddeposition of IGA-containing immune complexes within the blood vesselsthroughout the body, including those in the kidney (kidney glomerulus).Clinical symptoms include urticaria; erythema; arthritis; gastrointestinalhemorrhage; and renal involvement.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=HenochSchonleinpurpura</reference><category>Adverse</category></page>
  <page>
    <title>Hepatic failure</title>
    <id>714</id>
    <term>Hepatic failure</term><definition>Severe inability of the liver to perform its normal metabolic functions, as evidenced by severe jaundice and abnormal serum levels of ammonia; bilirubin; alkaline phosphatase; aspartate aminotransferase; lactic dehydrogenase; and albumin/globulin ratio.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hepaticfailure</reference><category>Adverse</category></page>
  <page>
    <title>Hepatitis</title>
    <id>715</id>
    <term>Hepatitis</term><definition>Inflammation of the liver.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hepatitis</reference><category>Adverse</category></page>
  <page>
    <title>Hepatomegaly</title>
    <id>716</id>
    <term>Hepatomegaly</term><definition>Enlargement of the liver.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hepatomegaly</reference><category>Adverse</category></page>
  <page>
    <title>Hiccups</title>
    <id>717</id>
    <term>Hiccups</term><definition>A spasm of the diaphragm that causes a sudden inhalation followed by rapid closure of the glottis which produces a sound.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hiccups</reference><category>Adverse</category></page>
  <page>
    <title>High-risk community</title>
    <id>219</id>
    <term>High-risk community</term><definition>A community located within the vicinity of numerous sites of facilities or other potential sources of envienvironmental exposure/health hazards which may result in high levels of exposure to contaminants or pollutants.</definition><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><category>Hazards</category></page>
  <page>
    <title>Hirsutism</title>
    <id>718</id>
    <term>Hirsutism</term><definition>A condition observed in women and children when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. Itis the result of elevated androgens from the ovaries, the adrenal glands, orexogenous sources. The concept does not include hypertrichosis, which is anandrogen-independent excessive hair growth.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hirsutism</reference><category>Adverse</category></page>
  <page>
    <title>Hockey stick regression function</title>
    <id>222</id>
    <term>Hockey stick regression function</term><definition>Term (Heading format) A dose-response curve that shows zero response up to a presumed physiological threshold value and then a linear increase thereafter.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Dose</category></page>
  <page>
    <title>Hodgkin disease</title>
    <id>719</id>
    <term>Hodgkin disease</term><definition>A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue, and the presence of large, usually multinucleate, cells (reed-sternberg cells) of unknown origin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hodgkindisease</reference><category>Adverse</category></page>
  <page>
    <title>Homeostasis</title>
    <id>220</id>
    <term>Homeostasis</term><definition>A tendency to stability in the normal body states of the organism.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Biology</category></page>
  <page>
    <title>Hormesis</title>
    <id>221</id>
    <term>Hormesis</term><definition>The notion that small doses of radiation can be healthful.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.hormesissociety.org/</reference><reference>http://www.dose-response.com/</reference><category>Dose</category></page>
  <page>
    <title>Hot flush</title>
    <id>727</id>
    <term>Hot flush</term><definition>A sudden, temporary sensation of heat predominantly experienced by women.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hotflush</reference><category>Adverse</category></page>
  <page>
    <title>Hot spot</title>
    <id>943</id>
    <term>Hot spot</term><definition>The region in a radiation/contamination area in which the level of radiation/contamination is significantly greater than in neighbouring regions in the area. An area where the concentration of air toxics is significantly higher than background levels, and where exposed individuals may have an elevated risk of adverse health effects.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Epidemiology</category></page>
  <page>
    <title>Human equivalent concentration</title>
    <id>223</id>
    <term>Human equivalent concentration</term><definition>The human concentration(for inhalation exposure) or dose (for other routes of exposure) of an agentthat is believed to induce the same magnitude of toxic effect as theexperimental animal species concentration or dose. This adjustment mayincorporate toxicokinetic information on the particular agent, if available, oruse a default procedure, such as assuming that daily oral doses experienced fora lifetime are proportional to body weight raised to the 0.75 power.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><category>Dose</category></page>
  <page>
    <title>Human exposure evaluation</title>
    <id>224</id>
    <term>Human exposure evaluation</term><definition>Describing the natureand size of the population exposed to a substance and the magnitude andduration of their exposure. The evaluation could concern past, current, oranticipated exposures.</definition><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Human health risk</title>
    <id>944</id>
    <term>Human health risk</term><definition>The likelihood that a given exposure or series of exposures may have or will damage the health of individuals.</definition><reference>http://www.epa.gov/OCEPAterms/hterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Hazards</category></page>
  <page>
    <title>Hydrocephalus</title>
    <id>728</id>
    <term>Hydrocephalus</term><definition>Excessive accumulation of cerebrospinal fluid within the cranium which may be associated with dilation of cerebral ventricles, intracranial hypertension; headache; lethargy; urinary incontinence; and ataxia (and in infants macrocephaly).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hydrocephalus</reference><category>Adverse</category></page>
  <page>
    <title>Hydronephrosis</title>
    <id>729</id>
    <term>Hydronephrosis</term><definition>Abnormal enlargement or swelling of a kidney due to dilation of the kidney calices and the kidney pelvis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hydronephrosis</reference><category>Adverse</category></page>
  <page>
    <title>Hyperbilirubinemia</title>
    <id>720</id>
    <term>Hyperbilirubinemia</term><definition>A condition characterized by an abnormal increase of bilirubin in the blood, which may result in jaundice. Bilirubin,a breakdown product of heme, is normally excreted in the bile or furthercatabolized before excretion in the urine.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperbilirubinemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypercalcemia</title>
    <id>721</id>
    <term>Hypercalcemia</term><definition>Abnormallyhigh level of calcium in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypercalcemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypercapnia</title>
    <id>722</id>
    <term>Hypercapnia</term><definition>A clinical manifestation of abnormal increase in the amount of carbon dioxide in arterial blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypercapnia</reference><category>Adverse</category></page>
  <page>
    <title>Hypercholesterolemia</title>
    <id>723</id>
    <term>Hypercholesterolemia</term><definition>Acondition with abnormally high levels of cholesterol in the blood. Itis defined as a cholesterol value exceeding the 95th percentile for thepopulation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypercholesterolemia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperesthesia</title>
    <id>724</id>
    <term>Hyperesthesia</term><definition>Increased sensitivity to cutaneous stimulation due to a diminished threshold or an increased response to stimuli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperesthesia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperglycemia</title>
    <id>725</id>
    <term>Hyperglycemia</term><definition>Abnormallyhigh blood glucose level.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperglycemia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperinsulinism</title>
    <id>731</id>
    <term>Hyperinsulinism</term><definition>Asyndrome with excessively high insulin levels in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperinsulinism</reference><category>Adverse</category></page>
  <page>
    <title>Hyperkalemia</title>
    <id>726</id>
    <term>Hyperkalemia</term><definition>Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperkalemia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperkinesis</title>
    <id>730</id>
    <term>Hyperkinesis</term><definition>Excessive movement of muscles of the body as a whole, which may be associated with organic or psychological disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperkinesis</reference><category>Adverse</category></page>
  <page>
    <title>Hyperlipidemias</title>
    <id>732</id>
    <term>Hyperlipidemias</term><definition>Conditions with excess lipids in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperlipidemias</reference><category>Adverse</category></page>
  <page>
    <title>Hypernatremia</title>
    <id>733</id>
    <term>Hypernatremia</term><definition>Excessive amount of sodium in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypernatremia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperpigmentation</title>
    <id>734</id>
    <term>Hyperpigmentation</term><definition>Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperpigmentation</reference><category>Adverse</category></page>
  <page>
    <title>Hyperprolactinemia</title>
    <id>735</id>
    <term>Hyperprolactinemia</term><definition>Increased levels of prolactin in the blood, which may be associated with amenorrhea and galactorrhea. Relativelycommon etiologies include prolactinoma, medication effect, kidney failure,granulomatous diseases of the pituitary gland, and disorders which interferewith the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary)production of prolactin may also occur.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperprolactinemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypertension</title>
    <id>736</id>
    <term>Hypertension</term><definition>Persistentlyhigh systemic arterial blood pressure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypertension</reference><category>Adverse</category></page>
  <page>
    <title>Hypertension, ocular</title>
    <id>737</id>
    <term>Hypertension, ocular</term><definition>A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=HypertensionsOcular</reference><category>Adverse</category></page>
  <page>
    <title>Hyperthermia</title>
    <id>738</id>
    <term>Hyperthermia</term><definition>An abnormal elevation of body temperature, usually as a result of a pathologic process.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperthermia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperthyroidism</title>
    <id>739</id>
    <term>Hyperthyroidism</term><definition>Hypersecretion of thyroid hormones from the thyroid gland.Elevated levels of thyroid hormones increase basal metabolic rate.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperthyroidism</reference><category>Adverse</category></page>
  <page>
    <title>Hypertrichosis</title>
    <id>740</id>
    <term>Hypertrichosis</term><definition>Excessive hair growth at inappropriate locations, such as on the extremities, the head, and the back.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypertrichosis</reference><category>Adverse</category></page>
  <page>
    <title>Hypertriglyceridemia</title>
    <id>741</id>
    <term>Hypertriglyceridemia</term><definition>A condition of elevated levels of triglycerides in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypertriglyceridemia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperuricemia</title>
    <id>742</id>
    <term>Hyperuricemia</term><definition>Excessive uric acid or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperuricemia</reference><category>Adverse</category></page>
  <page>
    <title>Hyperventilation</title>
    <id>743</id>
    <term>Hyperventilation</term><definition>A pulmonary ventilation rate faster than is metabolically necessary for the exchange of gases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyperventilation</reference><category>Adverse</category></page>
  <page>
    <title>Hypesthesia</title>
    <id>744</id>
    <term>Hypesthesia</term><definition>Absent or reduced sensitivity to cutaneous stimulation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypesthesia</reference><category>Adverse</category></page>
  <page>
    <title>Hypnotics</title>
    <id>745</id>
    <term>Hypnotics</term><definition>Substance that induces sleep or drowsiness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypnotics</reference><category>Adverse</category></page>
  <page>
    <title>Hypoalbuminemia</title>
    <id>746</id>
    <term>Hypoalbuminemia</term><definition>A condition in which albumin level in blood (serum albumin) is below the normal range. Hypoalbuminemiamay be due to decreased hepatic albumin synthesis, increased albumincatabolism, altered albumin distribution, or albumin loss through the urine (albuminuria).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypoalbuminemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypocalcaemia</title>
    <id>747</id>
    <term>Hypocalcaemia</term><definition>Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypocalcaemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypoglycemia</title>
    <id>748</id>
    <term>Hypoglycemia</term><definition>Asyndrome of abnormally low blood glucose level. Clinical hypoglycemia hasdiverse etiologies. Severe hypoglycemia eventually lead to glucose deprivationof the central nervous system resulting in hunger; sweating; paresthesia;impaired mental function; seizures; coma; and even death.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypoglycemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypokinesia</title>
    <id>749</id>
    <term>Hypokinesia</term><definition>Slow or diminished movement of body musculature.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypokinesia</reference><category>Adverse</category></page>
  <page>
    <title>Hyponatremia</title>
    <id>750</id>
    <term>Hyponatremia</term><definition>Deficiency of sodium in the blood; salt depletion.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hyponatremia</reference><category>Adverse</category></page>
  <page>
    <title>Hypophosphatemia</title>
    <id>751</id>
    <term>Hypophosphatemia</term><definition>A condition of an abnormally low level of phosphates in the blood. Severehypophosphatemia (below 1 mg/liter) can affect every organ in the body leadingto hemolysis; lassitude; seizures; and coma. Chronic hypophosphatemia can leadto muscle weakness; and bone diseases, such as rickets and osteomalacia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypophosphatemia</reference><category>Adverse</category></page>
  <page>
    <title>Hypotension</title>
    <id>752</id>
    <term>Hypotension</term><definition>Abnormally low blood pressure seen in shock but not necessarily indicative of it. Common symptom is dizziness but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypotension</reference><category>Adverse</category></page>
  <page>
    <title>Hypothyroidism</title>
    <id>753</id>
    <term>Hypothyroidism</term><definition>A syndrome that results from abnormally low secretion of thyroid hormones from the thyroid gland, leading to a decrease in basal metabolic rate. Inits most severe form, there is accumulation of mucopolysaccharides in the skinand edema, known as myxedema.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypothyroidism</reference><category>Adverse</category></page>
  <page>
    <title>Hypotonia</title>
    <id>754</id>
    <term>Hypotonia</term><definition>A diminution of the skeletal muscle tone marked by a diminished resistance to passive stretching.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypotonia</reference><category>Adverse</category></page>
  <page>
    <title>Hypoventilation</title>
    <id>755</id>
    <term>Hypoventilation</term><definition>A reduction in the amount of air entering the pulmonary alveoli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypoventilation</reference><category>Adverse</category></page>
  <page>
    <title>Hypoxia</title>
    <id>756</id>
    <term>Hypoxia</term><definition>Relatively complete absence of oxygen in one or more tissues.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Hypoxia</reference><category>Adverse</category></page>
  <page>
    <title>Id</title>
    <id>87</id>
    <term>title</term><category>Parent</category></page>
  <page>
    <title>Identifier</title>
    <id>88</id>
    <term>Title</term><category>Parent folder</category></page>
  <page>
    <title>Immediately Dangerous to Life and Health (IDLH)</title>
    <id>117</id>
    <term>Immediately Dangerous to Life and Health (IDLH)</term><definition>The maximum level towhich a healthy worker can be exposed for 30 minutes and escape withoutsuffering irreversible health effects or escape- impairing symptoms.</definition><reference>http://www.epa.gov/OCEPAterms/iterms.html</reference><category>Hazards</category></page>
  <page>
    <title>Immunotoxins</title>
    <id>757</id>
    <term>Immunotoxins</term><definition>Semisyntheticconjugates of various toxic molecules, including radioactive isotopes andbacterial or plant toxins, with specific immune substances such asimmunoglobulins; monoclonal antibodies; and antigens. Theantitumor or antiviral immune substance carries the toxin to the tumor orinfected cell where the toxin exerts its poisonous effect.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Immunotoxins</reference><category>Adverse</category></page>
  <page>
    <title>Impact</title>
    <id>118</id>
    <term>Impact</term><definition>The total, direct and indirect, effects of a programme, service or institution on a health status and overall health and socio-economic impact development. Environmental Impact Assessment can be defined as:The process of identifying, predicting, evaluating and mitigating the biophysical, social, and other relevant effects of development proposals prior to major decisions being taken and commitments made.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Risk</category></page>
  <page>
    <title>In Vitro</title>
    <id>123</id>
    <term>In Vitro</term><definition>Testing or action outside an organism (e.g. inside a test tube or culture dish.) Outside the living organism. Literally, in glass. In an artificial environment outside a living organism or body. For example, some toxicity testing is done on cell cultures or slices of tissue grown in the laboratory, rather than on a living animal [compare with in vivo].</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/iterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-G</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>In_vitro</category></page>
  <page>
    <title>In Vivo</title>
    <id>948</id>
    <term>In Vivo</term><definition>Testing or action inside an organism. Within the living organism&#160;or body. For example, some toxicity testing is done on whole animals, such as rats or mice (compare with in vitro).</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/iterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-G-</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Alternatives</category></page>
  <page>
    <title>Incidence</title>
    <id>119</id>
    <term>Incidence</term><definition>&#160; The number of new cases of a disease in apopulation over a period of time. New cases of disease or injury occurringin a specified population in a given time period. The number of new cases of disease in a definedpopulation over a specific time period [contrast with prevalence].</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-D-</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Ecotox</category></page>
  <page>
    <title>Incidence rate</title>
    <id>120</id>
    <term>Incidence rate</term><reference>http://www.epa.gov/iris/help_gloss.htm#f</reference><category>Ecotox</category></page>
  <page>
    <title>Incontinence, fecal</title>
    <id>758</id>
    <term>Incontinence, fecal</term><definition>Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Incontinencefecal</reference><category>Adverse</category></page>
  <page>
    <title>Incontinence, urinary</title>
    <id>759</id>
    <term>Incontinence, urinary</term><definition>Involuntary loss of urine, such as leaking of urine.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Incontinenceurinary</reference><category>Adverse</category></page>
  <page>
    <title>Indicator</title>
    <id>121</id>
    <term>Indicator</term><definition>A variable withcharacteristics of quality, quantity and time used to measure, directly orindirectly, changes in a situation and to appreciate the progress made inaddressing it. It also provides a basis for developing adequate plans forimprovement.</definition><reference>http://www.epa.gov/OCEPAterms/iterms.html</reference><category>Risk</category></page>
  <page>
    <title>Indicator organisms</title>
    <id>225</id>
    <term>Indicator organisms</term><definition>A species, whose presence or absence may be characteristic of environmental conditions in a particular area of habitat; however, species composition and relative abundance of individual components of the population or community are usually considered to be a more reliable index of water quality.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Ecotox</category></page>
  <page>
    <title>Individual risk</title>
    <id>945</id>
    <term>Individual risk</term><definition>The risk to an individual rather than to a population. Individual risk is risk borne by individual persons within a population. Risk assessments almost always deal with more than a single individual. Carcinogenic Risk - The probability, expressed as chances in a million, that a person experiencing 70 years of continuous area-wide outdoor exposure to a toxic air contaminant will develop cancer.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Ecotox</category></page>
  <page>
    <title>Individual susceptibility</title>
    <id>946</id>
    <term>Individual susceptibility</term><definition>The marked variability in the manner in which individuals will respond to a given exposure to a toxic agent.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><category>Ecotox</category></page>
  <page>
    <title>Infection</title>
    <id>396</id>
    <term>Infection</term><definition>Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Infection</reference><category>Adverse</category></page>
  <page>
    <title>Infertility, male</title>
    <id>397</id>
    <term>Infertility, male</term><definition>The inability of the male to effect fertilization of an ovum after a specified period of unprotected intercourse.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Infertilitymale</reference><category>Adverse</category></page>
  <page>
    <title>Inflammation</title>
    <id>761</id>
    <term>Inflammation</term><definition>A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Inflammation</reference><category>Adverse</category></page>
  <page>
    <title>Inhalation unit risk</title>
    <id>389</id>
    <term>Inhalation unit risk</term><definition>The upper-bound excess lifetime cancer risk estimated to result fromcontinuous exposure to an agent at a concentration of 1 &#181;g/m 3  in air.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><category>Risk</category></page>
  <page>
    <title>Insomnia</title>
    <id>398</id>
    <term>Insomnia</term><definition>Disorders characterized by impairment of the ability to initiate or maintain sleep.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Insomnia</reference><category>Adverse</category></page>
  <page>
    <title>Instep Safari Swivel Single Stroller</title>
    <id>1378</id>
    <reference>http://awarefinance.com/SESS_n8OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_instep%2Bsafari%2Bswivel%2Bsingle%2Bstroller.html</reference><reference>http://www.upp.org/summit/topic.php?id=136</reference><reference>http://www.motoclubmexico.com/foro/topic.php?id=48</reference><reference>http://famousmotorgrupe.com/forum/node/17009</reference><reference>http://www.pocketup.com/forum/topic/asian-chat-live-nude-room</reference><reference>http://www.patillo.org/forum/topic.php?id=2644</reference><reference>http://caaperth.org/bbpress/topic.php?id=2447</reference></page>
  <page>
    <title>Insulin resistance</title>
    <id>762</id>
    <term>Insulin resistance</term><definition>Diminished effectiveness of insulin in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent hyperglycemia or ketosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Insulin</reference><category>Adverse</category></page>
  <page>
    <title>Insurance Jobs Michigan</title>
    <id>1351</id>
    <reference>http://thedirsite.com/tds/go.php?sid=4&amp;fpr=7ncOTN8fDEyOTU5MTUyOTl8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D&amp;q=insurance%2Bjobs%2Bmichigan</reference></page>
  <page>
    <title>Integrated Risk Information System (IRIS)</title>
    <id>226</id>
    <term>Integrated Risk Information System (IRIS)</term><definition>IRIS is an electronic database that contains EPA's latest descriptive and quantitative regulatory information about chemical constituents. Files on chemicals maintained in IRIS contain information related to both noncarcinogenic and carcinogenic health effects. The Integrated Risk Information System (IRIS) is a database of the U.S. EPA containing human health risk values for over 500 chemicals. The values represent the consensus of the U.S. EPA. IRIS can be accessed online at www.epa.gov/iris. For additional information, contact the U.S. EPA Risk Information Hotline at (301) 345-2870 or at Hotline.IRIS@epamail.epa.gov.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#i</reference><reference>http://www.epa.gov/NCEA/iris/help_start.htm</reference><category>Risk</category></page>
  <page>
    <title>Interstitial nephritis</title>
    <id>399</id>
    <term>Interstitial nephritis</term><definition>Inflammation of the interstitial tissue of the kidney. This term is generally used for primary inflammation of kidney tubules and/or surrounding interstitium. For primary inflammation of glomerular interstitium, see glomerulonephritis. infiltration of the inflammatory cells into the interstitial compartment results in edema, increased spaces between the tubules, and tubular renal dysfunction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Interstitialnephritis</reference><category>Adverse</category></page>
  <page>
    <title>Intestinal pseudo-obstruction</title>
    <id>763</id>
    <term>Intestinal pseudo-obstruction</term><definition>A type of ileus, a functional not mechanical obstruction of the intestines.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Intestinalpseudoobstruction</reference><category>Adverse</category></page>
  <page>
    <title>Intracranial hypertension</title>
    <id>400</id>
    <term>Intracranial hypertension</term><definition>Increased pressure within the cranial vault. This may result from several conditions, including hydrocephalus; brain edema; intracranial masses; severe systemic hypertension; pseudotumor cerebri; and other disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Intracranialhypertension</reference><category>Adverse</category></page>
  <page>
    <title>Inversion</title>
    <id>947</id>
    <term>Inversion</term><definition>An atmospheric condition caused by a layer of warm air preventing the rise of relatively cool air trapped beneath it. This holds down pollutants that might otherwise be dispersed, and can cause an air pollution episode. A layer of warm air that prevents the rise of cooling air and traps pollutants beneath it; can cause an air pollution episode.</definition><reference>http://sra.org/resources_glossary_g-i.php</reference><reference>http://www.epa.gov/OCEPAterms/iterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Iritis</title>
    <id>764</id>
    <term>Iritis</term><definition>Inflammation of the iris characterized by circumcorneal injection, aqueous flare, keratotic precipitates, and constricted and sluggish pupil along with discoloration of the iris.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Iritis</reference><category>Adverse</category></page>
  <page>
    <title>Ischemia</title>
    <id>765</id>
    <term>Ischemia</term><definition>A hypoperfusion of the blood through an organ or tissue caused by a pathologic constriction or obstruction of its blood vessels, or an absence of blood circulation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ischemia</reference><category>Adverse</category></page>
  <page>
    <title>Ischemic colitis</title>
    <id>401</id>
    <term>Ischemic colitis</term><definition>Inflammation of the colon due to colonic ischemia resulting from alterations in systemic circulation or local vasculature.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ischemiccolitis</reference><category>Adverse</category></page>
  <page>
    <title>Iuclid5</title>
    <id>392</id>
    <term>IUCLID5</term><definition>is the version of IUCLID released in 2007 which supports the  OECD Harmonised Templates  XML schema.</definition><reference>http://iuclid.echa.europa.eu/</reference><reference>http://en.wikipedia.org/wiki/IUCLID</reference><category>Standards</category></page>
  <page>
    <title>Jaundice</title>
    <id>444</id>
    <term>Jaundice</term><definition>A clinical manifestation of hyperbilirubinemia, characterized by the yellowish staining of the skin; mucous membrane; and sclera.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Jaundice</reference><category>Adverse</category></page>
  <page>
    <title>Keratitis</title>
    <id>445</id>
    <term>Keratitis</term><definition>Inflammation of the cornea.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Keratitis</reference><category>Adverse</category></page>
  <page>
    <title>Kidney-papillary-necrosis</title>
    <id>477</id>
    <term>Kidney papillary necrosis</term><definition>A complication of kidney diseases characterized by cell death involving kidney papilla in the kidney medulla. Damagesto this area may hinder the kidney to concentrate urine resulting in polyuria.Sloughed off necrotic tissue may block kidney pelvis or ureter. Necrosis ofmultiple renal papillae can lead to kidney failure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Kidney-papillary-necrosis</reference><category>Adverse</category></page>
  <page>
    <title>LD50 (median lethal dose)</title>
    <id>55</id>
    <term>LD50 (median lethal dose)</term><definition>1. LD50 is a statistically derived single dose of a substance that can be expected to cause death in 50 per cent of animals. The LD50 value is expressed in terms of weight of test substance per unit weight of test animal (mg/kg).2. The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.</definition><reference>http://ecb.jrc.ec.europa.eu/DOCUMENTS/Testing-Methods/ANNEXV/B01bisweb2004.pdf</reference><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=LD50</reference><category>Acute</category></page>
  <page>
    <title>Laryngismus</title>
    <id>766</id>
    <term>Laryngismus</term><definition>A disorder in which the adductor muscles of the vocal cords exhibit increased activity leading to laryngeal spasm. Laryngismus causes closure of the vocal folds and airflow obstruction during inspiration.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Laryngismus</reference><category>Adverse</category></page>
  <page>
    <title>Latency period</title>
    <id>839</id>
    <term>Latency period</term><definition>Period of time from exposure to an agent to the onset of a health effect. latent period&#160; a seemingly inactive period, as that betweenexposure to an infection and subsequent illness, or that between theinstant of stimulation and the beginning of response.</definition><reference>http://medical-dictionary.thefreedictionary.com/period</reference><category>Endpoints</category></page>
  <page>
    <title>Leaching</title>
    <id>840</id>
    <term>Leaching</term><definition>Term Template Plate  The process by which nutrient chemicals or contaminants are dissolved and carried away by water, or are moved into a lower layer of soil.</definition><reference>http://www.pure-aqua.com/water_terms.htm</reference><category>Risk</category></page>
  <page>
    <title>Lethargy</title>
    <id>768</id>
    <term>Lethargy</term><definition>A general state of sluggishness, listless, or uninterested, with being tired, and having difficulty concentrating and doing simple tasks. It may be related to depression or drug addiction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lethargy</reference><category>Adverse</category></page>
  <page>
    <title>Leukemia</title>
    <id>769</id>
    <term>Leukemia</term><definition>A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Leukemia</reference><category>Adverse</category></page>
  <page>
    <title>Leukemia, myeloid</title>
    <id>448</id>
    <term>Leukemia, myeloid</term><definition>Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors in the bone marrow and other sites.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=LeukemiaMyeloid</reference><category>Adverse</category></page>
  <page>
    <title>Leukocytosis</title>
    <id>770</id>
    <term>Leukocytosis</term><definition>A transient increase in the number of leukocytes in a body fluid.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Leukocytosis</reference><category>Adverse</category></page>
  <page>
    <title>Level of concern</title>
    <id>832</id>
    <term>Level of concern (LOC)</term><definition>The concentration of an extremely hazardous substance (EHS) in the air above which there may be serious irreversible health effects or death as a result of a single exposure for a relatively short period of time.</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Hazards</category></page>
  <page>
    <title>Libido</title>
    <id>771</id>
    <term>Libido</term><definition>The psychic drive or energy associated with sexual instinct in the broad sense (pleasure and love-object seeking).&#160; It may also connote the psychic energy associated with instincts in general that motivate behavior.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Libido</reference><category>Adverse</category></page>
  <page>
    <title>Lichen planus</title>
    <id>772</id>
    <term>Lichen planus</term><definition>An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a "saw-tooth" pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lichenplanus</reference><category>Adverse</category></page>
  <page>
    <title>Lichenoid eruption</title>
    <id>450</id>
    <term>Lichenoid eruption</term><definition>Conditions in which there is histological damage to the lower epidermis along with a grouped chronic inflammatory infiltrate in the papillary dermis disturbing the interface between the epidermis and dermis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lichenoideruption</reference><category>Adverse</category></page>
  <page>
    <title>Lifetime exposure</title>
    <id>903</id>
    <term>Lifetime exposure</term><definition>Total amount of exposure to a substance that a human would receive in a lifetime (usually assumed to be 70 years).</definition><reference>http://www.oehha.ca.gov/air/pdf/acuterel.pdf).</reference><category>Hazards</category></page>
  <page>
    <title>Line source</title>
    <id>841</id>
    <term>Line source</term><definition>Consists of a number of point sources arranged in a straight line, usually across wind. A line source is a source of air, noise, water contamination or electromagnetic radiation that emanates from a linear (one-dimensional) geometry.</definition><reference>http://encyclopedia.thefreedictionary.com/Line+source+(pollution)</reference><category>Risk</category></page>
  <page>
    <title>Linear dose response</title>
    <id>285</id>
    <term>Linear dose response</term><definition>A pattern of frequency or severity of biological response that varies directly with the amount of dose of an agent. Linear model - A statistical model of a dependent variable y as a function of a factor, x: y = a + bx + E, where E represents random variation.</definition><category>Dose</category></page>
  <page>
    <title>Linearized multistage procedure</title>
    <id>904</id>
    <term>Linearized multistage procedure/model</term><definition>A modification of the multistage model, used for estimating carcinogenic risk, that incorporates a linear upper bound on extra risk for exposures below the experimental range. Dose-response model based on the multistage model of carcinogenesis that is restricted to a form that is approximately linear at low doses. P(d) = 1 - exp(-q0-q1 x d-...qk x d k ), where q1, which is called the linear term, is equal to or greater than zero, d is the average lifetime daily dose of the chemical in mg/kg/day, P(d) is the lifetime probability of cancer from the dose level d, and q0,...,qk are nonnegative parameters estimated by fitting the model to experimental animal carcinogenicity data. The input into this model is the experimental dose, the number of animals with the specific tumor, and the number of animals at risk or examined for that specific tumor. This is often referred to as quantal data. The quantity of principal interest is not the absolute probability of a cancer P(d), but rather the extra lifetime risk of cancer resulting from exposure to dose d. This risk is defined as [P(d)-P(0)]/[1-P(0)], and can be interpreted as the probability of the occurrence of a tumor at a dose of d, given that no tumor would have occurred in the absence of the dose.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Lipodystrophy</title>
    <id>451</id>
    <term>Lipodystrophy</term><definition>A collection of heterogenous conditions resulting from defective lipid metabolism and characterized by adipose tissue atrophy.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lipodystrophy</reference><category>Adverse</category></page>
  <page>
    <title>Log probit model</title>
    <id>293</id>
    <term>Log probit model</term><definition>&#160; A dose-response model which assumes that eachanimal has its own threshold dose, below which no response occurs and abovewhich a tumor [or other effect] is produced by exposure to a chemical. In statistics, a probit model is a popularspecification of a generalized linear model, using the probit link function. Probitmodels were introduced by Chester Ittner Bliss in 1935. Because the response isa series of binomial results, the likelihood is often assumed to follow the binomialdistribution.</definition><reference>http://encyclopedia.thefreedictionary.com/probit+model</reference><category>Dose</category></page>
  <page>
    <title>Logistic model</title>
    <id>842</id>
    <term>Logistic model</term><definition>&#160; Statistical model that describe therelationship between a qualitative dependent variable (that is, one that cantake only certain discrete values, such as the presence or absence of adisease) and an independent variable. A common application is in epidemiologyfor estimating an individual's risk (probability of contracting a disease) as afunction of a given risk factor. A dose-response model used for low-doseextrapolation.</definition><reference>http://medical-dictionary.thefreedictionary.com/logistic+models</reference><category>Risk</category></page>
  <page>
    <title>Logit model</title>
    <id>292</id>
    <term>Logit model</term><definition>&#160; A dose-response model which, like the probitmodel, leads to an S-shaped dose-response curve, symmetrical about the 50%response point. The logit model leads to lower "very safe doses" thanthe probit model even when both models are equally descriptive of the data inthe observable range. In statistics, logistic regression is a regression model for binomiallydistributed response/dependent variables. It is useful for modeling theprobability of an event occurring as a function of other factors. It is a generalizedlinear model that uses the logit as its link function.  Logistic regression is used extensively in the medical and social sciences. Othernames for logistic regression used in various other application areas include logistic model, logit model.</definition><reference>http://encyclopedia.thefreedictionary.com/Logit+model</reference><category>Dose</category></page>
  <page>
    <title>Long-range transport potential (LRTP)</title>
    <id>843</id>
    <term>Long-range transport potential </term><definition>Long-range transport potential&#160; (LRTAP) Preliminaryselection of priority persistentorganic pollutants (POPs)based on the assessment of potential health effects and on the potentialcontribution of long-range transport to population exposure and risk.</definition><reference>http://www.euro.who.int/InformationSources/Publications/Catalogue/20080102_1</reference><category>Dose</category></page>
  <page>
    <title>Longer-term exposure</title>
    <id>227</id>
    <term>Longer-term exposure</term><definition>Repeated exposure by theoral, dermal, or inhalation route for more than 30 days, up to approximately 10%of the life span in humans (more than 30 days up to approximately 90 days intypically used laboratory animal species).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#i</reference><category>Dose</category></page>
  <page>
    <title>Low birth weight</title>
    <id>773</id>
    <term>Low birth weight</term><definition>An infant having a birth weight of 2500 gm. (5.5 lb.) or less but infant, very low birth weight is available for infants having a birth weight of 1500 grams (3.3 lb.) or less.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lowbirthweight</reference><category>Adverse</category></page>
  <page>
    <title>Lower and upper confidence interval</title>
    <id>844</id>
    <term>Lower and upper confidence interval</term><definition>Confidence Interval (Two-Sided): an estimated interval from the lower to upper confidence limit of an estimate of a parameter. This interval is expected to include the true value of the parameter with a specified confidence percentage, e.g., 95% of such intervals are expected to include the true values of the estimated parameters. Confidence Interval (One-Sided ): an interval below the estimated upper confidence limit, or interval above the estimated lower confidence limit, that is expected to include the true value of an estimated parameter with a specified confidence ( percent of the time). Confidence Limit: an estimated value below (or above) which the true value of an estimated parameter is expected to lie for a specified percentage of such estimated limits.</definition><reference>http://www.inchem.org/documents/ehc/ehc/ehc228.htm</reference><category>Risk</category></page>
  <page>
    <title>Lower effective dose</title>
    <id>266</id>
    <term>Lower effective dose (LED)</term><reference>http://www.euro.who.int/document/e76979.pdf</reference><category>Dose</category></page>
  <page>
    <title>Lower effective dose (LED10)</title>
    <id>436</id>
    <term>Lower Limit on Effective Dose10</term><definition>Lower Limit on Effective Dose 10  - The 95% lower confidence limit of the dose of a chemical needed to produce an adverse effect in 10 percent of those exposed to the chemical, relative to control.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><category>Dose</category></page>
  <page>
    <title>Lowest observed adversw effect level</title>
    <id>845</id>
    <term>Lowest observed adversw effect level </term><definition>(LOAEL) The lowest dose in an experiment which produced an observable adverse effect.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Lowest observed effect level</title>
    <id>905</id>
    <term>Lowest observed effect level</term><definition>The Lowest-Observed-Effect-Level (LOEL) is the lowest exposure level at which there are statistically or biologically significant increases in frequency or severity of an effect between the exposed population and its appropriate control group. In a study, the lowest dose or exposure level at which a statistically or biologically significant effect is observed in the exposed population compared with an appropriate unexposed control group.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Lymphedema</title>
    <id>452</id>
    <term>Lymphedema</term><definition>Edema due to obstruction of lymph vessels or disorders of the lymph nodes.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphedema</reference><category>Adverse</category></page>
  <page>
    <title>Lymphocytosis</title>
    <id>774</id>
    <term>Lymphocytosis</term><definition>Excess of normal lymphocytes in the blood or in any effusion.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphocytosis</reference><category>Adverse</category></page>
  <page>
    <title>Lymphoma</title>
    <id>775</id>
    <term>Lymphoma</term><definition>A general term for various neoplastic diseases of the lymphoid tissue.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphoma</reference><category>Adverse</category></page>
  <page>
    <title>Lymphoma-Non-Hodgkin</title>
    <id>415</id>
    <term>Lymphoma, Non-Hodgkin</term><definition>Any of a group of malignant tumors of lymphoid tissue that differ from Hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. Theonly common feature among these tumors is the absence of giant reed-sternbergcells, a characteristic of Hodgkin's disease.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphoma-Non-Hodgkin</reference><category>Adverse</category></page>
  <page>
    <title>Lymphopenia</title>
    <id>453</id>
    <term>Lymphopenia</term><definition>Reduction in the number of lymphocytes.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphopenia</reference><category>Adverse</category></page>
  <page>
    <title>Lymphoproliferative disorder</title>
    <id>454</id>
    <term>Lymphoproliferative disorder</term><definition>Disorders characterized by proliferation of lymphoid tissue, general or unspecified.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Lymphoproliferativedisorder</reference><category>Adverse</category></page>
  <page>
    <title>Macular Edema</title>
    <id>611</id>
    <term>Macular edema</term><definition>Macular Edema Fluid accumulation in the outer layer of the macula lutea at the center of the retina.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=MacularEdema</reference><category>Adverse</category></page>
  <page>
    <title>Margin of Exposure (MOE)</title>
    <id>907</id>
    <term>Margin of Exposure </term><definition>(MOE) The LED10 or other point of departure divided by the actual or projected environmental exposure of interest. Ratio of the no-observed-adverse-effect level (NOAEL) for the critical effect to the theoretical, predicted, or estimated exposure dose or concentration.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Margin of safety (MOS)</title>
    <id>908</id>
    <term>Margin of safety</term><definition>For some experts the Margin of Safety has the same meaning as the Margin of Exposure, while for others, the Margin of Safety means the margin between the reference dose and the actual exposure dose or concentration.</definition><category>Dose</category></page>
  <page>
    <title>Mass Median Aerodynamic Diameter (MMAD)</title>
    <id>909</id>
    <term>Mass Median Aerodynamic Diameter </term><definition>(MMAD) Median of the distribution of airborne particle mass with respect to the aerodynamic diameter. MMADs are usually accompanied by the geometric standard deviation (g or sigma g) which characterizes the variability of the particle size distribution. The diameter that divides the mass distribution of an aerosol in half.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Ecotox</category></page>
  <page>
    <title>Maximum Likelihood (ML) Method, Maximum Likelihood Estimate (MLE)</title>
    <id>169</id>
    <term>Maximum Likelihood Method, Maximum Likelihood Estimate </term><definition>Maximum Likelihood (ML) Method, Maximum Likelihood Estimate (MLE) Statistical method for estimating a population parameter most likely to have produced the sample observations.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Measurement endpoint</title>
    <id>170</id>
    <term>Measurement endpoint</term><definition>Measurable (ecological) characteristic that is related to the valued characteristic chosen as an assessment point.</definition><category>Dose</category></page>
  <page>
    <title>Melena</title>
    <id>403</id>
    <term>Melena</term><definition>The black, tarry, foul-smelling feces that contain degraded blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Melena</reference><category>Adverse</category></page>
  <page>
    <title>Memory disorders</title>
    <id>455</id>
    <term>Memory disorders</term><definition>Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with dementia; craniocerebral trauma; encephalitis; alcoholism (see also alcohol amnestic disorder); schizophrenia; and other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=MemoryDisorders</reference><category>Adverse</category></page>
  <page>
    <title>Menorrhagia</title>
    <id>456</id>
    <term>Menorrhagia</term><definition>Excessive uterine bleeding during menstruation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Menorrhagia</reference><category>Adverse</category></page>
  <page>
    <title>Menstruation disturbance</title>
    <id>776</id>
    <term>Menstruation disturbance</term><definition>Variations of menstruation which may be indicative of disease.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Menstruationdisturbance</reference><category>Adverse</category></page>
  <page>
    <title>Metabolic disorders</title>
    <id>777</id>
    <term>Metabolic disorders</term><definition>Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (metabolism, inborn errors) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Metabolicdisorders</reference><category>Adverse</category></page>
  <page>
    <title>Methemoglobinemia</title>
    <id>778</id>
    <term>Methemoglobinemia</term><definition>The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Methemoglobinemia</reference><category>Adverse</category></page>
  <page>
    <title>Metrorrhagia</title>
    <id>556</id>
    <term>Metrorrhagia</term><definition>Abnormal uterine bleeding that is not related to menstruation, usually in females without regular menstrual cycle. The irregular and unpredictable bleeding usually comes from a dysfunctional endometrium.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Metrorrhagia</reference><category>Adverse</category></page>
  <page>
    <title>Migraine</title>
    <id>779</id>
    <term>Migraine</term><definition>A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Migraine</reference><category>Adverse</category></page>
  <page>
    <title>Minimal risk level (MRL)</title>
    <id>294</id>
    <term>Minimal risk level  </term><definition>Minimal risk level (MRL) An MRL is an estimate ofthe daily human exposure to a hazardous substance that is likely to be withoutappreciable risk of adverse noncancer health effects over a specified durationof exposure. MRLs are based on noncancer health effects only and are not basedon a consideration of cancer effects. These substance-specific estimates, whichare intended to serve as screening levels, are used by ATSDR health assessorsto identify contaminants and potential health effects that may be of concern athazardous waste sites. It is important to note that MRLs are not intended todefine clean-up or action levels. MRLs are derived for hazardous substancesusing the no-observed-adverse-effect level/uncertainty factor approach. Theyare below levels that might cause adverse health effects in the people mostsensitive to such chemical-induced effects. MRLs are derived for acute (1&#8211;14days), intermediate (15&#8211;364 days), and chronic (365 days and longer) durationsand for the oral and inhalation routes of exposure.</definition><reference>http://www.atsdr.cdc.gov/mrls/</reference><category>Dose</category></page>
  <page>
    <title>Mobile source</title>
    <id>228</id>
    <term>Mobile source</term><definition>A moving producer of air pollution, mainly forms of transportation - cars, motorcycles, planes. Any non-stationary source of air pollution such as cars, trucks, motorcycles, buses, airplanes, and locomotives.</definition><reference>http://www.epa.gov/OCEPAterms/mterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Mobility</title>
    <id>881</id>
    <term>Mobility</term><definition>The ability of achemical element or a pollutant to move into and through the environment (e.g.,the mobilization of an element from a water column to sediment). State of being ill or diseased. Morbidity is the occurrence of a disease or condition that alters health and quality of life.</definition><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J-</reference><reference>http://sra.org/resources_glossary_m-o.php</reference><category>Ecotox</category></page>
  <page>
    <title>Monitoring</title>
    <id>229</id>
    <term>Monitoring</term><definition>Periodic or continuoussurveillance or testing to determine the level of compliance with statutoryrequirements and/or pollutant levels in various media or in humans, plants, andanimals.</definition><reference>http://sra.org/resources_glossary_m-o.php</reference><category>Risk</category></page>
  <page>
    <title>Monte Carlo technique</title>
    <id>906</id>
    <term>Monte Carlo technique</term><definition>A repeated random sampling from the distribution of values for each of the parameters in a calculation (e.g., lifetime average daily exposure), to derive a distribution of estimates (of exposures) in the population. One of several mathematical techniques for performing probabilistic assessments. The method relies on the computational powers of modern computers to simulate the range and frequency of all possible outcomes of a process based on repeatedly sampling from the inputs provided by the user. These inputs are combined according to the model that is specified by the user.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>QSAR</category></page>
  <page>
    <title>Mood disorders</title>
    <id>780</id>
    <term>Mood disorders</term><definition>Those disorders that have a disturbance in mood as their predominant feature.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Mood</reference><category>Adverse</category></page>
  <page>
    <title>Morbidity</title>
    <id>882</id>
    <term>Morbidity</term><definition>Rate of disease incidence. Death. Usually the cause (a specific disease, a condition, or an injury) is stated. &#160; A departure from a state of physical or mental well-being,                   resulting from disease or injury. Frequently used only if                   the affected individual is aware of the condition. Awareness                   itself connotes a degree of measurable impact. Frequently,                   but not always, there is a further restriction that some                   action has been taken such as restriction of activity, loss                   of work, seeking of medical advice, etc.</definition><reference>http://sra.org/resources_glossary_m-o.php</reference><reference>http://www.epa.gov/OCEPAterms/mterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J-</reference><category>Adverse</category></page>
  <page>
    <title>Mortality rate</title>
    <id>883</id>
    <term>Mortality rate</term><definition>Death; the death rate;ratio of number of deaths to a given population. The number of deaths that occur in a given population during a given time interval; usually deaths per 10 3  or 10 5 people per year. Can be age, sex, race, and cause specific.</definition><reference>http://sra.org/resources_glossary_m-o.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Risk</category></page>
  <page>
    <title>Movement disorders</title>
    <id>781</id>
    <term>Movement disorders</term><definition>Syndromes which feature dyskinesias as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Movementdisorder</reference><category>Adverse</category></page>
  <page>
    <title>Mucositis</title>
    <id>782</id>
    <term>Mucositis</term><definition>An inflammation of the mucosa with burning or tingling sensation. Itis characterized by atrophy of the squamous epithelium, vascular damage,inflammatory infiltration, and ulceration. It usually occurs at the mucouslining of the mouth, the gastrointestinal tract or the airway due to chemicalirritations, chemotherapy, or radiation therapy (radiotherapy).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Mucositis</reference><category>Adverse</category></page>
  <page>
    <title>Multi-media approach</title>
    <id>884</id>
    <term>Multi-media approach</term><definition>Joint approach to several environmental media, such as air, water, and land.</definition><reference>http://www.epa.gov/OCEPAterms/mterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Multiple organ failure</title>
    <id>783</id>
    <term>Multiple organ failure</term><definition>A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Multipleorganfailure</reference><category>Adverse</category></page>
  <page>
    <title>Multistage Weibull model</title>
    <id>168</id>
    <term>Multistage Weibull model</term><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Multistage model</title>
    <id>167</id>
    <term>Multistage model</term><definition>A carcinogenesisdose-response model where it is assumed that cancer originates as a"malignant" cell, which is initiated by a series of somatic-likemutations occurring in finite steps. It is also assumed that each mutationalstage can be depicted as a Poisson process in which the transition rate isapproximately linear in dose rate.</definition><category>Dose</category></page>
  <page>
    <title>Muscle rigidity</title>
    <id>339</id>
    <term>Muscle rigidity</term><definition>Continuous involuntary sustained muscle contraction which is often a manifestation of basal ganglia diseases. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This featurehelps to distinguish rigidity from muscle spasticity.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Muscle</reference><category>Adverse</category></page>
  <page>
    <title>Muscle spasticity</title>
    <id>156</id>
    <term>Muscle spasticity</term><definition>A form of muscle hypertonia associated with upper motor neuron disease. Resistance to passive stretch of a spastic muscle results in minimal initial resistance (a "free interval") followed by an incremental increase in muscle tone.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Muscle-spasticity</reference><category>Adverse</category></page>
  <page>
    <title>Muscle weakness</title>
    <id>458</id>
    <term>Muscle weakness</term><definition>A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Muscleweakness</reference><category>Adverse</category></page>
  <page>
    <title>Muskegon Job Listings</title>
    <id>1354</id>
    <reference>http://mysearchends.com/tds/go.php?sid=4&amp;fpr=3clOTN8fDEyOTU5MTUyOTl8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D&amp;q=muskegon%2Bjob%2Blistings</reference></page>
  <page>
    <title>Mutagen</title>
    <id>338</id>
    <term>Mutagenicity</term><category>Mutagen</category></page>
  <page>
    <title>Mutism</title>
    <id>459</id>
    <term>Mutism</term><definition>The inability to generate oral-verbal expression, despite normal comprehension of speech. Thismay be associated with brain diseases or mental disorders. Organic mutism maybe associated with damage to the frontal lobe; brain stem; thalamus; andcerebellum. Selective mutism is a psychological condition that usually affectschildren characterized by continuous refusal to speak in social situations by achild who is able and willing to speak to selected persons. Kussmal aphasiarefers to mutism in psychosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Mutism</reference><category>Adverse</category></page>
  <page>
    <title>Myocardial infarction</title>
    <id>460</id>
    <term>Myocardial infarction</term><definition>Necrosisof the myocardium caused by an obstruction of the blood supply to the heart(coronary circulation).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myocardialinfarction</reference><category>Adverse</category></page>
  <page>
    <title>Myocardial ischemia</title>
    <id>784</id>
    <term>Myocardial ischemia</term><definition>A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myocardialischemia</reference><category>Adverse</category></page>
  <page>
    <title>Myocarditis</title>
    <id>785</id>
    <term>Myocarditis</term><definition>Inflammatory processes of the muscular walls of the heart (myocardium) which result in injury to the cardiac muscle cells (myocytes, cardiac). Manifestationsrange from subclinical to sudden death (death, sudden). Myocarditis inassociation with cardiac dysfunction is classified as inflammatory cardiomyopathyusually caused by infection, autoimmune diseases, or responses to toxicsubstances. myocarditis is also a common cause of dilated cardiomyopathy andother cardiomyopathies.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myocarditis</reference><category>Adverse</category></page>
  <page>
    <title>Myoclonus</title>
    <id>461</id>
    <term>Myoclonus</term><definition>Involuntary shock-like contractions, irregular in rhythm and amplitude, followed by relaxation, of a muscle or a group of muscles. Thiscondition may be a feature of some central nervous system diseases; (e.g.,epilepsy, myoclonic). Nocturnal myoclonus is the principal feature of the nocturnalmyoclonus syndrome.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myoclonus</reference><category>Adverse</category></page>
  <page>
    <title>Myopia</title>
    <id>462</id>
    <term>Myopia</term><definition>A refractive error in which rays of light entering the eye parallel to the optic axis are brought to a focus in front of the retina when accommodation (accommodation, ocular) is relaxed. This results from an overly curved CORNEA or from the eyeball being too long from front to back. It is also called nearsightedness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myopia</reference><category>Adverse</category></page>
  <page>
    <title>Myositis</title>
    <id>786</id>
    <term>Myositis</term><definition>Inflammation of skeletal muscle.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myositis</reference><category>Adverse</category></page>
  <page>
    <title>Myotonia</title>
    <id>463</id>
    <term>Myotonia</term><definition>Prolonged failure of muscle relaxation after contraction. Thismay occur after voluntary contractions, muscle percussion, or electricalstimulation of the muscle. Myotonia is a characteristic feature of myotonicdisorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Myotonia</reference><category>Adverse</category></page>
  <page>
    <title>Narcotics</title>
    <id>787</id>
    <term>Narcotics</term><definition>Agentsthat induce narcosis. This term is considered outdated due to imprecision butcontinues to be widely used. Originally, agents that caused somnolence orinduced sleep (stupor); now, any derivative, natural or synthetic, of opium ormorphine or any substance that has their effects. Narcotics are potent inducersof analgesia and opioid-related disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Narcotics</reference><category>Adverse</category></page>
  <page>
    <title>National Emissions Standards for Hazardous Air Pollutants (NESHAPS)</title>
    <id>885</id>
    <term>National Emissions Standards for Hazardous Air Pollutants (NESHAPS)</term><definition>Emissions standards setby EPA for an air pollutant not covered by NAAQS that may cause an increase infatalities or in serious, irreversible, or incapacitating illness. Primarystandards are designed to protect human health, secondary standards to protectpublic welfare (e.g., building facades, visibility, crops, and domesticanimals).</definition><reference>http://www.epa.gov/OCEPAterms/nterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Hazards</category></page>
  <page>
    <title>National Priorities List (NPL)</title>
    <id>124</id>
    <term>National Priorities List (NPL)</term><definition>EPA's list of the mostserious uncontrolled or abandoned hazardous waste sites identified for possiblelong-term remedial action under Superfund. The list is based primarily on thescore a site receives from the Hazard Ranking System. EPA is required to updatethe NPL at least once a year.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://www.epa.gov/OCEPAterms/nterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J-</reference><category>Hazards</category></page>
  <page>
    <title>Nausea</title>
    <id>464</id>
    <term>Nausea</term><definition>An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Nausea</reference><category>Adverse</category></page>
  <page>
    <title>Neckpain</title>
    <id>465</id>
    <term>Neck pain</term><definition>Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neckpain</reference><category>Adverse</category></page>
  <page>
    <title>Necrosis</title>
    <id>404</id>
    <term>Necrosis</term><definition>The pathological process occurring in cells that are dying from irreparable injuries. Itis caused by the progressive, uncontrolled action of degradative enzymes,leading to mitochondrial swelling, nuclear flocculation, and cell lysis.Distinguish it from apoptosis which is a normal, regulated cellular process.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Necrosis</reference><category>Adverse</category></page>
  <page>
    <title>Necrotizing enterocolitis</title>
    <id>466</id>
    <term>Necrotizing enterocolitis</term><definition>Enterocolitis with extensive ulceration (ulcer) and necrosis. it is observed primarily in low birth weight infant.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Necrotizingenterocolitis</reference><category>Adverse</category></page>
  <page>
    <title>Nephritis</title>
    <id>467</id>
    <term>Nephritis</term><definition>Inflammation of any part of the kidney.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Nephritis</reference><category>Adverse</category></page>
  <page>
    <title>Nephrolithiasis</title>
    <id>468</id>
    <term>Nephrolithiasis</term><definition>Formation of stones in the kidney.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Nephrolithiasis</reference><category>Adverse</category></page>
  <page>
    <title>Nephrotic syndrome</title>
    <id>340</id>
    <term>Nephrotic syndrome</term><definition>A condition characterized by severe proteinuria, greater than 3.5 g/day in an average adult. Thesubstantial loss of protein in the urine results in complications such as hypoproteinemia;generalized edema; hypertension; and hyperlipidemias. Diseases associated withnephrotic syndrome generally cause chronic kidney dysfunction.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Nephroticsyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Neural tube defect</title>
    <id>341</id>
    <term>Neural tube defect</term><definition>Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy generally occurring between days 18-29 of gestation. Ectodermaland mesodermal malformations (mainly involving the skull and vertebrae) mayoccur as a result of defects of neural tube closure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neuraltubedefect</reference><category>Adverse</category></page>
  <page>
    <title>Neuritis</title>
    <id>469</id>
    <term>Neuritis</term><definition>A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include pain; paresthesias; paresis; or hypesthesia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neuritis</reference><category>Adverse</category></page>
  <page>
    <title>Neuroleptic malignant syndrome</title>
    <id>470</id>
    <term>Neuroleptic malignant syndrome</term><definition>A potentially fatal syndrome associated primarily with the use of neuroleptic agents&#160; which are in turn associated with dopaminergic receptor blockade in the basal ganglia and hypothalamus, and sympathetic dysregulation. Clinicalfeatures include diffuse muscle rigidity; tremor; high fever; diaphoresis;labile blood pressure; cognitive dysfunction; and autonomic disturbances. SerumCPK level elevation and a leukocytosis may also be present.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neurolepticmalignantsyndrome</reference><category>Adverse</category></page>
  <page>
    <title>Neuromuscular block</title>
    <id>405</id>
    <term>Neuromuscular block</term><definition>The intentional interruption of transmission at the neuromuscular junction by external agents, usually neuromuscular blocking agents. Itis distinguished from nerve block in which nerve conduction (neural conduction)is interrupted rather than neuromuscular transmission. Neuromuscular blockadeis commonly used to produce muscle relaxation as an adjunct to anesthesiaduring surgery and other medical procedures. It is also often used as anexperimental manipulation in basic research. It is not strictly speakinganesthesia but is grouped here with anesthetic techniques. The failure of neuromusculartransmission as a result of pathological processes is not included here.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neuromuscularblock</reference><category>Adverse</category></page>
  <page>
    <title>Neurotoxicity syndromes</title>
    <id>471</id>
    <term>Neurotoxicity syndromes</term><definition>Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neurotoxicity-Syndromes</reference><category>Adverse</category></page>
  <page>
    <title>Neutropenia</title>
    <id>406</id>
    <term>Neutropenia</term><definition>A decrease in the number of neutrophilic leukocytes in the blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Neutropenia</reference><category>Adverse</category></page>
  <page>
    <title>No-Observed-Adverse-Effect Level (NOAEL)</title>
    <id>295</id>
    <term>No-Observed-Adverse-Effect Level</term><definition>&#160; From long-term toxicological studies of agriculture chemical active ingredients, levels at which indicate a safe, lifetime exposure level for a given chemical. Used to establish tolerance for human diets. Also written, NOEL. The highest exposure level at which there are no biologically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control; some effects may be produced at this level, but they are not considered adverse or precursors of adverse effects. The maximum concentration of a substance that is found to have no adverse effects upon the test subject.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><reference>http://medical-dictionary.thefreedictionary.com/NOAEL</reference><category>Dose</category></page>
  <page>
    <title>No-Observed-Effect Level (NOEL)</title>
    <id>172</id>
    <term>No-Observed-Effect Level </term><definition>(NOEL)  An exposure level atwhich there are no statistically or biologically significant increases in thefrequency or severity of any effect between the exposed population and itsappropriate control.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Non-Linear Dose Response</title>
    <id>171</id>
    <term>Non-Linear Dose Response</term><definition>A pattern of frequency or severity of biological response that does not vary directly with the amount of dose of an agent. Relationship that cannot be expressed simply as the change in response being proportional to the amount of change of some function of dose.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Nonpoint source</title>
    <id>230</id>
    <term>Nonpoint source</term><definition>A contributing factor towater pollution that cannot be traced to a specific spot; like agriculturalfertilizer runoff, sediment from construction. &#160; Diffuse pollution sources (i.e.without a single point of origin or not introduced into a receiving stream froma specific outlet). The pollutants are generally carried off the land by stormwater. Common non-point sources are agriculture, forestry, urban, mining,construction, dams, channels, land disposal, saltwater intrusion, and citystreets.</definition><reference>http://rais.ornl.gov/home/glossary.html#N</reference><reference>http://www.epa.gov/OCEPAterms/nterms.html</reference><reference>http://sra.org/resources_glossary_m-o.php</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#n</reference><category>Ecotox</category></page>
  <page>
    <title>Nystagmus</title>
    <id>348</id>
    <term>Nystagmus</term><definition>Involuntary movements of the eye that are divided into two types, jerk and pendular.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Nystagmus</reference><category>Adverse</category></page>
  <page>
    <title>OECD Harmonised Templates</title>
    <id>394</id>
    <term>OECD Harmonised Templates</term><definition>The OECD Harmonised Templates (OECD HTs) list all of the data elements which could be relevant for a summary of toxicology studies as well as the format in which the information should be entered and stored electronically.&#160; Each template has a corresponding XML schema (i.e., a common electronic data export/import format which describes the data structure) and a schematron&#8221; which describes the relation / condition and constraints, or validation rules, between multiple fields. OECD HTs are implemented in  IUCLID5  for chemical safety regulatory reporting in the EU.</definition><reference>http://www.oecd.org/document/13/0,3343,en_2649_34365_36206733_1_1_1_1,00.html</reference><category>Standards</category></page>
  <page>
    <title>OECD Principles for (Q)SAR Model Validation</title>
    <id>393</id>
    <term>OECD Principles for (Q)SAR Model Validation</term><definition>In November 2004, the OECD member countries agreed on the principles for validating (Q)SAR models for their use in the regulatory assessment of chemical safety.</definition><reference>http://www.oecd.org/document/4/0,3343,en_2649_34379_42926724_1_1_1_1,00.html</reference><category>Standards</category></page>
  <page>
    <title>Obsessive-compulsive disorder</title>
    <id>792</id>
    <term>Obsessive-compulsive disorder</term><definition>An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Obsessive-compulsive-disorder</reference><category>Adverse</category></page>
  <page>
    <title>Occupational Safety and Health Administration (OSHA)</title>
    <id>299</id>
    <term>Occupational Safety and Health Administration </term><definition>(OSHA) Occupational Safety and Heath Administration of the U.S. Department of Labor. Federal agency with safety and health regulatory and enforcement authorities for most U.S. industry and business. Federal agency charged with establishing guidelines and regulations regarding worker safety. These guidelines include storage and disposal of toxic chemicals and hazardous materials and the safety and proper use of clinical and office equipment.</definition><reference>http://medical-dictionary.thefreedictionary.com/Occupational+Safety+and+Health+Administration</reference><reference>http://www.osha.gov/about.html</reference><reference>http://www.osha.gov/index.html</reference><category>Risk</category></page>
  <page>
    <title>Odds Ratio (OR)</title>
    <id>296</id>
    <term>Odds Ratio</term><definition>A relative measure of the difference in exposure between the diseased (cases) and not diseased (controls) individuals in a case-control study. The OR is interpreted similarly to the relative risk. It is defined as the ratio of the odds of an event occurring in one group to the odds of it occurring in another group, or to a sample-based estimate of that ratio. These groups might be men and women, an experimental group and a control group, or any other dichotomous classification.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Oligospermia</title>
    <id>349</id>
    <term>Oligospermia</term><definition>A condition of suboptimal concentration of spermatozoa in the ejaculated semen to ensure successful fertilization of an ovum. In humans, oligospermia is defined as a sperm count below 20 million per milliliter semen.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Oligospermia</reference><category>Adverse</category></page>
  <page>
    <title>Oliguria</title>
    <id>350</id>
    <term>Oliguria</term><definition>Decreased urine output that is below the normal range. Oliguria can be defined as urine output of less than or equal to 0.5 or 1 ml/kg/hr depending on the age.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Oliguria</reference><category>Adverse</category></page>
  <page>
    <title>Oncogenic</title>
    <id>297</id>
    <term>Oncogenic</term><definition>A substance that causes tumors, whether benign or malignant. Resulting from a gene that can induce neoplastic transformations in the cell in which it occurs or into which it is introduced.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Carcinogenicity</category></page>
  <page>
    <title>One hit model</title>
    <id>298</id>
    <term>One hit model</term><definition>The basic dose-response model based on the concept that a tumor can be induced by a single receptor that has been exposed to a single quantum or effective dose unit of a chemical. A dose-response model based on a mechanistic argument that there is a response after a target site has been hit by a single biologically effective unit of dose within a given time period.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Dose</category></page>
  <page>
    <title>Onycholysis</title>
    <id>351</id>
    <term>Onycholysis</term><definition>Separation of nail plate from the underlying nail bed. Itcan be a sign of skin disease, infection (such as onychomycosis) or tissueinjury.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Onycholysis</reference><category>Adverse</category></page>
  <page>
    <title>Ophthalmoplegia</title>
    <id>352</id>
    <term>Ophthalmoplegia</term><definition>Paralysis of one or more of the ocular muscles due to disorders of the eye muscles, neuromuscular junction, supporting soft tissue, tendons, or innervation to the muscles.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ophthalmoplegia</reference><category>Adverse</category></page>
  <page>
    <title>Opportunistic infections</title>
    <id>416</id>
    <term>Opportunistic infections</term><definition>An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Opportunistic-infections</reference><category>Adverse</category></page>
  <page>
    <title>Optic atrophy</title>
    <id>417</id>
    <term>Optic atrophy</term><definition>Atrophy of the optic disk which may be congenital or acquired. Thiscondition indicates a deficiency in the number of nerve fibers which arise inthe retina and converge to form the optic disk; optic nerve; optic chiasm; andoptic tracts. glaucoma; ischemia; inflammation, a chronic elevation ofintracranial pressure, toxins, optic nerve compression, and inheritedconditions (see optic atrophies, hereditary) are relatively common causes ofthis condition.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Optic-atrophy</reference><category>Adverse</category></page>
  <page>
    <title>Optic neuritis</title>
    <id>794</id>
    <term>Optic neuritis</term><definition>Inflammation of the optic nerve. Commonlyassociated conditions include autoimmune disorders such as multiple sclerosis,infections, and granulomatous diseases. Clinical features include retro-orbitalpain that is aggravated by eye movement, loss of color vision, and contrastsensitivity that may progress to severe visual loss, an afferent pupillarydefect (Marcus-Gunn pupil), and in some instances optic disc hyperemia andswelling. Inflammation may occur in the portion of the nerve within the globe(neuropapillitis or anterior optic neuritis) or the portion behind the globe(retrobulbar neuritis or posterior optic neuritis).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Optic-neuritis</reference><category>Adverse</category></page>
  <page>
    <title>Organoleptic</title>
    <id>846</id>
    <term>Organoleptic</term><definition>Affecting or involving a sense organ such as that of taste, smell, or sight.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#l</reference><category>Biology</category></page>
  <page>
    <title>Osteoporosis</title>
    <id>418</id>
    <term>Osteoporosis</term><definition>Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primaryosteoporosis can be of two major types: postmenopausal osteoporosis (osteoporosis,postmenopausal) and age-related or senile osteoporosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Osteoporosis</reference><category>Adverse</category></page>
  <page>
    <title>Pain</title>
    <id>475</id>
    <term>Pain</term><definition>Anunpleasant sensation induced by noxious stimuli which are detected by nerveendings of nociceptive neurons.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pain</reference><category>Adverse</category></page>
  <page>
    <title>Pallor</title>
    <id>476</id>
    <term>Pallor</term><definition>A clinical manifestation consisting of an unnatural paleness of the skin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pallor</reference><category>Adverse</category></page>
  <page>
    <title>Pancreatitis</title>
    <id>799</id>
    <term>Pancreatitis</term><definition>Inflammation of the pancreas. Pancreatitisis classified as acute unless there are computed tomographic or endoscopicretrograde cholangiopancreatographic findings of chronic pancreatitis. The twomost common forms of acute pancreatitis are alcoholic pancreatitis andgallstone pancreatitis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pancreatitis</reference><category>Adverse</category></page>
  <page>
    <title>Pancytopenia</title>
    <id>355</id>
    <term>Pancytopenia</term><definition>Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pancytopenia</reference><category>Adverse</category></page>
  <page>
    <title>Panic</title>
    <id>356</id>
    <term>Panic</term><definition>A state of extreme acute, intense anxiety and unreasoning fear accompanied by disorganization of personality function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Panic</reference><category>Adverse</category></page>
  <page>
    <title>Papilledema</title>
    <id>793</id>
    <term>Papilledema</term><definition>Swelling of the optic disk, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronicpapilledema may cause optic atrophy and visual loss.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Papilledema</reference><category>Adverse</category></page>
  <page>
    <title>Paralysis</title>
    <id>478</id>
    <term>Paralysis</term><definition>A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Paralysis</reference><category>Adverse</category></page>
  <page>
    <title>Paranoia</title>
    <id>357</id>
    <term>Paranoia</term><definition>Chronic mental disorders in which there has been an insidious development of a permanent and unshakeable delusional system (persecutory delusions or delusions of jealousy), accompanied by preservation of clear and orderly thinking. Emotional responses and behavior are consistent with the delusional state.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Paranoia</reference><category>Adverse</category></page>
  <page>
    <title>Paraplegia</title>
    <id>479</id>
    <term>Paraplegia</term><definition>Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. Thiscondition is most often associated with spinal cord diseases, although braindiseases; peripheral nervous system diseases; neuromuscular diseases; andmuscular diseases may also cause bilateral leg weakness.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Paraplegia</reference><category>Adverse</category></page>
  <page>
    <title>Paresis</title>
    <id>800</id>
    <term>Paresis</term><definition>A general term referring to a mild to moderate degree of muscular weakness, occasionally used as a synonym for PARALYSIS (severe or complete loss of motor function).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Paresis</reference><category>Adverse</category></page>
  <page>
    <title>Parkinsonian disorders</title>
    <id>422</id>
    <term>Parkinsonian disorders</term><definition>A group of disorders which feature impaired motor control characterized by bradykinesia, muscle rigidity; tremor; and postural instability. Parkinsoniandiseases are generally divided into primary parkinsonism, secondaryparkinsonism &#160;and inherited forms. Theseconditions are associated with dysfunction of dopaminergic or closely relatedmotor integration neuronal pathways in the basal ganglia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Parkinsonian-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Paronychia</title>
    <id>423</id>
    <term>Paronychia</term><definition>An inflammatory reaction involving the folds of the skin surrounding the fingernail. It is characterized by acute or chronic purulent, tender, and painful swellings of the tissues around the nail, caused by an abscess of the nail fold. The pathogenic yeast causing paronychia is most frequently Candida albicans. Saprophytic fungi may also be involved. The causative bacteria are usually Staphylococcus, Pseudomonas aeruginosa, or Streptococcus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Paronychia</reference><category>Adverse</category></page>
  <page>
    <title>Particle</title>
    <id>886</id>
    <term>Particle</term><definition>A tiny mass of material.Airborne particles, materials that exist in the atmosphere as a solid orliquid, can be natural, caused by stirring of soil dusts, or anthropogenic.They vary in size from coarse (diameter &gt; 3 &#181;m) to fine (&lt; 3&#181;m).Sometimes inhalable or respirable is used to describe those particles (&lt; 2&#181;m) which can be inhaled through the nose and enter the lungs.</definition><reference>http://rais.ornl.gov/home/glossary.html#N</reference><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Ecotox</category></page>
  <page>
    <title>Pathway of exposure</title>
    <id>910</id>
    <term>Pathway of exposure</term><definition>The physical course a pesticide takes from the source to the organism exposed (e.g., through food or drinking water consumption or residential pesticide uses).</definition><category>Ecotox</category></page>
  <page>
    <title>Pellagra</title>
    <id>801</id>
    <term>Pellagra</term><definition>A disease due to deficiency of niacin, a B-complex vitamin, or its precursor tryptophan. Itis characterized by scaly dermatitis which is often associated with diarrheaand dementia (the three D's).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pellagra</reference><category>Adverse</category></page>
  <page>
    <title>Pelvic pain</title>
    <id>802</id>
    <term>Pelvic pain</term><definition>Pain in the pelvic region of genital and non-genital origin and of organic or psychogenic etiology. Frequent causes of pain are distension or contraction of hollow viscera, rapid stretching of the capsule of a solid organ, chemical irritation, tissue ischemia, and neuritis secondary to inflammatory, neoplastic, or fibrotic processes in adjacent organs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pelvic-pain</reference><category>Adverse</category></page>
  <page>
    <title>Pemphigus</title>
    <id>358</id>
    <term>Pemphigus</term><definition>Group of chronic blistering diseases characterized histologically by acantholysis and blister formation within the epidermis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pemphigus</reference><category>Adverse</category></page>
  <page>
    <title>Pericardial effusion</title>
    <id>480</id>
    <term>Pericardial effusion</term><definition>Fluidaccumulation within the pericardium. Serouseffusions are associated with pericardial diseases. Hemopericardium isassociated with trauma. Lipid-containing effusion (chylopericardium) resultsfrom leakage of thoracic duct. Severe cases can lead to cardiac tamponade.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pericardial-effusion</reference><category>Adverse</category></page>
  <page>
    <title>Pericarditis</title>
    <id>359</id>
    <term>Pericarditis</term><definition>Inflammationof the pericardium from various origins, such as infection, neoplasm,autoimmune process, injuries, or drugs-induced. Pericarditis usually leads to pericardialeffusion, or constrictive pericarditis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pericarditis</reference><category>Adverse</category></page>
  <page>
    <title>Peritonitis</title>
    <id>360</id>
    <term>Peritonitis</term><definition>Inflammationof the peritoneum lining the abdominal cavity as the result of infectious,autoimmune, or chemical processes. Primary peritonitis is due to infection ofthe peritoneal cavity via hematogenous or lymphatic spread and withoutintra-abdominal source. Secondary peritonitis arises from the abdominal cavityitself through rupture or abscess of intra-abdominal organs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Peritonitis</reference><category>Adverse</category></page>
  <page>
    <title>Persistence</title>
    <id>231</id>
    <term>Persistence</term><definition>Persistence generallyrefers to environmental persistence: the length of time a chemical stays in theenvironment, once introduced. Persistent chemicals do not break down easily inthe environment. The quality of remaining for a long period of time (such as inthe environment or the body). Persistent chemicals (such as DDT and PCBs) arenot easily broken down. Refers to the length of time a compound stays in theenvironment, once introduced. A compound may persist for less than a second orindefinitely.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Ecotox</category></page>
  <page>
    <title>Pharyngitis</title>
    <id>481</id>
    <term>Pharyngitis</term><definition>Inflammation of the throat.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pharyngitis</reference><category>Adverse</category></page>
  <page>
    <title>Phlebitis</title>
    <id>482</id>
    <term>Phlebitis</term><definition>Inflammationof a vein, often a vein in the leg. Phlebitis associated with a blood clot iscalled (thrombophlebitis).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Phlebitis</reference><category>Adverse</category></page>
  <page>
    <title>Phone Chat Hotlines</title>
    <id>1360</id>
    <reference>http://esecuritys.com/SESS_gn3OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_phone%2Bchat%2Bhotlines.html</reference><reference>http://Herbencyclopedia.org/index.php/Dating_Network_With_Chat_Facilities_That_Would_Let</reference><reference>http://fargo68.com/?q=node/26958</reference><reference>http://www.krullsim.com/krullsim/CMS/node/6681</reference><reference>http://dronepedia.com/index.php?title=Delaware_Family_Home_Ryan_Single</reference><reference>http://www.northbayscene.ca/forums/topic.php?id=1727</reference><reference>http://mathesonsundance.myknet.org/?q=node/4539</reference><reference>http://apgcrtwa.org/drupal/node/11004</reference><reference>http://wiki.flxer.net/wiki/Sermon_On_Teen_Dating</reference><reference>http://www.hotcase.org/index.php?title=New_Relationship_My_Children_Disapprove</reference><reference>http://www.pkrtilt.com/forum/topic.php?id=20</reference><reference>http://psymeca.org/bbpress/topic.php?id=933</reference></page>
  <page>
    <title>Photoallergy dermatitis</title>
    <id>483</id>
    <term>Photoallergy dermatitis</term><definition>A delayed hypersensitivity involving the reaction between sunlight or other radiant energy source and a chemical substance to which the individual has been previously exposed and sensitized. It manifests as a papulovesicular, eczematous, or exudative dermatitis occurring chiefly on the light-exposed areas of the skin.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Photoallergy-dermatitis</reference><category>Adverse</category></page>
  <page>
    <title>Photophobia</title>
    <id>361</id>
    <term>Photophobia</term><definition>Abnormal sensitivity to light. Thismay occur as a manifestation of eye diseases; migraine; subarachnoidhemorrhage; meningitis; and other disorders. Photophobia may also occur inassociation with depression and other mental disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Photophobia</reference><category>Adverse</category></page>
  <page>
    <title>Pigmentation</title>
    <id>362</id>
    <term>Pigmentation</term><definition>Coloration or discoloration of a part by a pigment.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pigmentation</reference><category>Adverse</category></page>
  <page>
    <title>Piloerection</title>
    <id>803</id>
    <term>Piloerection</term><definition>Involuntary erection or bristling of hairs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Piloerection</reference><category>Adverse</category></page>
  <page>
    <title>Pleural effusion</title>
    <id>363</id>
    <term>Pleural effusion</term><definition>Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pleural-effusion</reference><category>Adverse</category></page>
  <page>
    <title>Pleurisy</title>
    <id>484</id>
    <term>Pleurisy</term><definition>Inflammation of pleura, the lining of the lung. Whenparietal pleura is involved, there is pleuritic chest pain.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pleurisy</reference><category>Adverse</category></page>
  <page>
    <title>Pneumonia</title>
    <id>804</id>
    <term>Pneumonia</term><definition>Inflammation of any part, segment or lobe, of the lung parenchyma.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pneumonia</reference><category>Adverse</category></page>
  <page>
    <title>Pneumoperitoneum</title>
    <id>805</id>
    <term>Pneumoperitoneum</term><definition>A condition with trapped gas or air in the peritoneal cavity, usually secondary to perforation of the internal organs such as the lung and the gastrointestinal tract, or to recent surgery. Pneumoperitoneum may be purposely introduced to aid radiological examination.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pneumoperitoneum</reference><category>Adverse</category></page>
  <page>
    <title>Polymyositis</title>
    <id>364</id>
    <term>Polymyositis</term><definition>Diseases characterized by inflammation involving multiple muscles. Thismay occur as an acute or chronic condition associated with medication toxicity(drug toxicity); connective tissue diseases; infections; malignant neoplasms;and other disorders. The term polymyositis is frequently used to refer to aspecific clinical entity characterized by subacute or slowly progressingsymmetrical weakness primarily affecting the proximal limb and trunk muscles.The illness may occur at any age, but is most frequent in the fourth to sixthdecade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lungdisease, and inflammation of the myocardium may also occur. Muscle biopsyreveals widespread destruction of segments of muscle fibers and an inflammatorycellular response.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Polymyositis</reference><category>Adverse</category></page>
  <page>
    <title>Polyuria</title>
    <id>485</id>
    <term>Polyuria</term><definition>Urination of a large volume of urine with an increase in urinary frequency.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Polyuria</reference><category>Adverse</category></page>
  <page>
    <title>Porphyria</title>
    <id>806</id>
    <term>Porphyria</term><definition>A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of heme in the liver, the bone marrow, or both.They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Porphyria</reference><category>Adverse</category></page>
  <page>
    <title>Porphyria cutanea tarda</title>
    <id>424</id>
    <term>Porphyria cutanea tarda</term><definition>An autosomal dominant or acquired porphyria due to a deficiency of uroporphyrinogen decarboxylase in the liver. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Porphyria-cutanea-tarda</reference><category>Adverse</category></page>
  <page>
    <title>Portal hypertension</title>
    <id>807</id>
    <term>Portal hypertension</term><definition>Abnormal increase of resistance to blood flow within the hepatic portal system, frequently seen in liver cirrhosis and conditions with obstruction of the portal vein.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Portal-hypertension</reference><category>Adverse</category></page>
  <page>
    <title>Postural (orthostatic) hypotension</title>
    <id>425</id>
    <term>Postural (orthostatic) hypotension</term><definition>Asignificant drop in blood pressure after assuming a standing position. Orthostatichypotension is a finding, and defined as a 20-mm Hg decrease in systolicpressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the personhas risen from supine to standing. Symptoms generally include dizziness,blurred vision, and syncope.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Postural-orthostatic-hypotension</reference><category>Adverse</category></page>
  <page>
    <title>Ppb</title>
    <id>173</id>
    <term>ppb</term><definition>A unit of measure expressed as parts per billion. Equivalent to 1 x 10-9.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><category>Chemistry</category></page>
  <page>
    <title>Ppm</title>
    <id>174</id>
    <term>ppm</term><definition>Parts per million. A unit of measure expressed as parts per million. Equivalent to 1 x 10-6. A measurement of concentration such as 1 &#181;g per gram. To convert from ppm to mg/m 3 . mg/m 3  = (ppm) x (molecular weight of the substance)/(24.45). For example, formaldehyde: 1.23 mg/m 3  = (1 ppm) x (30.03)/(24.45).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><category>Chemistry</category></page>
  <page>
    <title>Premature birth</title>
    <id>486</id>
    <term>Premature birth</term><definition>Childbirth before 37 weeks of pregnancy (259days from the first day of the mother's last menstrual period, or 245 daysafter fertilization).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Premature-birth</reference><category>Adverse</category></page>
  <page>
    <title>Prevalence</title>
    <id>175</id>
    <term>Prevalence</term><definition>Actual number of cases of disease or injury present in a population at any particular moment in time. The proportion of disease cases that exist within a population at a specific point in time, relative to the number of individuals within that population at the same point in time. In epidemiology, the prevalence of a disease in a statistical population is defined as the total number of cases of the disease in the population at a given time, or the total number of cases in the population, divided by the number of individuals in the population.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><reference>http://encyclopedia.thefreedictionary.com/prevalence</reference><category>Risk</category></page>
  <page>
    <title>Prevention</title>
    <id>911</id>
    <term>Prevention</term><definition>Prevention is any activity which reduces the burden of mortality or morbidity from disease. It is defined as the promotion of health by the individual and the community, and includes identifying departures from good health and intervening to correct them or to minimize their effects.  &#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Primary poisons prevention  activities intervene before the event, aiming to prevent it happening, either by controlling the victim&#8217;s access to the agent, controlling the action of an agent upon the victim, or controlling or changing hostile environmental factors. Primary prevention strategies may beactive or passive. &#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Active strategies  seek to change attitudes, lifestyles and behaviours of individuals and groups, for example, by educating communities and individuals about poison awareness and safety practices, or campaigning for initiatives such as safer packaging, labelling and storage of chemical products. &#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Passive strategies  automatically protect people, by improving the safety of products and the environment where they are used. Once these changes are made, they require little individual effort from the beneficiary and can have a far-reaching impact. &#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  Secondary poisons prevention  is the action taken after an exposure has occurred, to prevent the poisoning from progressing to a more serious, irreversible or chronic stage and to restore the victim to his/her former state of health. It includes the initial steps to minimize the effects of the toxic agent, the diagnosis, decontamination and first aid treatment, and specific antidote therapy. This may include educating both the community and professionals about how to recognize and manage poisonings and how to give first aid after a toxic exposure by, for example, washing the skin and eyes immediately after contamination by a pesticide. Tertiary poisons prevention deals with the diagnosis and treatment of poisoning victims who cannot be treated to full recovery, to prevent death or permanent disability. It is also concerned with educating victims and their relatives about how to make the most of the remaining potential for healthy living, including the avoidance of unnecessary hardships, restrictions and complications, i.e., rehabilitation and physiotherapy in cases of toxic polyneuropathy.</definition><reference>http://encyclopedia.thefreedictionary.com/Prevention+(medical</reference><category>Biology</category></page>
  <page>
    <title>Priapism</title>
    <id>487</id>
    <term>Priapism</term><definition>A prolonged painful erection that may lasts hours and is not associated with sexual activity. It is seen in patients with SICKLE CELL ANEMIA, advanced malignancy, spinal trauma; and certain drug treatments.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Priapism</reference><category>Adverse</category></page>
  <page>
    <title>Promoter</title>
    <id>847</id>
    <term>Promoter</term><definition>An agent that is not carcinogenic itself, but when administered after an initiator of carcinogenesis, stimulates the clonal expansion of the initiated cell to produce a neoplasm.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><category>Biology</category></page>
  <page>
    <title>Proportionate Mortality Ratio (PMR)</title>
    <id>912</id>
    <term>Proportionate Mortality Ratio</term><definition>The fraction of all deaths from a given cause in the study population divided by the same fraction from a standard population. A tool for investigating cause-specific risks when only data on deaths are available. If data on the population at risk are also available, SMRs are preferred. The proportion of deaths due to the disease of interest in the exposed population divided by the proportion of deaths due to the disease of interest in the unexposed or reference population. It is frequently converted to a percent by multiplying the ratio by 100.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><category>Risk</category></page>
  <page>
    <title>Prospective study</title>
    <id>913</id>
    <term>Prospective study</term><definition>An inquiry in which groups of individuals are selected in terms of whether they are or are not exposed to certain factors, and then followed over time to determine differences in the rate at which disease develops in relation to exposure to the factor. Also see cohort study. Prospective studies, also called cohort studies, select subjects based on their exposure status, and subjects are generally healthy at the beginning of the study. The cohort is followed through time to assess their later disease or outcome status. An example of a cohort study would be watching a group of smokers versus nonsmokers through time and measuring incidence of eventual lung cancer. The same 2x2 table is constructed as with the case control study. However, the statistic generated is the Relative Risk (RR), which is the incidence of disease in the exposured group (A/A+B) over the incidence in the unexposed (C/C+D). As with the OR, a RR greater than 1 shows association, where the conclusion can be read "those with the exposure were more likely to develop disease." Prospective studies have many benefits over case control studies. The RR is a more powerful statistic than the OR, as the OR is just an estimation of the RR, since true incidence cannot be calculated in a case control study where subjects are selected based on disease status. Temporality can be established in a prospective study, and confounders are more easily controlled for. However, they are more costly, and there is a greater chance of losing subjects to follow-up based on the long time period over which the cohort is followed.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#p</reference><reference>http://encyclopedia.thefreedictionary.com/cohort+study</reference><category>Risk</category></page>
  <page>
    <title>Proteinuria</title>
    <id>426</id>
    <term>Proteinuria</term><definition>Thepresence of proteins in the urine, an indicator of kidney diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Proteinuria</reference><category>Adverse</category></page>
  <page>
    <title>Pruritus</title>
    <id>427</id>
    <term>Pruritus</term><definition>An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pruritus</reference><category>Adverse</category></page>
  <page>
    <title>Pseudolymphoma</title>
    <id>808</id>
    <term>Pseudolymphoma</term><definition>A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pseudolymphoma</reference><category>Adverse</category></page>
  <page>
    <title>Pseudotumor cerebri</title>
    <id>428</id>
    <term>Pseudotumor cerebri</term><definition>A condition marked by raised intracranial pressure and characterized clinically by headaches; nausea; papilledema, peripheral constriction of the visual fields, transient visual obscurations, and pulsatile tinnitus. Obesityis frequently associated with this condition, which primarily affects womenbetween 20 and 44 years of age. Chronic papilledema may lead to optic nerveinjury (see optic nerve diseases) and visual loss (see blindness).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pseudotumor-cerebri</reference><category>Adverse</category></page>
  <page>
    <title>Psoriasis</title>
    <id>488</id>
    <term>Psoriasis</term><definition>A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Thelesions have a predilection for nails, scalp, genitalia, extensor surfaces, andthe lumbosacral region. Accelerated epidermopoiesis is considered to be thefundamental pathologic feature in psoriasis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Psoriasis</reference><category>Adverse</category></page>
  <page>
    <title>Psychomotor agitation</title>
    <id>506</id>
    <term>Psychomotor agitation</term><definition>Psychomotor Agitation A feeling of restlessness associated with increased motor activity. This may occur as a manifestation of nervous system drug toxicity or other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=PsychomotorAgitation</reference><category>Adverse</category></page>
  <page>
    <title>Psychomotor disorders</title>
    <id>429</id>
    <term>Psychomotor disorders</term><definition>Abnormalities of motor function that are associated with organic and non-organic cognitive disorders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Psychomotor-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Psychoses</title>
    <id>430</id>
    <term>Psychoses</term><definition>Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Psychoses</reference><category>Adverse</category></page>
  <page>
    <title>Psychosexual disorders</title>
    <id>489</id>
    <term>Psychosexual disorders</term><definition>Disturbances in sexual desire and the psychophysiologic changes that characterize the sexual response cycle and cause marked distress and interpersonal difficulty.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Psychosexual-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Pulmonary edema</title>
    <id>431</id>
    <term>Pulmonary edema</term><definition>Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonaryedema prevents efficient pulmonary gas exchange in the pulmonary alveoli, andcan be life-threatening.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pulmonary-edema</reference><category>Adverse</category></page>
  <page>
    <title>Pulmonary embolism</title>
    <id>490</id>
    <term>Pulmonary embolism</term><definition>Blockingof the pulmonary artery or one of its branches by an embolus.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pulmonary-embolism</reference><category>Adverse</category></page>
  <page>
    <title>Pulmonary fibrosis</title>
    <id>491</id>
    <term>Pulmonary fibrosis</term><definition>Aprocess in which normal lung tissues are progressively replaced by fibroblastsand collagen causing an irreversible loss of the ability to transfer oxygeninto the bloodstream via pulmonary alveoli.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pulmonary-fibrosis</reference><category>Adverse</category></page>
  <page>
    <title>Pulmonary hypertension</title>
    <id>432</id>
    <term>Pulmonary hypertension</term><definition>Increased vascular resistance in the pulmonary circulation, usually secondary to heart diseases or lung diseases.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pulmonary-hypertension</reference><category>Adverse</category></page>
  <page>
    <title>Pure red cell aplasia</title>
    <id>809</id>
    <term>Pure red cell aplasia</term><definition>Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Pure-red-cell-aplasia</reference><category>Adverse</category></page>
  <page>
    <title>Purpura</title>
    <id>810</id>
    <term>Purpura</term><definition>Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Purpura</reference><category>Adverse</category></page>
  <page>
    <title>Purpura, thrombotic thrombocytopenic</title>
    <id>831</id>
    <term>Purpura, thrombotic thrombocytopenic</term><definition>Anacquired, congenital, or familial disorder caused by platelet aggregation withthrombosis in terminal arterioles and capillaries. Clinicalfeatures include thrombocytopenia; hemolytic anemia; azotemia; fever; andthrombotic microangiopathy. The classical form also includes neurologicalsymptoms and end-organ damage, such as renal failure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Purpura-thrombotic-thrombocytopenic</reference><category>Adverse</category></page>
  <page>
    <title>Pychic Personals Love</title>
    <id>1377</id>
    <reference>http://rocketcarrental.com/SESS_q4hOTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_pychic%2Bpersonals%2Blove.html</reference><reference>http://www.physicsfundamentalized.com/PhysicsII/ForumTwo/topic.php?id=9414</reference><reference>http://cfptalk.com/forums/bbpress/topic/kids-best-chat-sites</reference><reference>http://www.ohiovr.com/polywell-faq/index.php?title=Dating_Melbourne_Florida_Escorts</reference><reference>http://www.pocketup.com/forum/topic/customer-relationship-management-center-contact-crm-services</reference><reference>http://www.dartless.com/sanba/content/free-2005-love-dating-site-personals-servcies</reference><reference>http://oinkoinkpiggy.com/node/6046</reference><reference>http://www.observium.org/wiki/Texas_Dating_Big_Park_Arizona</reference><reference>http://gordyvision.com/?q=node/26230</reference><reference>http://www.theartificialstupidity.net/wiki/index.php/Disadvantages_Of_Online_Dating</reference><reference>http://www.fiestamanizales.com/node/43388</reference><reference>http://www.buddhafart.com/ILLUMINATUS//index.php?title=Linda_Stevens_Dating_Nj</reference><reference>http://www.discusstree.com/forum/topic/affect-business-can-communication-nonverbal-relationship-2</reference></page>
  <page>
    <title>Qsar</title>
    <id>380</id>
    <term>QSAR</term><definition>Structure&#8211;Activity Relationship ([Q]SAR) is the process of model building in the biochemical context. Structure&#8211;activity relationships (SARs) are models based on structural features, and quantitative structure&#8211;activity relationships (QSARs) rely on quantitative (frequently physicochemical) properties. The most general mathematical form of a (Q)SAR is Activity = f ( physicochemical properties and/or structural features). The training compounds are stored in databases together with their activity values. Formally, we have observed data for n cases ([x1, y1], ... , [xn, yn]), where each xi = (xi1, &#8230;, xim) is a feature vector of m input values and each yi is the associated activity (dependent variable). The observations and corresponding activities can therefore be compactly represented in a data matrix, X (sometimes also referred to as set X), and a corresponding activity vector y. Our primary interest is to predict the unknown activity value yq for a query compound xq. A predicted value for xq is commonly referred to as f(xq), associated with a confidence value, c, which is derived from certain properties of the model that describe the goodness of the fit. Taken from:   [http://eu.wiley.com/WileyCDA/Section/id-302479.html?query=Konstantin+V.+Balakin  Konstantin V. Balakin] ,  [http://eu.wiley.com/WileyCDA/Section/id-302479.html?query=Sean+Ekins Sean Ekins]  (Series Editor)  "Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery", ch.</definition><category>QSAR APPROACH</category></page>
  <page>
    <title>Radiodermatitis</title>
    <id>365</id>
    <term>Radiodermatitis</term><definition>A cutaneous inflammatory reaction occurring as a result of exposure to ionizing radiation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Radiodermatitis</reference><category>Adverse</category></page>
  <page>
    <title>Random error</title>
    <id>887</id>
    <term>Random error</term><definition>Indefiniteness of result due to finite precision of experiment. Measure of fluctuation in result upon repeated experimentation.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>QSAR</category></page>
  <page>
    <title>Reasonable Maximum Exposure (RME)</title>
    <id>889</id>
    <term>Reasonable Maximum Exposure (RME)</term><definition>The maximum exposure reasonably expected        to occur in a population.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Risk</category></page>
  <page>
    <title>Reasonable Worst Case</title>
    <id>232</id>
    <term>Reasonable Worst Case</term><definition>An estimate of the individual dose, exposure,        or risk level received by an individual in a defined population that is        greater than the 90th percentile but less than that received by anyone        in the 98th percentile in the same population.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><category>Epidemiology</category></page>
  <page>
    <title>Receptor</title>
    <id>888</id>
    <term>Receptor</term><definition>		The ecological entity exposed to the stressor.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><category>Biology</category></page>
  <page>
    <title>Receptor population</title>
    <id>233</id>
    <term>Receptor Population</term><definition>		The exposed individual relative to the exposure pathway considered.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J-</reference><category>Biology</category></page>
  <page>
    <title>Recommended Maximum Contaminant Level (RMCL)</title>
    <id>234</id>
    <term>Recommended Maximum Contaminant Level (RMCL)</term><definition>he maximum level        of a contaminant in drinking water at which no known or anticipated adverse        effect on human health would occur, and that includes an adequate margin        of safety. Recommended levels are nonenforceable health goals.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><category>Risk</category></page>
  <page>
    <title>Reconstruction of dose</title>
    <id>949</id>
    <term>Reconstruction of dose</term><definition>An approach to quantifying exposure from internal dose, which is in turn reconstructed after exposure has occurred, from evidence within an organism such as chemical levels in tissues or fluids or from evidence of other biomarkers of exposure.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><category>Dose</category></page>
  <page>
    <title>Recovery</title>
    <id>235</id>
    <term>Recovery</term><definition>The rate and extent of return of a population or community to some aspect(s) of its previous condition. Because of the dynamic nature of ecological systems, the attributes of a &#8220;recovered&#8221; system should be carefully defined.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#r</reference><category>Risk</category></page>
  <page>
    <title>Reference Dose (RfD)</title>
    <id>950</id>
    <term>Reference Dose (RfD)</term><definition>The RfD is a numerical estimate of a daily oral exposure to the human population, including sensitive subgroups such as children, that is not likely to cause harmful effects during a lifetime. RfDs are generally used for health effects that are thought to have a threshold or low dose limit for producing effects.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><reference>http://www.atsdr.cdc.gov/glossary.html#Reference%20Dose</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><reference>http://www.epa.gov/opptintr/rsei/tools/glossary.html</reference><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Dose</category></page>
  <page>
    <title>Reference Value (RfV)</title>
    <id>951</id>
    <term>Reference Value (RfV)</term><definition>An estimate of an exposure for a given duration to the human population (including susceptible subgroups) that is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived from a BMDL, a NOAEL, a LOAEL, or another suitable point of departure, with uncertainty/variability factors applied to reflect limitations of the data used.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Risk</category></page>
  <page>
    <title>Regional Deposited Dose (RDD)</title>
    <id>952</id>
    <term>Regional Deposited Dose (RDD)</term><definition>The deposited dose of particles calculated for the region of interest as related to the observed effect. For respiratory effects of particles, the deposited dose is adjusted for ventilatory volumes and the surface area of the respiratory region effected (mg/min-sq.cm).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><category>Risk</category></page>
  <page>
    <title>Regional Deposited Dose Ratio (RDDR)</title>
    <id>236</id>
    <term>Regional Deposited Dose Ratio (RDDR)</term><definition>The ratio of the regional deposited dose calculated for a given exposure in the animal species of interest to the regional deposited dose of the same exposure in a human. This ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a human equivalent concentration for particles.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Dose</category></page>
  <page>
    <title>Regional Gas Dose (RGD)</title>
    <id>237</id>
    <term>Regional Gas Dose (RGD)</term><definition>The gas dose calculated for the region of interest as related to the observed effect for respiratory effects. The deposited dose is adjusted for ventilatory volumes and the surface area of the respiratory region effected (mg/min-sq.cm).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Dose</category></page>
  <page>
    <title>Regional Gas Dose Ratio (RGDR)</title>
    <id>238</id>
    <term>Regional Gas Dose Ratio (RGDR)</term><definition>The ratio of the regional gas dose calculated for a given exposure in the animal species of interest to the regional gas dose of the same exposure in humans. This ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a human equivalent concentration for gases with respiratory effects.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Dose</category></page>
  <page>
    <title>Relative Risk (or Risk Ratio (RR))</title>
    <id>125</id>
    <term>Relative Risk (or Risk Ratio (RR))</term><definition>The relative measure of the difference in risk between the exposed and unexposed populations in a cohort study. The relative risk is defined as the rate of disease among the exposed divided by the rate of the disease among the unexposed. A relative risk of 2 means that the exposed group has twice the disease risk as the unexposed group. The ratio of the rate of the disease (usually incidence or mortality) among those exposed to the rate among those not exposed.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><reference>http://sra.org/resources_glossary_p-r.php</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><category>Risk</category></page>
  <page>
    <title>Relative potency</title>
    <id>953</id>
    <term>Relative potency</term><definition>A comparison of the potency of two or more reference chemicals. Potency of a test chemical is reviewed at all levels of biological organization (subcellular, cellular, animal, human).</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Risk</category></page>
  <page>
    <title>Relative risk assessment</title>
    <id>126</id>
    <term>Relative risk assessment</term><definition>Estimating the risks associated with different stressors or management actions. &#160;A process similar to comparative risk assessment. It involves estimating the risks associated with different stressors or management actions. To some, relative risk connotes the use of quantitative risk techniques, while comparative risk approaches more often rely on professional judgment. Others do not make this distinction.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#r</reference><category>Risk</category></page>
  <page>
    <title>Release rate</title>
    <id>127</id>
    <term>Release rate</term><definition>The quantity of apollutant released from a source over a specified period of time.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Risk</category></page>
  <page>
    <title>Reletive Dating</title>
    <id>1365</id>
    <reference>http://esecuritys.com/SESS_us5OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_reletive%2Bdating.html</reference><reference>http://www.bedroomgenius.com/content/trinidad-chat</reference><reference>http://wiki.sfbace.org/index.php?title=Everett_Area_Chat_Rooms</reference><reference>http://decodeyourmessages.com/content/charlie-russells-relationship-indians</reference><reference>http://gribskov-motion.dk/forum/topic.php?id=8</reference><reference>http://wiki.mobileconnectevent.com/index.php/Do_Any_Yahoo_Chat_Rooms_Work</reference><reference>http://www.musinity.com/wiki/Cell_Crystal_Efficiency_Single_Solar</reference><reference>http://www.holdthatclass.com/school/west-liberty-state-college/need_class/horny-local-chat</reference><reference>http://www.amazonca.com/content/espaol-chat</reference><reference>http://www.gsic.uva.es/wikis/cscl-erem/index.php/Free_Cool_Dating_Sites</reference><reference>http://wiki.global-anycast.net/index.php/0906_Premium_Rate_Numbers_Sex_Chat</reference><reference>http://www.rosenstiehl.net/forum/topic.php?id=6</reference><reference>http://ryandlane.com/wiki/Dating_Free_Philippine_Service</reference><reference>http://tugospelradio.com/foro/topic.php?id=8</reference></page>
  <page>
    <title>Reliability</title>
    <id>239</id>
    <term>Reliability</term><definition>The probability a system performs a specified function                   or mission under given conditions for a prescribed time.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Risk</category></page>
  <page>
    <title>Renal insufficiency</title>
    <id>816</id>
    <term>Renal insufficiency</term><definition>Conditions in which the kidneys perform below the normal level in the ability to remove wastes, concentrate urine, and maintain electrolyte balance; blood pressure; and calcium metabolism. Renalinsufficiency can be classified by the degree of kidney damage (as measured bythe level of PROTEINURIA) and reduction in glomerular filtration rate. The mostsevere form is KIDNEY FAILURE. Renal function may deteriorate slowly (renalinsufficiency, chronic) or precipitously (renal insufficiency, acute).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Renal-insufficiency</reference><category>Adverse</category></page>
  <page>
    <title>Reportable Quantity (RQ)</title>
    <id>890</id>
    <term>Reportable Quantity (RQ)</term><definition>		The RQ is the quantity of hazardous substances that, when released into 		the environment, can cause substantial endangerment to public health or 		the environment. Under CERCLA, the federal government must be notified 		when quantities equaling or exceeding RQs specified in regulations are 		released.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Hazards</category></page>
  <page>
    <title>Reproducibility</title>
    <id>128</id>
    <term>Reproducibility</term><definition>The degree of variation obtained when the same measurement                   is made with similar instruments and many operators.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Ecotox</category></page>
  <page>
    <title>Reproductive Toxicity</title>
    <id>240</id>
    <term>Reproductive Toxicity</term><definition>Adverse effects on the male and/or female reproductive systems caused by exposure to                a toxic chemical. Reproductive toxicity may be expressed as alterations in sexual behavior,                decreases in fertility or fetal loss during pregnancy. Some official definitions of reproductive                toxicity, for example in California's Proposition 65, include developmental toxicity as part of                reproductive toxicity.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Reprotox</category></page>
  <page>
    <title>Reprotox</title>
    <id>383</id>
    <term>Reproductive Toxicity</term><category>Reprotox</category></page>
  <page>
    <title>Reserve volume</title>
    <id>241</id>
    <term>Reserve volume</term><definition>The volume of air remaining in the lungs after a maximal expiration.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Endpoints</category></page>
  <page>
    <title>Residence time</title>
    <id>129</id>
    <term>Residence time</term><definition>The period of time during which a substance resides in a designated area.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Endpoints</category></page>
  <page>
    <title>Residual Volume (RV)</title>
    <id>954</id>
    <term>Residual Volume (RV)</term><definition>The lung volume aftermaximal expiration (TLC - VC).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Endpoints</category></page>
  <page>
    <title>Respirable particle</title>
    <id>955</id>
    <term>Respirable particle</term><definition>Particle of the size(&lt;5.0 &#181;m) most likely to be deposited in the pulmonary portion of therespiratory tract.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Chemistry</category></page>
  <page>
    <title>Respiratory failure</title>
    <id>367</id>
    <term>Respiratory failure</term><definition>Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Respiratory-failure</reference><category>Adverse</category></page>
  <page>
    <title>Response</title>
    <id>242</id>
    <term>Response</term><definition>The proportion or absolute size of a population that demonstrates                   a specific effect.&#160; May also refer to thenature of the effect . Changedeveloped in the state or dynamics of an organism, system or (sub) populationin reaction to exposure to an agent. change developed in the state or dynamics of a system in reaction to theaction of an agent.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Biology</category></page>
  <page>
    <title>Restless legs syndrome</title>
    <id>817</id>
    <term>Restless legs syndrome</term><definition>A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep. Complyingwith an irresistible urge to move the affected limbs brings temporary relief.Sleep may become disrupted, resulting in excessive daytime hypersomnolence.This condition may be associated with uremia; diabetes mellitus; and rheumatoidarthritis. restless legs syndrome differs from nocturnal myoclonus syndrome inthat in the latter condition the individual does not report adverse sensorystimuli and it is primarily a sleep-associated movement disorder.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Restless-leg-syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Reticulocytosis</title>
    <id>150</id>
    <term>Reticulocytosis</term><definition>An increase in circulating reticulocytes, which is among the simplest and most reliable signs of accelerated erythrocyte production.      Reticulocytosis occurs during active blood regeneration (stimulation of red bone marrow) and in certain types of anemia, particularly congenital hemolytic anemia.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Reticulocytosis</reference><category>Adverse</category></page>
  <page>
    <title>Retinal hemorrhage</title>
    <id>151</id>
    <term>Retinal hemorrhage</term><definition>Bleeding from the vessels of the retina.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Retinal-hemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Retroperitoneal fibrosis</title>
    <id>152</id>
    <term>Retroperitoneal fibrosis</term><definition>A slowly progressive condition of unknown etiology, characterized by deposition of fibrous tissue in the retroperitoneal space compressing the ureters, great vessels, bile duct, and other structures. When associated with abdominal aortic aneurysm, it may be called chronic periaortitis or inflammatory perianeurysmal fibrosis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Retroperitoneal-fibrosis</reference><category>Adverse</category></page>
  <page>
    <title>Retrospective Risk Assessment</title>
    <id>130</id>
    <term>Retrospective Risk Assessment</term><definition>An evaluation of thecausal linkages between observed ecological effects and stressor(s) in theenvironment.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Rhabdomyolysis</title>
    <id>818</id>
    <term>Rhabdomyolysis</term><definition>Necrosis or disintegration of skeletal muscle often followed by myoglobinuria.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Rhabdomyolysis</reference><category>Adverse</category></page>
  <page>
    <title>Rhinitis</title>
    <id>260</id>
    <term>Rhinitis</term><definition>Inflammation of the mucous membrane of the nose.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Rhinitis</reference><category>Adverse</category></page>
  <page>
    <title>Risk (in the context of human health)</title>
    <id>956</id>
    <term>Risk (in the context of human health)</term><definition>The probability        of adverse effects resulting from exposure to an environmental agent or        mixture of agents.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Risk</category></page>
  <page>
    <title>Risk Management (in the context of human health)</title>
    <id>246</id>
    <term>Risk Management (in the context of human health)</term><definition>A        decision making process that accounts for political, social, economic        and engineering implications together with risk-related information in        order to develop, analyze and compare management options and select the        appropriate managerial response to a potential chronic health hazard.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><category>Risk</category></page>
  <page>
    <title>Risk analysis</title>
    <id>131</id>
    <term>Risk analysis</term><definition>A detailed examinationincluding risk assessment, risk evaluation, and risk management alternatives,performed to understand the nature of unwanted, negative consequences to humanlife, health, property, or the environment; an analytical process to provideinformation regarding undesirable events; the process of quantification of theprobabilities and expected consequences for identified risks.</definition><reference>http://rais.ornl.gov/home/glossary.html#R</reference><category>Risk</category></page>
  <page>
    <title>Risk assessment</title>
    <id>386</id>
    <term>Risk assessment</term><definition>&#160; Riskassessment - The evaluation of scientific information on thehazardous properties of environmental agents (hazard characterization), thedose-response relationship (dose-response assessment), and the extent of humanexposure to those agents (exposure assessment) 		Qualitative or quantitative evaluation of the risk posed to human health 		and/or the environment by the actual or potential presence or release 		of hazardous substances, pollutants or contaminants.</definition><reference>http://www.atsdr.cdc.gov/mrls.html</reference><reference>http://www.bio.hw.ac.uk/edintox/glossall.htm</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Risk</category></page>
  <page>
    <title>Risk characterization</title>
    <id>891</id>
    <term>Risk characterization</term><definition>The last phase of the risk assessment process that estimates the potential for adverse health or ecological effects to occur from exposure to a stressor and evaluates the uncertainty involved. Risk Characterization: The integration of information on hazard, exposure, and dose-response to provide an estimate of the likelihood that any of the identified adverse effects will occur in exposed people.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><reference>http://www.epa.gov/iris/help_gloss.htm#r%D1%8A</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Risk communication</title>
    <id>957</id>
    <term>Risk communication</term><definition>The exchange of information about health or environmental risks among risk assessors and managers, the general public, news media, interest groups, etc. Risk communication - The exchange of information to increase understanding of health risks. &#160; Risk communication, the exchange of information about health or environmental risks among risk assessors, risk managers, the local community, news media and interest groups, is the process of informing members of the local community about environmental risks associated with a site and the steps that are being taken to manage those risks.</definition><reference>http://www.epa.gov/OCEPAterms/rterms.html</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J-</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Risk estimation</title>
    <id>243</id>
    <term>Risk estimation</term><definition>&#160; The scientific determination of the characteristics of                   risks, usually in as quantitative a way as possible. These                   include the magnitude, spatial scale, duration and intensity                   of adverse consequences and their associated probabilities                   as well as a description of the cause and effect links.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><reference>http://rais.ornl.gov/home/glossary.html#R</reference><category>Risk</category></page>
  <page>
    <title>Risk evaluation</title>
    <id>892</id>
    <term>Risk evaluation</term><definition>A component of risk assessment in which judgments are made                   about the significance and acceptability of risk.</definition><reference>http://rais.ornl.gov/home/glossary.html#R</reference><reference>http://sra.org/resources_glossary_p-r.php</reference><category>Risk</category></page>
  <page>
    <title>Risk factor</title>
    <id>244</id>
    <term>Risk factor</term><definition>Characteristic (e.g., race, sex, age, obesity) or variable (e.g., smoking, occupational exposure level) associated with increased probability of a toxic effect.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Risk</category></page>
  <page>
    <title>Risk identification</title>
    <id>245</id>
    <term>Risk identification</term><definition>Recognizing that a hazard exists and trying to define its characteristics. Often risks exist and are even measured for some time before their adverse consequences are recognized.In other cases, risk identification is a deliberate procedure to review, and it is hoped, anticipate possible hazards.</definition><reference>http://sra.org/resources_glossary_p-r.php</reference><reference>http://rais.ornl.gov/home/glossary.html#C</reference><category>Risk</category></page>
  <page>
    <title>Route of exposure</title>
    <id>247</id>
    <term>Route of Exposure</term><definition>The way in which a person may contact a chemical substance. For example, drinking (ingestion) and bathing (skin contact) are two different routes of exposure to contaminants that may be found in water. The avenue by which a chemical comes into contact with an organism (such as a person). Possible routes include inhalation, ingestion, and dermal contact.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Risk</category></page>
  <page>
    <title>SIDS (Screening Information Data Set)</title>
    <id>249</id>
    <term>SIDS (Screening Information Data Set)</term><definition>The Screening Information Data Set created by the member countries of the Organization for Economic Cooperation and Development (OECD) in 1990, for purposes of screening high-production-volume chemicals used in those countries (including the U.S.). The purpose of the SIDS program is to complete initial screening tests on those chemicals to identify their potential hazards to human health and the environment, so that risk assessments can then be done for the chemicals with sufficient hazard potential. The data set is a list of the tests and other information about a chemical that OECD considers to be the necessary minimum for purposes of this preliminary screening.</definition><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Regulatory</category></page>
  <page>
    <title>Safety</title>
    <id>132</id>
    <term>Safety</term><definition>Relative protection from adverse consequences.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Risk</category></page>
  <page>
    <title>Scotoma</title>
    <id>368</id>
    <term>Scotoma</term><definition>A localized defect in the visual field bordered by an area of normal vision. Thisoccurs with a variety of eye diseases (e.g., retinal diseases and glaucoma);optic nerve diseases, and other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Scotoma</reference><category>Adverse</category></page>
  <page>
    <title>Scriptures On Men And Women Relationships</title>
    <id>1369</id>
    <reference>http://mysearchends.com/SESS_pb0OTN8fDEyOTYwODMxOTd8fDE5MDZ8fChFTkdJTkUpIE1lZGlhV2lraQ%3D%3D_scriptures%2Bon%2Bmen%2Band%2Bwomen%2Brelationships.html</reference><reference>http://www.amazonca.com/content/espaol-chat</reference><reference>http://wiki.sfbace.org/index.php?title=Everett_Area_Chat_Rooms</reference><reference>http://wiki.mobileconnectevent.com/index.php/Do_Any_Yahoo_Chat_Rooms_Work</reference><reference>http://www.holdthatclass.com/school/west-liberty-state-college/need_class/horny-local-chat</reference><reference>http://tugospelradio.com/foro/topic.php?id=8</reference><reference>http://www.bedroomgenius.com/content/trinidad-chat</reference><reference>http://www.rosenstiehl.net/forum/topic.php?id=6</reference><reference>http://wiki.global-anycast.net/index.php/0906_Premium_Rate_Numbers_Sex_Chat</reference></page>
  <page>
    <title>Secondary effect</title>
    <id>133</id>
    <term>Secondary effect</term><definition>An effect where the stressor acts on supporting components of the ecosystem, which in turn have an effect on the ecological component of interest (synonymous with indirect effects; compare with definition for primary effect).</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Ecotox</category></page>
  <page>
    <title>Sedative</title>
    <id>153</id>
    <term>Sedative</term><definition>Substance that exerts a soothing or tranquilizing effect. Substance that reduces excitability and calms a person.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sedative</reference><category>Adverse</category></page>
  <page>
    <title>Self-injurious behavior</title>
    <id>261</id>
    <term>Self-injurious behavior</term><definition>Behavior in which persons hurt or harm themselves without the motive of suicide or of sexual deviation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Self-injurious-behavior</reference><category>Adverse</category></page>
  <page>
    <title>Sensation disorders</title>
    <id>262</id>
    <term>Sensation disorders</term><definition>Disorders of the special senses (i.e., vision; hearing; taste; and smell) or somatosensory system (i.e., afferent components of the peripheral nervous system).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sensation-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Sensorineural hearing loss</title>
    <id>369</id>
    <term>Sensorineural hearing loss</term><definition>Hearing loss resulting from damage to the cochlea and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the auditory nerve and its connections in the brainstem.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sensorineural-hearing-loss</reference><category>Adverse</category></page>
  <page>
    <title>Septic shock</title>
    <id>370</id>
    <term>Septic shock</term><definition>Sepsis associated with hypotension or hypoperfusion despite adequate fluid resuscitation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Septic-shock</reference><category>Adverse</category></page>
  <page>
    <title>Serotonin syndrome</title>
    <id>263</id>
    <term>Serotonin syndrome</term><definition>An adverse drug interaction characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Serotonin-syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Serum sickness</title>
    <id>371</id>
    <term>Serum sickness</term><definition>Immune complex disease caused by the administration of foreign serum or serum proteins and characterized by fever, lymphadenopathy, arthralgia, and urticaria.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Serum-sickness</reference><category>Adverse</category></page>
  <page>
    <title>Sexual dysfunction</title>
    <id>264</id>
    <term>Sexual dysfunction</term><definition>Physiological disturbances in normal sexual performance in either the male or the female.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sexual-dysfunction</reference><category>Adverse</category></page>
  <page>
    <title>Shivering</title>
    <id>372</id>
    <term>Shivering</term><definition>Involuntary trembling or quivering of the body caused by contraction or twitching of the muscles, a physiologic method of heat production in man and other mammals.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Shivering</reference><category>Adverse</category></page>
  <page>
    <title>Shock</title>
    <id>373</id>
    <term>Shock</term><definition>A pathological condition that can suddenly affect the hemodynamic equilibrium, usually manifested by failure to perfuse or oxygenate vital organs.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Shock</reference><category>Adverse</category></page>
  <page>
    <title>Short-term Reference Concentration (RfC)</title>
    <id>248</id>
    <term>Short-term Reference Concentration (RfC)</term><definition>An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure for short-term duration (up to 30 days) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Endpoints</category></page>
  <page>
    <title>Short-term Reference Dose (RfD)</title>
    <id>135</id>
    <term>Short-term Reference Dose (RfD)</term><definition>An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure for a short-term duration (up to 30 days) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Endpoints</category></page>
  <page>
    <title>Short-term exposure</title>
    <id>134</id>
    <term>Short-term exposure</term><definition>&#160;Repeated exposure by the oral, dermal, or inhalation route for more than 24 hours, up to 30 days.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Endpoints</category></page>
  <page>
    <title>Sialorrhea</title>
    <id>374</id>
    <term>Sialorrhea</term><definition>Increased salivary flow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sialorrhea</reference><category>Adverse</category></page>
  <page>
    <title>Sicca syndrome</title>
    <id>154</id>
    <term>Sicca syndrome</term><definition>Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears.      The primary form, often called sicca syndrome, involves both keratoconjunctivitis sicca and xerostomia. The secondary form includes, in addition, the presence ofa connective tissue disease, usually rheumatoid arthritis.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sicca-syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Sink</title>
    <id>136</id>
    <term>Sink</term><definition>Place in the environment where a compound or material collects. A place where pollutants are collected by means of processes such as absorption. The opposite of source.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Sinoatrial block</title>
    <id>375</id>
    <term>Sinoatrial block</term><definition>Disturbancein the atrial activation that is caused by transient failure of impulseconduction from the sinoatrial node to the heart atria. It is characterized bya delayed in heartbeat and pauses between P waves in an electrocardiogram.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sinoatrial-block</reference><category>Adverse</category></page>
  <page>
    <title>Sinusitis</title>
    <id>155</id>
    <term>Sinusitis</term><definition>Inflammation of the nasal mucosa in one or more of the paranasal sinuses.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sinusitis</reference><category>Adverse</category></page>
  <page>
    <title>Sixth nerve palsy</title>
    <id>265</id>
    <term>Sixth nerve palsy</term><definition>Diseases of the sixth cranial nerve or its nucleus in the pons. The nerve may be injured along its course in the pons, intracranially as it travels along the base of the brain, in the cavernous sinus, or at the level of superior orbital fissure or orbit.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sixth-nerve-palsy</reference><category>Adverse</category></page>
  <page>
    <title>Slope factor SF</title>
    <id>137</id>
    <term>Slope factor SF</term><definition>slope factor (SF, CPSF) Toxicity value for evaluating the probability of an individual developing cancer from exposure to contaminant levels over a lifetime. An upper bound, approximating a 95% confidence limit, on the increased cancer risk from a lifetime exposure to an agent. This estimate, usually expressed in units of proportion (of a population) affected per mg/kg-day, is generally reserved for use in the low-dose region of the dose-response relationship, that is, for exposures corresponding to risks less than 1 in 100.</definition><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Risk</category></page>
  <page>
    <title>Smoke</title>
    <id>138</id>
    <term>Smoke</term><definition>The visible aerosol that results from incomplete combustion. Particles suspended in air after incomplete combustion.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Sneezing</title>
    <id>819</id>
    <term>Sneezing</term><definition>The sudden, forceful, involuntary expulsion of air from the nose and mouth caused by irritation to the mucous membranes of the upper respiratory tract.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sneezing</reference><category>Adverse</category></page>
  <page>
    <title>Source</title>
    <id>250</id>
    <term>Source</term><definition>A place where pollutants are emitted, for example a chimney stack. An entity or action that releases to the environment or imposes on the environment a chemical, physical, or biological stressor or stressors.</definition><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Ecotox</category></page>
  <page>
    <title>Speech disorders</title>
    <id>157</id>
    <term>Speech disorders</term><definition>Acquired or developmental conditions marked by an impaired ability to comprehend or generate spoken forms of language.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Speech-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Splenomegaly</title>
    <id>820</id>
    <term>Splenomegaly</term><definition>Enlargement of the spleen.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Splenomegaly</reference><category>Adverse</category></page>
  <page>
    <title>Squamous cell carcinoma</title>
    <id>821</id>
    <term>Squamous cell carcinoma</term><definition>A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Squamous-cell-carcinoma</reference><category>Adverse</category></page>
  <page>
    <title>Stakeholder</title>
    <id>893</id>
    <term>Stakeholder</term><definition>Any organization, governmental entity, or individual that has a stake in or may be impacted by a given approach to environmental regulation, pollution prevention, energy conservation, etc. A person, group, or community who has an interest in activities at a hazardous waste site.</definition><reference>http://www.atsdr.cdc.gov/glossary.html#G-J</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><category>Regulatory</category></page>
  <page>
    <title>Standardized mortality ratio (SMR)</title>
    <id>958</id>
    <term>Standardized mortality ratio (SMR)</term><definition>The ratio of observed deaths in a population to the expected number of deaths as derived from rates in a standard population with adjustment of age and possibly other factors such as sex or race. This is the relative measure of the difference in risk between the exposed and unexposed populations in a cohort study. The SMR is similar to the relative risk in both definition and interpretation. This measure is usually standardized to control for any differences in age, sex, and/or race between the exposed and reference populations. It is frequently converted to a percent by multiplying the ratio by 100.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Epidemiology</category></page>
  <page>
    <title>Stationary source</title>
    <id>894</id>
    <term>Stationary source</term><definition>A pollution location that is fixed rather than moving.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><category>Ecotox</category></page>
  <page>
    <title>Statistical significance</title>
    <id>959</id>
    <term>Statistical significance</term><definition>The probability that a result is not likely to be due to chance alone. By convention, a difference between two groups is usually considered statistically significant if chance could explain it only 5% of the time or less. Study design considerations may influence the a priori choice of a different level of statistical significance. The statistical significance determined by using appropriate standard techniques of statistical analysis with results interpreted at the stated confidence level and based on data relating species which are present in sufficient numbers at control areas to permit a valid statistical comparison with the areas being tested.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>QSAR</category></page>
  <page>
    <title>Status epilepticus</title>
    <id>158</id>
    <term>Status epilepticus</term><definition>A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Status-epilepticus</reference><category>Adverse</category></page>
  <page>
    <title>Steady state exposure</title>
    <id>960</id>
    <term>Steady state exposure</term><definition>Exposure to an environmental pollutant whose concentration remains constant for a period of time.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Ecotox</category></page>
  <page>
    <title>Steatorrhea</title>
    <id>267</id>
    <term>Steatorrhea</term><definition>A condition that is characterized by chronic fatty diarrhea, a result of abnormal digestion and/or intestinal absorption of fats.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Steatorrhea</reference><category>Adverse</category></page>
  <page>
    <title>Stevens-Johnson syndrome</title>
    <id>822</id>
    <term>Stevens-Johnson syndrome</term><definition>A variant of bullous erythema multiforme. It ranges from mild skin and mucous membrane lesions to a severe, sometimes fatal systemic disorder.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stevens-Johnson-syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Stochastic model</title>
    <id>895</id>
    <term>Stochastic model</term><definition>A mathematical model which takes into consideration the presence of some randomness in one or more of its parameters or variables. The predictions of the model therefore do not give a single point estimate but a probability distribution of possible estimates. Contrast with deterministic.</definition><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>QSAR</category></page>
  <page>
    <title>Stomatitis</title>
    <id>268</id>
    <term>Stomatitis</term><definition>Inflammation of the soft tissues of the mouth, such as mucosa; palate; gingiva; and lip.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stomatitis</reference><category>Adverse</category></page>
  <page>
    <title>Stress regime</title>
    <id>961</id>
    <term>Stress regime</term><definition>The term "stress regime" has been used in at least three distinct ways: (1) to characterize exposure to multiple chemicals or to both chemical and nonchemical stressors (more clearly described as multiple exposure, complex exposure, or exposure to mixtures), (2) as a synonym for exposure that is intended to avoid overemphasis on chemical exposures, and (3) to describe the series of interactions of exposures and effects resulting in secondary exposures, secondary effects and, finally, ultimate effects (also known as risk cascade [Lipton et al., 1993]), or causal chain, pathway, or network (Andrewartha and Birch, 1984).</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Risk</category></page>
  <page>
    <title>Stressor-response profile</title>
    <id>963</id>
    <term>Stressor-response profile</term><definition>The product of characterization of ecological effects in the analysis phase of ecological risk assessment. The stressor-response profile summarizes the data on the effects of a stressor and the relationship of the data to the assessment endpoint.</definition><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Ecotox</category></page>
  <page>
    <title>Stressors</title>
    <id>962</id>
    <term>Stressors</term><definition>Physical, chemical, or biological entities that can induce adverse effects on ecosystems or human health.</definition><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Biology</category></page>
  <page>
    <title>Stridor</title>
    <id>269</id>
    <term>Stridor</term><definition>Noises, normal and abnormal, heard on auscultation over any part of the respiratory tract.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stridor</reference><category>Adverse</category></page>
  <page>
    <title>Stroke</title>
    <id>159</id>
    <term>Stroke</term><definition>A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to brain ischemia or intracranial hemorrhages.      Stroke is classified by the type of tissue necrosis, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stroke</reference><category>Adverse</category></page>
  <page>
    <title>Stupor</title>
    <id>823</id>
    <term>Stupor</term><definition>A state of reduced sensibility and response to stimuli which is distinguished from coma in that the person can be aroused by vigorous and repeated stimulation. Theperson is still conscious and can make voluntary movements. It can be inducedby central nervous system agents. The word derives from Latin stupere and isrelated to stunned, stupid, dazed or lethargy.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stupor</reference><category>Adverse</category></page>
  <page>
    <title>Stuttering</title>
    <id>824</id>
    <term>Stuttering</term><definition>A disturbance in the normal fluency and time patterning of speech that is inappropriate for the individual's age. This disturbance is characterized by frequent repetitions or prolongations of sounds or syllables. Various other types of speech dysfluencies may also be involved including interjections, broken words, audible or silent blocking, circumlocutions, words produced with an excess of physical tension, and monosyllabic whole word repetitions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Stuttering</reference><category>Adverse</category></page>
  <page>
    <title>Subarachnoid-hemorrhage</title>
    <id>825</id>
    <term>Subarachnoid hemorrhage</term><definition>Bleedinginto the intracranial or spinal subarachnoid space.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Subarachnoid-hemorrhage</reference><category>Adverse</category></page>
  <page>
    <title>Subchronic Reference Concentration (RfC)</title>
    <id>896</id>
    <term>Subchronic Reference Concentration (RfC)</term><definition>An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure for a subchronic duration (up to 10% of average lifespan) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Acute</category></page>
  <page>
    <title>Subchronic Reference Dose (RfD)</title>
    <id>897</id>
    <term>Subchronic Reference Dose (RfD)</term><definition>An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure for a subchronic duration (up to 10% of average lifespan) to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used. Generally used in EPA's noncancer health assessments.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Acute</category></page>
  <page>
    <title>Subchronic exposure</title>
    <id>251</id>
    <term>Subchronic exposure</term><definition>Multiple or continuous exposures lasting for approximately ten percent of an experimental species lifetime, usually over a three-month period. Repeated exposure by the oral, dermal, or inhalation route for more than 30 days, up to approximately 10% of the life span in humans (more than 30 days up to approximately 90 days in typically used laboratory animal species).</definition><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Acute</category></page>
  <page>
    <title>Subchronic study</title>
    <id>898</id>
    <term>Subchronic study</term><definition>A toxicity study designed to measure effects from subchronic exposure to a chemical.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Chronic</category></page>
  <page>
    <title>Sufficient evidence</title>
    <id>252</id>
    <term>Sufficient evidence</term><definition>The&#160;term used in evaluating study data for the classification of a carcinogen under the 1986 U.S. EPA guidelines for carcinogen risk assessment. This classification indicates that there is a causal relationship between the agent or agents and human cancer.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#r</reference><category>Risk</category></page>
  <page>
    <title>Suicide</title>
    <id>826</id>
    <term>Suicide</term><definition>The act of killing oneself.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Suicide</reference><category>Adverse</category></page>
  <page>
    <title>Superfund</title>
    <id>139</id>
    <term>Superfund</term><definition>Federal authority, established by the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) in 1980, to respond directly to releases or threatened releases of hazardous substances that may endanger health or welfare. The federal and state programs to investigate and clean up inactive hazardous waste sites. The program operated under the legislative authority of CERCLA and SARA that funds and carries out EPA solid waste emergency and long-term removal and remedial activities. These activities include establishing the National Priorities List, investigating sites for inclusion on the list, determining their priority, and conducting and/or supervising the cleanup and other remedial actions.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><category>Regulatory</category></page>
  <page>
    <title>Supporting studies</title>
    <id>140</id>
    <term>Supporting studies</term><definition>Studies that contain information useful for providing insight and support for conclusions.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Risk</category></page>
  <page>
    <title>Surrogate</title>
    <id>141</id>
    <term>Surrogate</term><definition>Something that serves as a substitute. In risk analysis, surrogates are often used when data on the item of interest (a chemical, an industry, an exposure, etc.) is lacking. As an example, underground mining of coal and hardrock minerals can be used as a surrogate for underground oil shale mining.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Risk</category></page>
  <page>
    <title>Susceptibility</title>
    <id>964</id>
    <term>Susceptibility</term><definition>Increased likelihood of an adverse effect, often discussed in terms of relationship to a factor that can be used to describe a human subpopulation (e.g., life stage, demographic feature, or genetic characteristic).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Risk</category></page>
  <page>
    <title>Susceptible subgroups</title>
    <id>965</id>
    <term>Susceptible subgroups</term><definition>May refer to life stages, for example, children or the elderly, or to other segments of the population, for example, asthmatics or the immune-compromised, but are likely to be somewhat chemical-specific and may not be consistently defined in all cases.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Risk</category></page>
  <page>
    <title>Sweating</title>
    <id>827</id>
    <term>Sweating</term><definition>The process of exocrine secretion of the sweat glands, including the aqueous sweat from the eccrine glands and the complex viscous fluids of the apocrine glands.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sweating</reference><category>Adverse</category></page>
  <page>
    <title>Sweet syndrome</title>
    <id>347</id>
    <term>Sweet syndrome</term><definition>Condition characterized by large, rapidly extending, erythematous, tender plaques on the upper body usually accompanied by fever and dermal infiltration of neutrophilic leukocytes.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Sweet-Syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Syncope</title>
    <id>828</id>
    <term>Syncope</term><definition>A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., brain ischemia). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Syncope</reference><category>Adverse</category></page>
  <page>
    <title>Synergetic</title>
    <id>142</id>
    <term>Synergetic</term><definition>Working together; an agent that works synergistically with one or more other agents.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Chemistry</category></page>
  <page>
    <title>Synergism</title>
    <id>253</id>
    <term>Synergism</term><definition>An interaction between two substances that results in a greater effect than either of the substances could have had acting independently.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/OCEPAterms/sterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Chemistry</category></page>
  <page>
    <title>Synergistic effects</title>
    <id>254</id>
    <term>Synergistic effects</term><definition>Joint effects of two or more agents, such as drugs that increase each other's effectiveness when taken together. A biologic response to multiple substances where one substance worsens the effect of another substance.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J</reference><category>Mechanism</category></page>
  <page>
    <title>Systematic error</title>
    <id>255</id>
    <term>Systematic error</term><definition>A reproducible inaccuracy introduced by faulty equipment, calibration, or technique.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Risk</category></page>
  <page>
    <title>Systemic Effects or Systemic Toxicity</title>
    <id>143</id>
    <term>Systemic Effects or Systemic Toxicity</term><definition>Toxic effects as a result of absorption and distribution of a toxicant to a site distant from its entry point. Systemic effects are those that require absorption and distribution of the toxicant to a site distant from its entry point, at which point effects are produced. Most chemicals that produce systemic toxicity do not cause a similar degree of toxicity in all organs, but usually demonstrate major toxicity to one or two organs. These are referred to as the target organs of toxicity for that chemical.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Risk</category></page>
  <page>
    <title>Systemic lupus erythematosus</title>
    <id>270</id>
    <term>Systemic lupus erythematosus</term><definition>A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Systemic-lupus-erythematosus</reference><category>Adverse</category></page>
  <page>
    <title>Tachycardia</title>
    <id>271</id>
    <term>Tachycardia</term><definition>Abnormally rapid heartbeat, usually with a heart rate above 100 beats per minute for adults.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tachycardia</reference><category>Adverse</category></page>
  <page>
    <title>Tachyphylaxis</title>
    <id>272</id>
    <term>Tachyphylaxis</term><definition>Rapidly decreasing response to a drug or physiologically active agent after administration of a few doses. In immunology, it is the rapid immunization against the effect of toxic doses of an extract or serum by previous injection of small doses.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tachyphylaxis</reference><category>Adverse</category></page>
  <page>
    <title>Target organ</title>
    <id>335</id>
    <term>Target organ</term><definition>- The biological organ(s) most adversely affected by exposure to a chemical, physical, or biological agent.</definition><reference>http://www.epa.gov/iris/help_gloss.htm</reference><category>Human_health</category></page>
  <page>
    <title>Target organ or system</title>
    <id>144</id>
    <term>Target organ/system</term><definition>The biological organ(s) most adversely affected by exposure to a chemical, physical, or biological agent. The organ or system of the body that is generally affected first as the dose of the chemical is increased from zero. For noncancer toxicity, the critical effect occurs in the primary target organ.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Biology</category></page>
  <page>
    <title>Taste disorders</title>
    <id>273</id>
    <term>Taste disorders</term><definition>Conditions characterized by an alteration in gustatory function or perception.      Taste disorders are frequently associated with olfaction disorders. Additional potential etiologies include metabolic diseases; drug toxicity; and taste pathway disorders (e.g., taste bud diseases; facial nerve diseases; glossopharyngeal nerve diseases; and brain stem diseases).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Taste-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Telangiectasis</title>
    <id>274</id>
    <term>Telangiectasis</term><definition>Permanent dilation of preexisting blood vessels (capillaries, arterioles, venules) creating small focal red lesions, most commonly in the skin or mucous membranes. Itis characterized by the prominence of skin blood vessels, such as vascularspiders.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Telangiectasis</reference><category>Adverse</category></page>
  <page>
    <title>Temperature inversion</title>
    <id>145</id>
    <term>Temperature inversion</term><definition>Layer of air in which temperature increases with altitude; very little turbulent exchange occurs within it.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Ecotox</category></page>
  <page>
    <title>Teratogenic</title>
    <id>966</id>
    <term>Teratogenic</term><definition>Substances that are suspected of causing malformations or serious deviations from the normal type, which can not be inherited in or on animal embryos or fetuses. Structural developmental defects due to exposure to a chemical agent during formation of individual organs.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Reprotox</category></page>
  <page>
    <title>Teratogens</title>
    <id>160</id>
    <term>Teratogens</term><definition>An agent that causes the production of physical defects in the developing embryo.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Teratogens</reference><category>Adverse</category></page>
  <page>
    <title>Teratology</title>
    <id>256</id>
    <term>Teratology</term><definition>Science that deals with abnormal development of the fetus and congenital malformation.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Reprotox</category></page>
  <page>
    <title>Test3</title>
    <id>1287</id>
    <term>Test3</term></page>
  <page>
    <title>Tetany</title>
    <id>161</id>
    <term>Tetany</term><definition>A disorder characterized by muscle twitches, cramps, and carpopedal spasm, and when severe, laryngospasm and seizures.      This condition is associated with unstable depolarization of axonal membranes, primarily in the peripheral nervous system. Tetany usually results from hypocalcemia or reduced serum levels of magnesium that may be associated with hyperventilation; hypoparathyroidism; rickets; uremia; or other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tetany</reference><category>Adverse</category></page>
  <page>
    <title>Thirst</title>
    <id>162</id>
    <term>Thirst</term><definition>A drive stemming from a physiological need for water.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thirst</reference><category>Adverse</category></page>
  <page>
    <title>Threshold</title>
    <id>967</id>
    <term>Threshold</term><definition>The dose or exposure below which no deleterious effect is expected to occur. A pollutant concentration [or dose] below which no deleterious effect occurs The lowest dose of a chemical at which a specified measurable effect is observed and below which it is not observed.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Risk</category></page>
  <page>
    <title>Threshold Limit Value (TLV)</title>
    <id>968</id>
    <term>Threshold Limit Value (TLV)</term><definition>Recommended guidelines for occupational exposure to airborne contaminants published by the American Conference of Governmental Industrial Hygienists (ACGIH). TLVs represent the average concentration in mg/m 3  for an 8-hour workday and a 40-hour work week to which nearly all workers may be repeatedly exposed, day after day, without adverse effect. Refers to airborne concentrations of substances and represents conditions under which it is believed that nearly all workers are protected while repeatedly exposed for an 8-hr day, 5 days a week (expressed as parts per million (ppm) for gases and vapors and as milligrams per cubic meter (mg/m 3 ) for fumes, mists, and dusts). &#160;The concentration of an airborne substance to which an average person can be repeatedly exposed without adverse effects. TLVs may be expressed in three ways: (1) TLV-TWA--Time weighted average, based on an allowable exposure averaged over a normal 8-hour workday or 40-hour work- week; (2) TLV-STEL--Short-term exposure limit or maximum concentration for a brief specified period of time, depending on a specific chemical (TWA must still be met); and (3) TLV-C--Ceiling Exposure Limit or maximum exposure concentration not to be exceeded under any circumstances. (TWA must still be met.</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Risk</category></page>
  <page>
    <title>Threshold dose</title>
    <id>257</id>
    <term>Threshold dose</term><definition>The minimum application of a given substance required to produce an observable effect.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Risk</category></page>
  <page>
    <title>Thrombocytopenia</title>
    <id>275</id>
    <term>Thrombocytopenia</term><definition>Asubnormal level of blood platelets.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thrombocytopenia</reference><category>Adverse</category></page>
  <page>
    <title>Thrombocytopenic purpura</title>
    <id>276</id>
    <term>Thrombocytopenic purpura</term><definition>Any form of purpura in which the platelet count is decreased. Many forms are thought to be caused by immunological mechanisms.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thrombocytopenic-purpura</reference><category>Adverse</category></page>
  <page>
    <title>Thrombocytosis</title>
    <id>277</id>
    <term>Thrombocytosis</term><definition>Increased numbers of platelets in the peripheral blood.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thrombocytosis</reference><category>Adverse</category></page>
  <page>
    <title>Thromboembolism</title>
    <id>278</id>
    <term>Thromboembolism</term><definition>Obstructionof a blood vessel (embolism) by a blood clot (thrombus) in the blood stream.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thromboembolism</reference><category>Adverse</category></page>
  <page>
    <title>Thrombophlebitis</title>
    <id>829</id>
    <term>Thrombophlebitis</term><definition>Inflammationof a vein associated with a blood clot (thrombus).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thrombophlebitis</reference><category>Adverse</category></page>
  <page>
    <title>Thrombosis</title>
    <id>830</id>
    <term>Thrombosis</term><definition>Formation and development of a thrombus or blood clot in the blood vessel.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thrombosis</reference><category>Adverse</category></page>
  <page>
    <title>Thyroiditis</title>
    <id>279</id>
    <term>Thyroiditis</term><definition>Inflammatory diseases of the thyroid gland. Thyroiditiscan be classified into acute (thyroiditis, suppurative), subacute(granulomatous and lymphocytic), chronic fibrous (riedel's), chroniclymphocytic (hashimoto disease), transient (postpartum thyroiditis), and otherautoimmune thyroiditis subtypes.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thyroiditis</reference><category>Adverse</category></page>
  <page>
    <title>Thyrotoxicosis</title>
    <id>376</id>
    <term>Thyrotoxicosis</term><definition>A hypermetabolic syndrome caused by excess thyroid hormones which may come from endogenous or exogenous sources. Theendogenous source of hormone may be thyroid hyperplasia; thyroid neoplasms; orhormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by nervousness;tachycardia; fatigue; weight loss; heat intolerance; and excessive sweating.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Thyrotoxicosis</reference><category>Adverse</category></page>
  <page>
    <title>Tinnitus</title>
    <id>280</id>
    <term>Tinnitus</term><definition>A nonspecific symptom of hearing disorder characterized by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear. Objectivetinnitus refers to noises generated from within the ear or adjacent structuresthat can be heard by other individuals. The term subjective tinnitus is usedwhen the sound is audible only to the affected individual. Tinnitus may occuras a manifestation of cochlear diseases; vestibulocochlear nerve diseases;intracranial hypertension; craniocerebral trauma; and other conditions.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tinnitus</reference><category>Adverse</category></page>
  <page>
    <title>Torsades de Pointes</title>
    <id>815</id>
    <term>Torsades de Pointes</term><definition>Amalignant form of polymorphic ventricular tachycardia that is characterized by heartrate between 200 and 250 beats per minute, and QRS complexes with changingamplitude and twisting of the points. Theterm also describes the syndrome of tachycardia with prolonged ventricularrepolarization, long QT intervals exceeding 500 milliseconds or bradycardia.Torsades de pointes may be self-limited or may progress to ventricularfibrillation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Torsades-de-Pointes</reference><category>Adverse</category></page>
  <page>
    <title>Torticollis</title>
    <id>377</id>
    <term>Torticollis</term><definition>A symptom, not a disease, of a twisted neck. In most instances, the head is tipped toward one side and the chin rotated toward the other.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Torticollis</reference><category>Adverse</category></page>
  <page>
    <title>Total Maximum Daily Load (TMDL)</title>
    <id>258</id>
    <term>Total Maximum Daily Load (TMDL)</term><definition>A calculation of the highest amount of a pollutant that a water body can receive and safely meet water quality standards set by the state, territory, or authorized tribe.</definition><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><category>Dose</category></page>
  <page>
    <title>Total suspended particulate matter (TSP)</title>
    <id>899</id>
    <term>Total suspended particulate matter (TSP)</term><definition>The total concentration of all airborne particles at a particular point in space.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Ecotox</category></page>
  <page>
    <title>Tourette's syndrome</title>
    <id>281</id>
    <term>Tourette's syndrome</term><definition>A neuropsychological disorder related to alterations in dopamine metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or a general medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tourette-syndrome</reference><category>Adverse</category></page>
  <page>
    <title>Toxic epidermal necrolysis</title>
    <id>378</id>
    <term>Toxic epidermal necrolysis</term><definition>An exfoliative disease of skin seen primarily in adults and characterized by flaccid bullae and spreading erythema so that the skin has the appearance of being scalded. It results primarily from a toxic reaction to various drugs, but occasionally occurs as a result of infection, neoplastic conditions, or other exposure.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Toxic-epidermal-necrolysis</reference><category>Adverse</category></page>
  <page>
    <title>Toxic substance</title>
    <id>259</id>
    <term>Toxic substance</term><definition>A chemical or mixture that may present an unreasonable risk of injury to health or the environment. A chemical, physical, or biological agent that may cause an adverse effect or effects to biological systems. A toxic substance is a chemical or mixture that may present an unreasonable risk of injury to health or the environment. Toxic Substances Control Act (TSCA) TSCA was enacted in 1976 to test, regulate, and screen all chemicals produced or imported into the U.S. TSCA requires that any chemical that reaches the consumer marketplace be tested for possible toxic effects prior to commercial manufacture. Any existing chemical that poses health and environmental hazards is tracked and reported under TSCA.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Hazards</category></page>
  <page>
    <title>Toxic wastes</title>
    <id>146</id>
    <term>Toxic wastes</term><definition>Wastes that contain substances in sufficient quantity to impinge harmfully on biological systems. A waste that can produce injury if inhaled, swallowed, or absorbed through the skin.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Ecotox</category></page>
  <page>
    <title>Toxicant</title>
    <id>901</id>
    <term>Toxicant</term><definition>A harmful substance or agent that may injure an exposed organism. A substance that kills or injures an organism through chemical or physical action or by altering the organism's environment; for example, cyanides, phenols, pesticides, or heavy metals; especially used for insect control.</definition><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://www.epa.gov/oswer/riskassessment/glossary.htm#l</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Ecotox</category></page>
  <page>
    <title>Toxicity</title>
    <id>282</id>
    <term>Toxicity</term><definition>Used with drugs and chemicals for experimental human and animal studies of their ill effects. It includes studies to determine the margin of safety or the reactions accompanying administration at various dose levels. It is used also for exposure to environmental agents. Poisoning should be considered for life-threatening exposure to environmental agents.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Toxicity</reference><category>Adverse</category></page>
  <page>
    <title>Toxicodynamics</title>
    <id>902</id>
    <term>Toxicodynamics</term><definition>The determination and quantification of the sequence of events at the cellular and molecular levels leading to a toxic response to an environmental agent (sometimes referred to as pharmacodynamics).</definition><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Hazards</category></page>
  <page>
    <title>Toxicological profile (toxicity profile)</title>
    <id>900</id>
    <term>Toxicological profile (toxicity profile)</term><definition>Toxicological profile ( toxicity profile ) An examination, summary, and interpretation of a hazardous substance to determine levels of exposure and associated health effects.</definition><reference>http://www.epa.gov/OCEPAterms/tterms.html</reference><reference>http://rais.ornl.gov/home/glossary.html#L</reference><category>Endpoints</category></page>
  <page>
    <title>Toxicology</title>
    <id>147</id>
    <term>Toxicology</term><definition>The study of the adverse effects of chemicals on living organisms. The study of harmful interactions between chemical, physical, or biological agents and biological systems.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><reference>http://www.atsdr.cdc.gov/glossary.html#G-J</reference><reference>http://www.epa.gov/iris/help_gloss.htm#s</reference><category>Hazards</category></page>
  <page>
    <title>Toxml</title>
    <id>395</id>
    <term>ToxML</term><definition>ToxML is a&#160;markup language initiated&#160;by Leadscope to promote adoption and use of controlled vocabularies and XML schema for storing chemical toxicity data. ToxML has the two-fold objective of: a) supporting broadly encompassing and meaningful representations of toxicology experiments, with hierarchical schemes including various levels of complexity; and b) indexing the data with the chemical structures so as to permit the widest range of chemical biological interrogations of the database.</definition><reference>http://www.leadscope.com/</reference><reference>http://www.epa.gov/ncct/dsstox/CoordinatingPublicEfforts.html</reference><reference>http://www.Toxml.org</reference><category>Standards</category></page>
  <page>
    <title>Trace</title>
    <id>148</id>
    <term>Trace</term><definition>A very small amount of a material. Usually used in reference to concentrations which are on the order of or less than 1-10 parts per million.</definition><reference>http://rais.ornl.gov/home/glossary.html#L</reference><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Hazards</category></page>
  <page>
    <title>Trace metals</title>
    <id>149</id>
    <term>Trace metals</term><definition>Metals normally found in trace amounts due to their insolubility or to their relative lack of abundance in the crust of the earth.</definition><reference>http://sra.org/resources_glossary_s-u.php</reference><category>Ecotox</category></page>
  <page>
    <title>Training set</title>
    <id>381</id>
    <term>Training set</term><definition>The dataset used to build&#160;a QSAR model.</definition><category>QSAR</category></page>
  <page>
    <title>Transient ischemic attack</title>
    <id>283</id>
    <term>Transient ischemic attack</term><definition>Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Transient-ischemic-attack</reference><category>Adverse</category></page>
  <page>
    <title>Tremor</title>
    <id>284</id>
    <term>Tremor</term><definition>Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intentionor action tremor, a common manifestation of cerebellar diseases, is aggravatedby movement. In contrast, resting tremor is maximal when there is no attempt atvoluntary movement, and occurs as a relatively frequent manifestation of Parkinsondisease.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Tremor</reference><category>Adverse</category></page>
  <page>
    <title>USEPA</title>
    <id>870</id>
    <term>US EPA</term><definition>EPA or U.S. EPA &#160;United States Environmental Protection Agency.</definition><reference>http://rais.ornl.gov/home/glossary.html#C</reference><reference>http://www.scorecard.org/about/glossary.tcl</reference><category>Ecotox</category></page>
  <page>
    <title>Ulcer</title>
    <id>379</id>
    <term>Ulcer</term><definition>A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Ulcer</reference><category>Adverse</category></page>
  <page>
    <title>Uremia</title>
    <id>833</id>
    <term>Uremia</term><definition>A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. Itis usually the result of renal insufficiency. Most uremic toxins are endproducts of protein or nitrogen catabolism, such as urea or creatinine. Severeuremia can lead to multiple organ dysfunctions with a constellation ofsymptoms.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Uremia</reference><category>Adverse</category></page>
  <page>
    <title>Urinary retention</title>
    <id>163</id>
    <term>Urinary retention</term><definition>Inability to empty the urinary bladder with voiding (urination).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Urinary-retention</reference><category>Adverse</category></page>
  <page>
    <title>Urinary stone</title>
    <id>834</id>
    <term>Urinary stone</term><definition>Low-density crystals or stones in any part of the urinary tract. Their chemical compositions often include calcium oxalate, magnesium ammonium phosphate (struvite), cystine, or uric acid.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Urinary-stone</reference><category>Adverse</category></page>
  <page>
    <title>Urticaria</title>
    <id>286</id>
    <term>Urticaria</term><definition>A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Urticaria</reference><category>Adverse</category></page>
  <page>
    <title>Uveitis</title>
    <id>835</id>
    <term>Uveitis</term><definition>Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina).</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Uveitis</reference><category>Adverse</category></page>
  <page>
    <title>Vaginitis</title>
    <id>836</id>
    <term>Vaginitis</term><definition>Inflammation of the vagina characterized by pain and a purulent discharge.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Vaginitis</reference><category>Adverse</category></page>
  <page>
    <title>Vascular disorders</title>
    <id>287</id>
    <term>Vascular disorders</term><definition>Pathological processes involving any of the blood vessels in the cardiac or peripheral circulation. Theyinclude diseases of arteries; veins; and rest of the vasculature system in thebody.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Vascular-disorders</reference><category>Adverse</category></page>
  <page>
    <title>Vasculitis</title>
    <id>288</id>
    <term>Vasculitis</term><definition>Inflammationof any one of the blood vessels, including the arteries; veins; and rest of thevasculature system in the body.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Vasculitis</reference><category>Adverse</category></page>
  <page>
    <title>Vasculitis, allergic cutaneous</title>
    <id>608</id>
    <term>Vasculitis, allergic cutaneous</term><definition>Inflammation of blood vessels caused by hypersensitivity to a drug or foreign agent and marked by cutaneous lesions. It is characterized by skin papules, macules, vesicles, urticarial wheals, PURPURA, small ulcers, itching, and usually a slight fever and malaise.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Vasculitisallergiccutaneous</reference><category>Adverse</category></page>
  <page>
    <title>Vasculitis, hypersensitivity</title>
    <id>449</id>
    <term>Vasculitis, hypersensitivity</term><definition>Heterogeneous group of disorders characterized by a vasculitic syndrome presumed to be associated with a hypersensitivity reaction following exposure to a drug, or other foreign or endogenous substance.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=VasculitisHypersensitivity</reference><category>Adverse</category></page>
  <page>
    <title>Venous thrombosis</title>
    <id>289</id>
    <term>Venous thrombosis</term><definition>The formation or presence of a thrombus within a vein.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Venous-thrombosis</reference><category>Adverse</category></page>
  <page>
    <title>Vertigo</title>
    <id>290</id>
    <term>Vertigo</term><definition>An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigomay be associated with disorders of the inner ear (ear, inner); vestibularnerve; brainstem; or cerebral cortex. Lesions in the temporal lobe and parietallobe may be associated with focal seizures that may feature vertigo as an ictalmanifestation.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Vertigo</reference><category>Adverse</category></page>
  <page>
    <title>Water intoxication</title>
    <id>291</id>
    <term>Water intoxication</term><definition>A condition resulting from the excessive retention of water with sodium depletion.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Water-intoxication</reference><category>Adverse</category></page>
  <page>
    <title>Weight gain</title>
    <id>838</id>
    <term>Weight gain</term><definition>Increase in body weight over existing weight.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Weight-gain</reference><category>Adverse</category></page>
  <page>
    <title>Weight loss</title>
    <id>164</id>
    <term>Weight loss</term><definition>Decrease in existing body weight.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Weight-loss</reference><category>Adverse</category></page>
  <page>
    <title>Xerostomia</title>
    <id>165</id>
    <term>Xerostomia</term><definition>Decreased salivary flow.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Xerostomia</reference><category>Adverse</category></page>
  <page>
    <title>Yawning</title>
    <id>166</id>
    <term>Yawning</term><definition>An involuntary deep inhalation with the mouth open, often accompanied by the act of stretching.</definition><reference>http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=mesh&amp;term=Yawning</reference><category>Adverse</category></page>
  </mediawiki>